WO2023022204A1 - 環状過酸化物、酸化反応生成物、酸化反応生成物の製造方法、及び、それらの用途 - Google Patents
環状過酸化物、酸化反応生成物、酸化反応生成物の製造方法、及び、それらの用途 Download PDFInfo
- Publication number
- WO2023022204A1 WO2023022204A1 PCT/JP2022/031273 JP2022031273W WO2023022204A1 WO 2023022204 A1 WO2023022204 A1 WO 2023022204A1 JP 2022031273 W JP2022031273 W JP 2022031273W WO 2023022204 A1 WO2023022204 A1 WO 2023022204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- chemical formula
- composition
- cyclic
- ring
- Prior art date
Links
- -1 Cyclic peroxide Chemical class 0.000 title claims abstract description 300
- 238000007254 oxidation reaction Methods 0.000 title claims description 448
- 239000007795 chemical reaction product Substances 0.000 title claims description 306
- 238000004519 manufacturing process Methods 0.000 title claims description 138
- 239000000126 substance Substances 0.000 claims abstract description 294
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 108
- 125000001424 substituent group Chemical group 0.000 claims abstract description 86
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 56
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 44
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 44
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 653
- 235000011187 glycerol Nutrition 0.000 claims description 314
- 239000000203 mixture Substances 0.000 claims description 292
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 201
- 230000014509 gene expression Effects 0.000 claims description 174
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 163
- 108090000623 proteins and genes Proteins 0.000 claims description 156
- 230000003647 oxidation Effects 0.000 claims description 150
- 230000008591 skin barrier function Effects 0.000 claims description 122
- 238000000034 method Methods 0.000 claims description 115
- 125000003118 aryl group Chemical group 0.000 claims description 98
- 230000001939 inductive effect Effects 0.000 claims description 97
- 230000001590 oxidative effect Effects 0.000 claims description 95
- 210000003491 skin Anatomy 0.000 claims description 88
- 239000003795 chemical substances by application Substances 0.000 claims description 86
- 150000003839 salts Chemical class 0.000 claims description 85
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 84
- 230000002087 whitening effect Effects 0.000 claims description 80
- 230000003078 antioxidant effect Effects 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 230000003938 response to stress Effects 0.000 claims description 53
- 239000003963 antioxidant agent Substances 0.000 claims description 52
- 239000000411 inducer Substances 0.000 claims description 50
- 239000004615 ingredient Substances 0.000 claims description 49
- 230000006872 improvement Effects 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 43
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 42
- 150000002314 glycerols Chemical class 0.000 claims description 39
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 35
- 125000004432 carbon atom Chemical group C* 0.000 claims description 33
- 230000035484 reaction time Effects 0.000 claims description 33
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 32
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
- 150000005846 sugar alcohols Polymers 0.000 claims description 25
- 150000001298 alcohols Chemical class 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 23
- 125000003172 aldehyde group Chemical group 0.000 claims description 23
- 125000004414 alkyl thio group Chemical group 0.000 claims description 23
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 239000002537 cosmetic Substances 0.000 claims description 19
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 claims description 19
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 19
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 19
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 108700041153 Filaggrin Proteins Proteins 0.000 claims description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 16
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 230000006698 induction Effects 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 15
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 15
- 230000001629 suppression Effects 0.000 claims description 14
- 108010018924 Heme Oxygenase-1 Proteins 0.000 claims description 13
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 13
- 229960002986 dinoprostone Drugs 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 13
- 101710149118 Quinone oxidoreductase 1 Proteins 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 108010024636 Glutathione Proteins 0.000 claims description 11
- 108010024814 Serine C-palmitoyltransferase Proteins 0.000 claims description 9
- 210000005175 epidermal keratinocyte Anatomy 0.000 claims description 9
- 108010033564 involucrin Proteins 0.000 claims description 9
- 229960003180 glutathione Drugs 0.000 claims description 8
- 230000019171 interleukin-1 alpha production Effects 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 229940122498 Gene expression inhibitor Drugs 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 11
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 11
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 238000010586 diagram Methods 0.000 description 108
- 239000000047 product Substances 0.000 description 94
- 230000000694 effects Effects 0.000 description 82
- 239000000243 solution Substances 0.000 description 73
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 62
- 238000004128 high performance liquid chromatography Methods 0.000 description 62
- 238000005259 measurement Methods 0.000 description 56
- 238000000926 separation method Methods 0.000 description 56
- 239000002904 solvent Substances 0.000 description 55
- 108091006146 Channels Proteins 0.000 description 45
- 235000006708 antioxidants Nutrition 0.000 description 45
- 238000004809 thin layer chromatography Methods 0.000 description 43
- 101150009136 tlcA gene Proteins 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 40
- 238000001819 mass spectrum Methods 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 239000007789 gas Substances 0.000 description 34
- 238000001228 spectrum Methods 0.000 description 34
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 32
- 238000012360 testing method Methods 0.000 description 32
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 30
- 102000003615 TRPM2 Human genes 0.000 description 25
- 101150095096 TRPM2 gene Proteins 0.000 description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 24
- 229910052760 oxygen Inorganic materials 0.000 description 24
- 239000001301 oxygen Substances 0.000 description 24
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical class OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 22
- 238000001362 electron spin resonance spectrum Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 22
- 239000002253 acid Substances 0.000 description 20
- 239000007800 oxidant agent Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 18
- 229910001882 dioxygen Inorganic materials 0.000 description 18
- 239000002552 dosage form Substances 0.000 description 18
- 230000003834 intracellular effect Effects 0.000 description 18
- 239000011575 calcium Substances 0.000 description 17
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 17
- 150000002978 peroxides Chemical class 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 239000002585 base Substances 0.000 description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 238000001237 Raman spectrum Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 125000001931 aliphatic group Chemical group 0.000 description 12
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 12
- 229930101531 artemisinin Natural products 0.000 description 12
- 229960004191 artemisinin Drugs 0.000 description 12
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- 239000002994 raw material Substances 0.000 description 11
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 10
- DVWSXZIHSUZZKJ-UHFFFAOYSA-N 18:3n-3 Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OC DVWSXZIHSUZZKJ-UHFFFAOYSA-N 0.000 description 10
- 102000016938 Catalase Human genes 0.000 description 10
- 108010053835 Catalase Proteins 0.000 description 10
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000012790 confirmation Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- DVWSXZIHSUZZKJ-YSTUJMKBSA-N methyl linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC DVWSXZIHSUZZKJ-YSTUJMKBSA-N 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 8
- 238000007599 discharging Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 229960002050 hydrofluoric acid Drugs 0.000 description 8
- 208000027866 inflammatory disease Diseases 0.000 description 8
- 150000007529 inorganic bases Chemical class 0.000 description 8
- 150000007522 mineralic acids Chemical class 0.000 description 8
- 125000001624 naphthyl group Chemical group 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 150000007524 organic acids Chemical class 0.000 description 8
- 150000007530 organic bases Chemical class 0.000 description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 8
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical group C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003125 aqueous solvent Substances 0.000 description 7
- 239000012911 assay medium Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 7
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 6
- 238000001069 Raman spectroscopy Methods 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000036252 glycation Effects 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000005273 aeration Methods 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 108091005996 glycated proteins Proteins 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000008099 melanin synthesis Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 4
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical group C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 4
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 4
- VCUVETGKTILCLC-UHFFFAOYSA-N 5,5-dimethyl-1-pyrroline N-oxide Chemical compound CC1(C)CCC=[N+]1[O-] VCUVETGKTILCLC-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 101000844510 Homo sapiens Transient receptor potential cation channel subfamily M member 1 Proteins 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 102000003617 TRPM1 Human genes 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 4
- 150000001241 acetals Chemical group 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 4
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 125000005577 anthracene group Chemical group 0.000 description 4
- 230000000078 anti-malarial effect Effects 0.000 description 4
- 239000003430 antimalarial agent Substances 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- JQXCGCPMGZBMLE-UHFFFAOYSA-N benzo[f]isoquinoline Chemical group N1=CC=C2C3=CC=CC=C3C=CC2=C1 JQXCGCPMGZBMLE-UHFFFAOYSA-N 0.000 description 4
- HCAUQPZEWLULFJ-UHFFFAOYSA-N benzo[f]quinoline Chemical group C1=CC=C2C3=CC=CC=C3C=CC2=N1 HCAUQPZEWLULFJ-UHFFFAOYSA-N 0.000 description 4
- RFQDDXWZZVRLKO-UHFFFAOYSA-N benzo[g]quinoline Chemical group N1=CC=CC2=CC3=CC=CC=C3C=C21 RFQDDXWZZVRLKO-UHFFFAOYSA-N 0.000 description 4
- WZJYKHNJTSNBHV-UHFFFAOYSA-N benzo[h]quinoline Chemical group C1=CN=C2C3=CC=CC=C3C=CC2=C1 WZJYKHNJTSNBHV-UHFFFAOYSA-N 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 4
- DKSMCEUSSQTGBK-UHFFFAOYSA-N bromous acid Chemical compound OBr=O DKSMCEUSSQTGBK-UHFFFAOYSA-N 0.000 description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 4
- 239000000920 calcium hydroxide Substances 0.000 description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 4
- 229940005991 chloric acid Drugs 0.000 description 4
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 4
- 229940077239 chlorous acid Drugs 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 229940105990 diglycerin Drugs 0.000 description 4
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 4
- 238000007876 drug discovery Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- CAPAZTWTGPAFQE-UHFFFAOYSA-N ethane-1,2-diol Chemical compound OCCO.OCCO CAPAZTWTGPAFQE-UHFFFAOYSA-N 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 229940071870 hydroiodic acid Drugs 0.000 description 4
- CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 4
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 4
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 4
- GEOVEUCEIQCBKH-UHFFFAOYSA-N hypoiodous acid Chemical compound IO GEOVEUCEIQCBKH-UHFFFAOYSA-N 0.000 description 4
- SRPSOCQMBCNWFR-UHFFFAOYSA-N iodous acid Chemical compound OI=O SRPSOCQMBCNWFR-UHFFFAOYSA-N 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 235000006408 oxalic acid Nutrition 0.000 description 4
- LLYCMZGLHLKPPU-UHFFFAOYSA-N perbromic acid Chemical compound OBr(=O)(=O)=O LLYCMZGLHLKPPU-UHFFFAOYSA-N 0.000 description 4
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical group C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000011736 potassium bicarbonate Substances 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000005581 pyrene group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 125000001422 pyrrolinyl group Chemical group 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- 230000011506 response to oxidative stress Effects 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 238000013319 spin trapping Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- MAAKQSASDHJHIR-UHFFFAOYSA-N trioxolane Chemical group C1COOO1 MAAKQSASDHJHIR-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- UENLDOJJKXLRJI-ZETCQYMHSA-N (2s)-6-amino-2-(2-carboxyethylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NCCC(O)=O UENLDOJJKXLRJI-ZETCQYMHSA-N 0.000 description 3
- JLCXTTXSLOWJBH-UHFFFAOYSA-N 8-(5-octyl-1,2,4-trioxolan-3-yl)octanoic acid Chemical compound CCCCCCCCC1OOC(CCCCCCCC(O)=O)O1 JLCXTTXSLOWJBH-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 229910008760 WITec Inorganic materials 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000752 ionisation method Methods 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 238000004651 near-field scanning optical microscopy Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000012451 post-reaction mixture Substances 0.000 description 3
- 239000000550 preparative sample Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- LJNDQMBPIQGDNB-YFKPBYRVSA-N (2s)-2-(carboxymethylamino)-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NCC(O)=O LJNDQMBPIQGDNB-YFKPBYRVSA-N 0.000 description 2
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229940043375 1,5-pentanediol Drugs 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 2
- 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- BOOXYSZJUWVNRE-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;2-oxopropanal Chemical class CC(=O)C=O.NCCCC[C@H](N)C(O)=O BOOXYSZJUWVNRE-JEDNCBNOSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- ZGCHLOWZNKRZSN-NTSWFWBYSA-N 3-deoxyglucosone Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)C=O ZGCHLOWZNKRZSN-NTSWFWBYSA-N 0.000 description 1
- UHPMJDGOAZMIID-UHFFFAOYSA-N 3-deoxyglucosone Natural products OCC1OC(O)C(=O)CC1O UHPMJDGOAZMIID-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710131282 FAD-linked oxidoreductase easE Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 231100000951 LabCyte EPI-MODEL Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710199728 Oxidoreductase 1 Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 101001109714 Rhizobium meliloti (strain 1021) NAD(P)H dehydrogenase (quinone) 1 Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000015785 Serine C-Palmitoyltransferase Human genes 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000005910 aminocarbonylation reaction Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
Definitions
- the present invention provides a cyclic peroxide, an oxidation reaction product, a method for producing an oxidation reaction product, a whitening composition, a whitening agent, a composition for inducing expression of a gene associated with skin barrier function, and a composition for improving skin barrier function.
- skin barrier function-related gene inducer skin barrier function improver, composition for inducing expression of antioxidant stress response gene, agent for inducing expression of antioxidant stress response gene, anti-inflammatory composition, anti-inflammatory agent, anti-glycation and anti-glycation agents.
- Peroxides such as hydrogen peroxide are substances that are used industrially due to their oxidizing ability.
- hydrogen peroxide for example, is known to be a TRP channel active substance.
- a TRP channel (TRP receptor) is one of the ion channel type receptors (receptors) present in the cell membrane, and is used as a target for drug discovery.
- Patent Document 1 describes the use of plant extracts such as peppermint and lemon balm as whitening ingredients that promote melanin decomposition.
- Non-Patent Document 1 Non-Patent Document 1
- the glycation reaction is a reaction in which proteins and carbohydrates such as reducing sugars bind in an enzyme-independent manner, and ultimately advanced glycation end products (AGEs) ) are known to produce
- AGEs advanced glycation end products
- the first object of the present invention is to provide a highly safe cyclic peroxide, an oxidation reaction product, and a method for producing an oxidation reaction product.
- a second object of the present invention is to provide a whitening composition and a whitening agent containing a new whitening ingredient.
- a third aspect of the present invention aims to provide a composition for inducing the expression of a skin barrier function-related gene containing a novel ingredient for inducing the expression of a skin barrier function-related gene and an agent for inducing the expression of a skin barrier function-related gene.
- the fourth aspect of the present invention aims to provide an anti-glycation composition and an anti-glycation agent containing a new anti-glycation ingredient.
- the cyclic peroxide in the first aspect of the present invention is characterized by being represented by the following chemical formula (I).
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the oxidation reaction product in the first aspect of the present invention is an oxidation reaction product obtained by oxidizing alcohol and characterized by containing a cyclic peroxide.
- the method for producing an oxidation reaction product according to the first aspect of the present invention is the method for producing an oxidation reaction product according to the present invention, which includes an alcohol oxidation step of oxidizing the alcohol.
- the whitening composition in the second aspect of the present invention contains glycerin and/or a glycerin derivative and a whitening ingredient
- the whitening ingredient contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the second whitening agent of the present invention contains a cyclic peroxide or a salt thereof represented by the following chemical formula (I):
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- a composition for inducing expression of a barrier function-related gene comprises glycerin and/or a glycerin derivative and a component for inducing expression of a skin barrier function-related gene
- the skin barrier function-related gene expression-inducing component contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may
- composition for improving skin barrier function in the third aspect of the present invention includes the composition for inducing the expression of the skin barrier function-related gene described in the third aspect of the present invention.
- the skin barrier function-related gene expression inducer in the third aspect of the present invention includes a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the skin barrier function-improving agent in the third aspect of the present invention includes the skin barrier function-related gene inducer in the third aspect of the present invention.
- a composition for inducing the expression of an antioxidant stress response gene in the third aspect of the present invention comprises glycerin and/or a glycerin derivative and a component for inducing the expression of an antioxidant stress response gene
- the antioxidant stress response gene expression-inducing component contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the antioxidant stress response gene expression inducer in the third aspect of the present invention includes a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the anti-inflammatory composition in the third aspect of the present invention comprises glycerin and/or glycerin derivatives and an anti-inflammatory component
- the anti-inflammatory ingredient contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the anti-inflammatory agent in the third aspect of the present invention includes a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the anti-glycation composition in the fourth aspect of the present invention comprises glycerin and / or comprising a glycerin derivative and an anti-glycation ingredient,
- the anti-glycation ingredient contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which
- the anti-glycation agent in the fourth aspect of the present invention includes a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- a composition for inducing the expression of skin barrier function-related genes containing a novel ingredient for inducing the expression of skin barrier function-related genes, and an agent for inducing the expression of skin barrier function-related genes. can be done.
- FIG. 1-1 is a 1 H NMR spectrum of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 1-2 is a 13 C NMR spectrum of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIGS. 1-3 are 13 C DEPT135 NMR spectra of the reaction mixture (TLC 1 spot product) of glycerin oxidation with ozone measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 1-4 is a COZY NMR spectrum diagram of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- Figures 1-5 are HSQC NMR spectra of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27°C) using DMSO-d 6 as a solvent.
- Figures 1-6 are HMBC NMR spectra of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27°C) using DMSO-d 6 as a solvent.
- FIG. 1-4 is a COZY NMR spectrum diagram of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d
- FIGS. 1-7 shows a total ion chromatogram (ESI -negative mode).
- FIGS. 1-8 are mass spectrum diagrams of peaks F, G and H (F, G and H fractions) in FIGS. 1-7.
- FIGS. 1-9 are diagrams showing the results of studies on improvement of separation (improvement of separation conditions) in HILIC (High Performance Liquid Chromatography).
- FIG. 1-10 shows the mass spectra (after separation improvement) of peaks 1 to 3 in FIG. 1-9.
- FIG. 1-11 shows the mass spectra (after separation improvement) of peaks 4 to 6 in FIG. 1-9.
- FIG. 1-12 shows the mass spectra (after separation improvement) of peaks 7-8 in FIG. 1-9.
- FIG. 1-17 is a diagram showing together the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (High Performance Liquid Chromatography) conditions of FIG. 1-9.
- FIG. 1-18 is a diagram showing together the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (High Performance Liquid Chromatography) conditions.
- 1-19 is an enlarged view of a portion of FIGS. 1-18.
- FIG. 1-21 is an ESR spectrum diagram of ozonated methyl linolenate.
- FIG. 1-22 is an ESR spectrum diagram of peaks 1-8 in FIG. 1-9.
- FIG. 1-23 shows the results of measuring the activities of peaks 1-8 in FIG. 1-9 by chemiluminescence.
- Figure 1-24 shows the effect of addition of G (glycerin), OG (ozonated glycerin), LOG (ozonated oxide) and HOG (heat treated ozonated glycerin) on TRPM2 (expressing cells) and Vector (TRPM2 non-expressing cells). It is a figure which shows.
- FIG. 1-25 shows TRP channel activity against TRPM2 (expressing cells) for G and OG under the same conditions as in FIG.
- FIG. 1-26 is a diagram confirming the TRP channel activity for TRPM2 (expressing cells) for G, OG, LOG and HOG.
- FIG. 1-27 shows TRP channel activity against TRPM2 (expressing cells) in LOG and OG under the same conditions as in FIG. 1-24 except that catalase was added at 500 units/ml. It is a figure which compared.
- FIG. 1-28 shows TRP channel activity against TRPM2 (expressing cells) for OG and LOG under the same conditions as in FIG. 1-24, except that the concentrations (% by mass) of the aqueous solutions were changed.
- Figure 1-29 shows TRPM2 (TRPM2 ( (expressing cells), and compared with the case where catalase and PJ34 were not added.
- Figure 1-30 confirms TRP channel activity against TRPM2 (expressing cells) under the same conditions as Figure 1-24, except that 100 ⁇ m of dipyridyl ( ⁇ , ⁇ '-dipyridyl) was added to 0.1 mass% LOG. and compared with the case where dipyridyl was not added.
- Figure 1-31 shows LOG except that the concentration (mass%) of the aqueous solution was changed and TRPM1 HEK (expressing cells) or HEK (expressing cells) was used instead of TRPM2 (expressing cells).
- 1-24 is a diagram confirming the TRP channel activity for each cell under the same conditions as in 1-24.
- FIG. 1-32 shows TRP channel activity for TRPM2 (expressing cells) and TRPMA1 (expressing cells) verified in the same manner as in FIG. 1-31 using F7 at various concentrations.
- FIG. 1-33 shows TRP channel activity for TRPM2 (expressing cells) and TRPMA1 (expressing cells) verified in the same manner as in FIG. 1-31 using F7 at various concentrations.
- FIG. 2-1 is a graph showing the results of melanin measurement values over time in Example 2-1.
- FIG. 2-2 is a graph showing the amount of change in measured melanin values over time in Example 2-1.
- FIG. 2-3 is a 1 H NMR spectrum of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 2-4 is a 13 C NMR spectrum of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 2-5 is a 13 C DEPT135 NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 2-6 is a COZY NMR spectrum diagram of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 2-7 is an HSQC NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- 2-8 are HMBC NMR spectra of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 2-9 shows a total ion chromatogram (ESI -negative mode).
- FIG. 2-10 is a mass spectrum diagram of peaks F, G and H (F, G and H fractions) in FIG. 2-9.
- FIGS. 2-11 are diagrams showing the results of studies on improvement of separation (improvement of separation conditions) in HILIC (High Performance Liquid Chromatography).
- FIG. 2-12 shows mass spectra (after separation improvement) of peaks 1 to 3 in FIG. 2-11.
- FIG. 2-13 shows the mass spectra (after separation improvement) of peaks 4 to 6 in FIG. 2-11.
- FIG. 2-14 shows the mass spectrum (after separation improvement) of peaks 7-8 in FIG. 2-11.
- FIG. 2-19 is a diagram showing together the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (High Performance Liquid Chromatography) conditions of FIG. 2-11.
- FIG. 2-20 is a diagram showing together HILIC chromatograms of a TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (High Performance Liquid Chromatography) conditions.
- Figure 2-21 is an enlarged view of a portion of Figure 2-20.
- FIG. 2-24 is an ESR spectrum diagram of ozonized methyl linolenate.
- FIG. 2-24 is an ESR spectrum diagram of peaks 1 to 8 in FIG. 2-11.
- FIG. 2-25 shows the results of measuring the activities of peaks 1 to 8 in FIG. 2-11 by chemiluminescence.
- FIG. 3-1 is a graph showing expression levels of skin barrier function-related genes in Example 3-1.
- FIG. 3-2 is a graph showing the expression levels of antioxidant stress-responsive genes in Example 3-1.
- FIG. 3-3 is a graph showing the amounts of glutathione peptides in Example 3-1.
- FIG. 3-4 is a graph showing cell viability in Example 3-1.
- FIG. 3-5 is a graph showing the amount of IL-1 ⁇ produced in Example 3-1.
- FIG. 3-7 is a 1 H NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- 3-8 are 13 C NMR spectra of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 3-7 is a 1 H NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 3-9 is a 13 C DEPT135 NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 3-10 is a COZY NMR spectrum diagram of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 3-11 is the HSQC NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 3-12 is a HMBC NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 3-13 shows a total ion chromatogram (ESI -negative mode).
- FIG. 3-14 is a mass spectrum diagram of peaks F, G and H (F, G and H fractions) in FIG. 3-13.
- FIGS. 3-15 are diagrams showing the results of studies on improvement of separation (improvement of separation conditions) in HILIC (High Performance Liquid Chromatography).
- FIG. 3-16 shows the mass spectra (after separation improvement) of peaks 1 to 3 in FIG. 3-15.
- FIG. 3-17 shows the mass spectra (after separation improvement) of peaks 4 to 6 in FIG. 3-15.
- FIG. 3-18 shows the mass spectrum (after separation improvement) of peaks 7-8 in FIG. 3-15.
- FIG. 3-23 is a diagram showing together the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (High Performance Liquid Chromatography) conditions of FIG. 3-15.
- FIG. 3-24 is a diagram showing together HILIC chromatograms of a TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (High Performance Liquid Chromatography) conditions.
- Figure 3-25 is an enlarged view of a portion of Figure 3-24.
- FIG. 3-23 is a diagram showing together the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (High Performance Liquid Chromatography) conditions of FIG. 3-15.
- FIG. 3-24 is a diagram showing together HILIC
- FIG. 3-27 is an ESR spectrum diagram of ozonated methyl linolenate.
- FIG. 3-28 is an ESR spectrum diagram of peaks 1-8 in FIG. 3-15.
- FIG. 3-29 shows the results of measuring the activities of peaks 1 to 8 in FIG. 3-15 by chemiluminescence.
- FIG. 4-1 is a graph showing the anti-glycation rate in Example 4-1.
- FIG. 4-2 is a 1 H NMR spectrum of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 4-3 is a 13 C NMR spectrum of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 4-4 is a 13 C DEPT135 NMR spectrum of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIG. 4-5 is a COZY NMR spectrum of the reaction mixture (TLC 1 spot product) for ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- FIGS. 4-6 are HSQC NMR spectra of the reaction mixture (TLC 1 spot product) for the ozone oxidation of glycerol measured at a temperature of 300 K (27° C.) using DMSO-d 6 as a solvent.
- Figures 4-7 are HMBC NMR spectra of the reaction mixture (TLC 1 spot product) of the ozone oxidation of glycerol measured at a temperature of 300 K (27°C) using DMSO-d 6 as a solvent.
- FIG. 4-8 shows a total ion chromatogram (ESI -negative mode).
- FIG. 4-9 is a mass spectrum diagram of peaks F, G and H (F, G and H fractions) in FIG. 4-8.
- FIG. 4-10 are diagrams showing the results of studies on improvement of separation (improvement of separation conditions) in HILIC (High Performance Liquid Chromatography).
- FIG. 4-11 is a diagram showing mass spectra (after separation improvement) of peaks 1 to 3 in FIG. 4-10.
- FIG. 4-12 shows the mass spectra (after separation improvement) of peaks 4 to 6 in FIG. 4-10.
- FIG. 4-13 shows the mass spectrum (after separation improvement) of peaks 7-8 in FIG. 4-10.
- FIG. 4-18 is a diagram showing together the HILIC chromatograms of the TLC1 spot product and the glyceraldehyde dimer under the HILIC (High Performance Liquid Chromatography) conditions of FIG. 4-10.
- FIG. 4-19 is a diagram showing together HILIC chromatograms of TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (High Performance Liquid Chromatography) conditions.
- FIG. 4-20 is an enlarged view of a portion of Figure 4-19.
- FIG. 4-22 is an ESR spectrum diagram of ozonized methyl linolenate.
- FIG. 4-23 is an ESR spectrum diagram of peaks 1 to 8 in FIG. 4-10.
- FIG. 4-24 shows the results of measuring the activities of peaks 1 to 8 in FIG. 4-10 by chemiluminescence.
- the salt when a substance can form a salt, the salt can also be used in the first aspect of the present invention unless otherwise specified.
- the salt may be an acid addition salt or a base addition salt.
- the acid forming the acid addition salt may be an inorganic acid or an organic acid
- the base forming the base addition salt may be an inorganic base or an organic base.
- inorganic acid examples include, but are not limited to, sulfuric acid, phosphoric acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, hypofluorous acid, hypochlorous acid, hypobromous acid, Hypoiodous acid, fluorous acid, chlorous acid, bromous acid, iodous acid, fluoric acid, chloric acid, bromic acid, iodic acid, perfluoric acid, perchloric acid, perbromic acid, periodic acid, etc. is given.
- the organic acid is also not particularly limited, but examples thereof include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid and acetic acid.
- the inorganic base include, but are not limited to, ammonium hydroxide, alkali metal hydroxide, alkaline earth metal hydroxide, carbonate and hydrogen carbonate. Examples include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydroxide and calcium carbonate.
- the organic base is also not particularly limited, and examples thereof include ethanolamine, triethylamine and tris(hydroxymethyl)aminomethane.
- the method for producing these salts is not particularly limited, either, and they can be produced, for example, by adding an acid or base as described above to the above compounds as appropriate by a known method.
- examples of the aromatic ring containing no heteroatom include benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, and pyrene ring.
- examples of heteroaromatic rings include pyridine rings and thiophene rings.
- the nitrogen-containing aromatic ring may or may not have a positive charge, for example.
- nitrogen-containing aromatic rings having no positive charge examples include pyrroline ring, pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring, quinoline ring, isoquinoline ring, acridine ring, 3,4-benzoquinoline ring, 5,6- benzoquinoline ring, 6,7-benzoquinoline ring, 7,8-benzoquinoline ring, 3,4-benzoisoquinoline ring, 5,6-benzoisoquinoline ring, 6,7-benzoisoquinoline ring, 7,8-benzoisoquinoline Rings, etc. can be mentioned.
- Positively charged nitrogen-containing aromatic rings include, for example, pyrrolinium ring, pyridinium ring, pyridazinium ring, pyrimidinium ring, pyrazinium ring, quinolinium ring, isoquinolinium ring, acridinium ring, 3,4-benzoquinolinium ring, 5,6 -benzoquinolinium ring, 6,7-benzoquinolinium ring, 7,8-benzoquinolinium ring, 3,4-benzoisoquinolinium ring, 5,6-benzoisoquinolinium ring, 6 ,7-benzoisoquinolinium ring, 7,8-benzoisoquinolinium ring, and the like.
- oxygen-containing aromatic ring or sulfur-containing aromatic ring for example, at least one of the carbon atoms or nitrogen atoms of the heteroatom-free aromatic ring or nitrogen-containing aromatic ring is replaced with at least one of an oxygen atom and a sulfur atom.
- Aromatic rings are mentioned.
- the "substituent” includes, for example, a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated fatty group hydrocarbon groups, aryl groups, heteroaryl groups, halogens, mercapto groups (-SH), alkylthio groups (-SR, R is an alkyl group) and the like.
- a chain substituent e.g., a hydrocarbon group such as an alkyl group or an unsaturated aliphatic hydrocarbon group
- the number of carbon atoms is not particularly limited, but is, for example, 1-40, 1-32, 1-24, 1-18, 1-12, 1-6, or 1-2 (2 or more ).
- the number of ring members (the number of atoms constituting the ring) of the cyclic group is not particularly limited, but for example, 5 to 32, It may be 5-24, 6-18, 6-12, or 6-10.
- any isomer may be used unless otherwise specified.
- naphthyl group it may be a 1-naphthyl group or a 2-naphthyl group.
- the first invention of the present invention will be described more specifically with examples.
- the first invention of the present invention is not limited by the following description.
- each description in the first aspect of the present invention can be used with each other unless otherwise specified.
- the expression “ ⁇ ” when used, it is used in the sense of including numerical values or physical values before and after it.
- the expression “A and/or B” includes “only A,” “only B,” and “both A and B.”
- the cyclic peroxide of the first aspect of the present invention is characterized by being represented by the following chemical formula (I).
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the heteroatom refers to an atom other than carbon and hydrogen, and may be one selected from the group consisting of, for example, an oxygen atom, a nitrogen atom, a sulfur atom, a selenium atom, a boron atom, and a silicon atom. .
- the substituent is not particularly limited, but may contain, for example, a hydroxyl group. is one selected from the group consisting of an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), and an alkylthio group (-SR, R is an alkyl group); may
- R 100 in the chemical formula (I) may be a cyclic structure having 5 to 10 ring members.
- the cyclic peroxide of the first aspect of the present invention may be, for example, a cyclic peroxide represented by the following chemical formula (II).
- the substituents are respectively a hydroxyl group (--OH), an aldehyde group (formyl group), and a hydroxyalkyl group.
- R is an alkyl group.
- the cyclic peroxide of the first aspect of the present invention may be, for example, a cyclic peroxide represented by the following chemical formula (1).
- the cyclic peroxide represented by the following chemical formula (1) corresponds to the case where all R 11 in the chemical formula (II) are hydrogen atoms.
- the method for producing the cyclic peroxide of the first aspect of the present invention is not particularly limited. be able to.
- the produced oxidation reaction product may be used as it is without purification, or only the cyclic peroxide of the first aspect of the present invention may be isolated and purified before use.
- the present inventors were the first to discover the phenomenon that a cyclic peroxide is obtained by oxidation of alcohol, for example, oxidation of glycerin by ozone. Although the mechanism by which the cyclic peroxide is obtained is unknown, it is speculated that, for example, by lengthening the reaction time of the oxidation reaction of alcohol as described later, a reaction product different from conventional reactions can be obtained.
- the cyclic peroxide of the first aspect of the present invention is, for example, chemically stable and easy to handle as compared to radicals and the like, so it is possible to isolate and formulate it.
- cyclic peroxides are substances that are industrially used due to their oxidizing ability.
- artemisinin having a seven-membered ring (trioxolane) skeleton similar to the structure of the cyclic peroxide of the first invention in the present invention is useful in antimalarial and has won the Nobel Prize in 2015, and is still present. Its derivatives have been investigated.
- a highly safe and highly water-soluble cyclic peroxide and an oxidation reaction product and a method for producing such an oxidation reaction product can be provided.
- a method for evaluating whether the cyclic peroxide of the first invention of the present invention or the oxidation reaction product of the first invention of the present invention is water-soluble and exhibits oxidizing ability for example, Example 1 described later
- a method for evaluating activity against TRP channels which are also used as targets for drug discovery.
- the mechanism by which the cyclic peroxide of the first invention of the present invention or the oxidation reaction product of the first invention of the present invention exhibits TRP channel activity is not particularly limited. The development is thought to indicate TRP channel activity.
- the oxidation reaction product of the first aspect of the present invention is, as described above, an oxidation reaction product characterized by containing a cyclic peroxide obtained by oxidizing alcohol.
- the method for producing the oxidation reaction product of the first aspect of the present invention is not limited to the oxidation of alcohol, and any substance produced by any production method may be used as long as it has the same structure.
- the method of oxidizing the alcohol is not particularly limited.
- the alcohol oxidation may be at least one of ozone oxidation and hydrogen peroxide oxidation.
- the method for producing an oxidation reaction product according to the first aspect of the present invention is not limited to the ozone oxidation of alcohol and the oxidation of hydrogen peroxide, and any production method can be used as long as the substance has the same structure. It may be a substance manufactured by
- the oxidation reaction product of the first aspect of the present invention may be, for example, a mixture containing multiple oxidation reaction products.
- the oxidation reaction product of the first aspect of the present invention may have, for example, oxidizing ability.
- the oxidation reaction product of the first aspect of the present invention may have, for example, reducing ability.
- the oxidation reaction product of the first aspect of the present invention may contain, for example, a TRP channel active substance.
- the alcohol as a raw material is not particularly limited.
- the alcohol may be a saturated alcohol.
- the alcohol may be a polyhydric alcohol.
- the alcohol may be at least one of glycerin and a glycerin derivative.
- the oxidation reaction product of the first aspect of the present invention may include, for example, an oxidation reaction product obtained by bonding two or more molecules of the alcohol.
- the oxidation reaction product of the first aspect of the present invention may contain, for example, the cyclic peroxide of the first aspect of the present invention.
- the alcohol which is the raw material for the oxidation reaction product of the first aspect of the present invention, is not particularly limited, and may be, for example, a saturated alcohol or an unsaturated alcohol as described above. Further, the alcohol may be linear or branched, and may or may not contain a cyclic structure. Moreover, the alcohol may be, for example, a polyhydric alcohol or a monohydric alcohol. The valence of the polyhydric alcohol is also not particularly limited, and may be, for example, divalent, trivalent, or tetravalent. Examples of monohydric saturated alcohols include saturated alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms.
- the alcohol may be linear or branched, may or may not contain a cyclic structure, and specifically includes, for example, methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, sec-butyl alcohol, tert-butyl alcohol and the like.
- saturated polyhydric alcohols include saturated polyhydric alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms.
- the saturated polyhydric alcohol may be linear or branched, may or may not contain a cyclic structure, and specifically includes, for example, ethylene glycol (ethane-1,2-diol), propylene glycol (propane-1,2-diol), glycerin, glycerin derivatives and the like.
- the glycerin derivative is not particularly limited, but may be, for example, a glycerin polymer or a compound in which at least one hydrogen atom of glycerin is substituted with a substituent (eg, an alkyl group, etc.). Examples of the glycerin derivative include diglycerin and polyglycerin.
- the oxidation reaction product of the first aspect of the present invention may be, for example, a substance having reducing ability, as described above.
- the oxidation reaction product of the first aspect of the present invention may have a reducing ability derived from the functional group by having a reducing ability functional group.
- the oxidation reaction product of the first aspect of the present invention may have a reducing ability by having an aldehyde group (formyl group), or the first aspect of the present invention. may have a reducing ability derived from the keto body by being a keto-enol tautomer.
- the oxidation reaction product of the first invention in the present invention obtained in Example 1 to be described later contains an acetal structure in the skeleton as confirmed by NMR. : Derived from ketones and aldehydes).
- the oxidation reaction product of the first aspect of the present invention may be, for example, a substance obtained by bonding two or more alcohol molecules as described above. Specifically, for example, it may have a structure in which two or more molecules of the alcohol are bonded together and further oxidized.
- the "binding" form of the two or more alcohol molecules is not particularly limited, and may be, for example, addition, condensation, or the like.
- the oxidation reaction product of the first aspect of the present invention is, for example, chemically stable and easy to handle as compared to radicals, etc., so it is possible to isolate and formulate it.
- the method for producing an oxidation reaction product according to the first aspect of the present invention is, as described above, the method for producing an oxidation reaction product according to the first aspect of the present invention, which includes an alcohol oxidation step of oxidizing the alcohol.
- the method of oxidizing alcohol is not particularly limited.
- the alcohol may be oxidized by at least one of ozone oxidation and hydrogen peroxide oxidation.
- the reaction time of the alcohol oxidation step is not particularly limited.
- the reaction time in the alcohol oxidation step is, for example, 24 hours or more or 1 day or more, 48 hours or more or 2 days or more, 72 hours or more or 3 days or more, 120 hours or more or 5 days or more, or 168 hours or more or 7 days. or more.
- the upper limit of the reaction time in the alcohol oxidation step is not particularly limited, but may be, for example, 720 hours or less or 30 days or less, or 360 hours or less or 15 days or less.
- the reaction time of the alcohol oxidation step is lengthened. preferably.
- the reaction time of the alcohol oxidation step is not too long for production efficiency.
- the method for producing an oxidation reaction product according to the first aspect of the present invention includes an alcohol oxidation step of oxidizing the alcohol.
- the oxidation reaction product of the first aspect of the present invention is not limited to the substance produced by this production method, and any substance produced by any production method as long as it has the same structure. It's okay.
- the method for producing an oxidation reaction product according to the first aspect of the present invention will be described more specifically with examples.
- the method for producing an oxidation reaction product according to the first aspect of the present invention is not limited to the following explanation.
- the following method can be similarly carried out using other alcohols instead of glycerin.
- the method of oxidizing alcohol in the alcohol oxidation step is not particularly limited and is arbitrary, and is not limited only to ozone oxidation.
- the oxidation method may be, for example, at least one of ozone oxidation and hydrogen peroxide oxidation.
- the concentration of each substance, reaction temperature, reaction time, and other reaction conditions can be changed as appropriate.
- the oxidation reaction product of the first aspect of the present invention is produced by, for example, contacting glycerin and ozone, more specifically, by mixing glycerin and ozone to oxidize glycerin ( (corresponding to the "alcohol oxidation step" of the first invention).
- the step of oxidizing glycerin may be, for example, a step of bringing a glycerin solution and an ozone-containing gas into gas-liquid contact to oxidize glycerin.
- the glycerin solution preferably has a high concentration of glycerin.
- a high-concentration glycerin solution for example, a glycerin solution having a glycerin concentration of 75% or more can be used.
- a concentrated glycerin solution with a glycerin concentration of 98% by weight or more is more preferable, and a purified glycerin solution with a concentration of 98.5% by weight or more is even more preferable.
- the solvent for glycerin is not particularly limited, and is, for example, an aqueous solvent such as water.
- the ozone-containing gas preferably has a high concentration of ozone.
- the method for producing the gas having a high ozone concentration is not particularly limited, and for example, an ozone generator that generates ozone by silently discharging oxygen gas can be used.
- oxygen gas for example, a medical oxygen cylinder may be used, or oxygen gas produced by an oxygen generator may be used.
- the method of bringing the glycerin solution and the ozone-containing gas into gas-liquid contact is not particularly limited.
- an ozone-treated glycerin solution with a hydrogen peroxide concentration of about 4,000 ppm can be produced.
- the duration of aeration is not particularly limited. For example, by conducting the aeration for a relatively long time, an ozone-treated glycerin solution containing a higher concentration of the oxidation reaction product of the first aspect of the present invention can be produced.
- the oxidation reaction product of the first aspect of the present invention may be used as it is without fractionating it from the mixture after the reaction (for example, the ozone-treated glycerin solution), or the reaction product of the first aspect of the present invention may be extracted from the mixture after the reaction. It may be used after fractionating the oxidation reaction product of the first invention.
- the method of separation is not particularly limited, the oxidation reaction product of the first aspect of the present invention can be separated from the reaction mixture by, for example, chromatography such as preparative thin layer chromatography.
- an oxidation reaction product having oxidizing power can be produced by a very simple and easy method.
- the oxidation reaction product of the first aspect of the present invention can generate, for example, hydrogen peroxide.
- the oxidation reaction product of the first invention in the present invention is, for example, 1 to 4000 ppm, 10 to 4000 ppm, 100 to 4000 ppm per oxidation reaction product of the first invention in terms of hydrogen peroxide concentration of about 4000 ppm. of hydrogen peroxide can be generated.
- the method of using the cyclic peroxide of the first invention in the present invention and the oxidation reaction product of the first invention in the present invention are not particularly limited.
- the cyclic peroxide of the first invention of the present invention or the oxidation reaction product of the first invention of the present invention may be used as a TRP channel active substance.
- the method of use in that case is not particularly limited, and may be the same as the method of use of general TRP channel active substances, for example.
- the cyclic peroxide of the first aspect of the present invention and the oxidation reaction product of the first aspect of the present invention are highly safe and can be used safely.
- the cyclic peroxide of the first invention in the present invention and the oxidation reaction product of the first invention in the present invention for example, as described above, it is used as it is without fractionating from the mixture after the reaction.
- the cyclic peroxide of the first aspect of the present invention or the oxidation reaction product of the first aspect of the present invention may be fractionated from the mixture after the reaction and then used.
- the cyclic peroxide of the first invention of the present invention and the oxidation reaction product of the first invention of the present invention have suppressed explosiveness, irritation, etc., and are highly safe. Useful.
- the cyclic peroxide of the first aspect of the present invention and the oxidation reaction product of the first aspect of the present invention can act on, for example, ion channels (eg, TRPA1, etc.) related to itching, pain, etc.; etc. can be used.
- the uses of the cyclic peroxide of the first invention in the present invention and the oxidation reaction product of the first invention in the present invention are not limited to these, for example, as cosmetics, pharmaceuticals, foods, or supplements. Applicable to various uses.
- the salt when the substance can form a salt, the salt can also be used in the second aspect of the present invention unless otherwise specified.
- the salt may be an acid addition salt or a base addition salt.
- the acid forming the acid addition salt may be an inorganic acid or an organic acid
- the base forming the base addition salt may be an inorganic base or an organic base.
- inorganic acid examples include, but are not limited to, sulfuric acid, phosphoric acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, hypofluorous acid, hypochlorous acid, hypobromous acid, Hypoiodous acid, fluorous acid, chlorous acid, bromous acid, iodous acid, fluoric acid, chloric acid, bromic acid, iodic acid, perfluoric acid, perchloric acid, perbromic acid, periodic acid, etc. is given.
- the organic acid is also not particularly limited, but examples thereof include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid and acetic acid.
- the inorganic base include, but are not limited to, ammonium hydroxide, alkali metal hydroxide, alkaline earth metal hydroxide, carbonate and hydrogen carbonate. Examples include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydroxide and calcium carbonate.
- the organic base is also not particularly limited, and examples thereof include ethanolamine, triethylamine and tris(hydroxymethyl)aminomethane.
- the method for producing these salts is not particularly limited, either, and they can be produced, for example, by adding an acid or base as described above to the above compounds as appropriate by a known method.
- examples of the aromatic ring containing no heteroatom include benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, pyrene ring and the like.
- examples of heteroaromatic rings include pyridine rings and thiophene rings.
- the nitrogen-containing aromatic ring may or may not have a positive charge, for example.
- nitrogen-containing aromatic rings having no positive charge examples include pyrroline ring, pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring, quinoline ring, isoquinoline ring, acridine ring, 3,4-benzoquinoline ring, 5,6- benzoquinoline ring, 6,7-benzoquinoline ring, 7,8-benzoquinoline ring, 3,4-benzoisoquinoline ring, 5,6-benzoisoquinoline ring, 6,7-benzoisoquinoline ring, 7,8-benzoisoquinoline Rings, etc. can be mentioned.
- Positively charged nitrogen-containing aromatic rings include, for example, pyrrolinium ring, pyridinium ring, pyridazinium ring, pyrimidinium ring, pyrazinium ring, quinolinium ring, isoquinolinium ring, acridinium ring, 3,4-benzoquinolinium ring, 5,6 -benzoquinolinium ring, 6,7-benzoquinolinium ring, 7,8-benzoquinolinium ring, 3,4-benzoisoquinolinium ring, 5,6-benzoisoquinolinium ring, 6 ,7-benzoisoquinolinium ring, 7,8-benzoisoquinolinium ring, and the like.
- oxygen-containing aromatic ring or sulfur-containing aromatic ring for example, at least one of the carbon atoms or nitrogen atoms of the heteroatom-free aromatic ring or nitrogen-containing aromatic ring is replaced with at least one of an oxygen atom and a sulfur atom.
- Aromatic rings are mentioned.
- the "substituent” includes, for example, a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated fatty group hydrocarbon groups, aryl groups, heteroaryl groups, halogens, mercapto groups (-SH), alkylthio groups (-SR, R is an alkyl group) and the like.
- the chain substituent for example, a hydrocarbon group such as an alkyl group or an unsaturated aliphatic hydrocarbon group
- the number of carbon atoms is not particularly limited, but is, for example, 1-40, 1-32, 1-24, 1-18, 1-12, 1-6, or 1-2 (2 or more ).
- the number of ring members (the number of atoms constituting the ring) of the cyclic group is not particularly limited, but examples include 5 to 32, 5 to 24, It may be 6-18, 6-12, or 6-10.
- any isomer may be used unless otherwise specified.
- naphthyl group it may be a 1-naphthyl group or a 2-naphthyl group.
- whitening means prevention and/or improvement of pigmentation.
- the above-mentioned “whitening” includes, for example, spots, dullness, freckles, sunburn, skin inflammation, darkening due to skin irritation, melanin production or production enhancement, melanin overaccumulation, and/or melanin It means prevention and/or amelioration of hyperpigmentation symptoms caused by abnormal deposition, etc.; hyperpigmentation symptoms caused by diseases causing pigmentation, such as skin melanosis caused by drugs such as steroids;
- the second invention of the present invention will be described more specifically with examples.
- the second invention of the present invention is not limited by the following description.
- each description in the second aspect of the present invention can be used with each other unless otherwise specified.
- the expression “ ⁇ ” when used, it is used in the sense of including numerical values or physical values before and after it.
- the expression “A and/or B” includes “only A,” “only B,” and “both A and B.”
- a second aspect of the present invention is a whitening composition (hereinafter referred to as "composition") comprising glycerin and/or a glycerin derivative and a whitening ingredient, wherein the whitening ingredient is a cyclic peroxide as an active ingredient. or containing its salt.
- the composition of the second aspect of the present invention is characterized by containing the cyclic peroxide or salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide is presumed to promote the decomposition of melanin, as described later. Therefore, according to the composition of the second aspect of the present invention, for example, when applied to the skin, it is possible to obtain a whitening effect on the skin.
- the whitening composition of the second aspect of the present invention includes, for example, a composition for improving spots, dullness, or freckles, a composition for suppressing melanin production, a composition for decomposing melanin, a composition for promoting melanin excretion, and a skin It can also be referred to as a pigmentation reducing composition, a skin whitening composition and the like.
- the composition of the second aspect of the present invention contains a whitening ingredient as described above.
- the composition of the second aspect of the present invention may contain the cyclic peroxide as an active ingredient of the whitening component, or may contain an oxidation reaction product containing the cyclic peroxide as described later. or both.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing an alcohol, which will be described later.
- the content of the whitening component is, for example, 0.001-10 w/v%, 0.05-5 w/v%, or 0.01-1 w/v%.
- the content of the cyclic peroxide is, for example, 0.001 to 10 w/v%, 0.05 to 5 w/v%, or 0.01 to 1 w/v%. v%.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the heteroatom refers to an atom other than carbon and hydrogen, and may be one selected from the group consisting of, for example, an oxygen atom, a nitrogen atom, a sulfur atom, a selenium atom, a boron atom, and a silicon atom. .
- the substituent is not particularly limited, but may contain, for example, a hydroxyl group. is one selected from the group consisting of an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), and an alkylthio group (-SR, R is an alkyl group); may
- R 100 in the chemical formula (I) may be a cyclic structure having 5 to 10 ring members.
- the cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (II).
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, It may be a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, R is an alkyl group).
- the cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (1).
- the cyclic peroxide represented by the following chemical formula (1) corresponds to the case where all R 11 in the chemical formula (II) are hydrogen atoms.
- the method for producing the cyclic peroxide is not particularly limited, but for example, it can be produced by oxidizing alcohol by the method for producing the oxidation reaction product described later.
- the produced oxidation reaction product may be used as it is without purification, or the cyclic peroxide alone may be isolated and purified before use.
- the present inventors were the first to discover the phenomenon that a cyclic peroxide is obtained by oxidation of alcohol, for example, oxidation of glycerin by ozone. Although the mechanism by which the cyclic peroxide is obtained is unknown, it is speculated that, for example, by lengthening the reaction time of the oxidation reaction of alcohol as described later, a reaction product different from conventional reactions can be obtained.
- the cyclic peroxide can be isolated and formulated into a formulation because it is chemically more stable and easier to handle than radicals and the like.
- cyclic peroxides are substances that are industrially used due to their oxidizing ability.
- artemisinin which has a 7-membered ring (trioxolane) skeleton similar to the structure of the cyclic peroxide, is useful in antimalarial and won the Nobel Prize in 2015, and its derivatives are still being studied. .
- a highly safe and highly water-soluble cyclic peroxide and an oxidation reaction product are used, so that they can be suitably used in living organisms.
- melanin can be decomposed by the oxidizing ability of the cyclic peroxide, thereby obtaining a whitening effect.
- the whitening action can be evaluated according to Example 2 described later.
- the cyclic peroxide may be a salt or a solvate such as a hydrate.
- the description of the cyclic peroxides can be incorporated into the description of the salts of the cyclic peroxides or solvates thereof.
- the oxidation reaction product is, as described above, an oxidation reaction product characterized by containing a cyclic peroxide obtained by oxidizing an alcohol.
- the method for producing the oxidation reaction product is not limited to alcohol oxidation, and any substance produced by any production method may be used as long as it has the same structure.
- the method of oxidizing the alcohol is not particularly limited.
- the alcohol oxidation may be at least one of ozone oxidation and hydrogen peroxide oxidation.
- the method for producing the oxidation reaction product is not limited to ozone oxidation of alcohol and hydrogen peroxide oxidation, and substances produced by any production method may be used as long as they have the same structure.
- the oxidation reaction product may be, for example, a mixture containing multiple oxidation reaction products.
- the oxidation reaction product may have oxidizing ability, for example.
- the oxidation reaction product may have, for example, reducing ability.
- the oxidation reaction product may contain, for example, a substance having melanolytic activity, melanogenesis inhibitory activity, and/or melanin excretion promoting activity.
- the alcohol used as a raw material in the oxidation reaction product is not particularly limited.
- the alcohol may be a saturated alcohol.
- the alcohol may be a polyhydric alcohol.
- the alcohol may be at least one of glycerin and a glycerin derivative.
- the oxidation reaction product may include, for example, an oxidation reaction product obtained by bonding two or more molecules of the alcohol.
- the oxidation reaction product may contain, for example, the cyclic peroxide.
- the alcohol used as the raw material for the oxidation reaction product is not particularly limited, and may be, for example, a saturated alcohol or an unsaturated alcohol as described above. Further, the alcohol may be linear or branched, and may or may not contain a cyclic structure. Moreover, the alcohol may be, for example, a polyhydric alcohol or a monohydric alcohol. The valence of the polyhydric alcohol is also not particularly limited, and may be, for example, divalent, trivalent, or tetravalent. Examples of monohydric saturated alcohols include saturated alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms.
- the alcohol may be linear or branched, may or may not contain a cyclic structure, and specifically includes, for example, methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, sec-butyl alcohol, tert-butyl alcohol and the like.
- saturated polyhydric alcohols include saturated polyhydric alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms.
- the saturated polyhydric alcohol may be linear or branched, may or may not contain a cyclic structure, and specifically includes, for example, ethylene glycol (ethane-1,2-diol), Examples include propylene glycol (propane-1,2-diol), glycerin, glycerin derivatives and the like.
- the glycerin derivative is not particularly limited, but may be, for example, a glycerin polymer or a compound in which at least one hydrogen atom of glycerin is substituted with a substituent (eg, an alkyl group, etc.). Examples of the glycerin derivative include diglycerin and polyglycerin.
- the glycerin derivative may be an oxidized form of glycerin.
- the oxidation reaction product may be, for example, a substance having reducing ability, as described above.
- the oxidation reaction product may have a reducing ability derived from the functional group by having a reducing ability functional group.
- the oxidation reaction product may have a reducing ability by having an aldehyde group (formyl group), or by being a keto-enol tautomer, the keto form It may have a reducing ability derived from.
- the oxidation reaction product obtained in Example 2 which will be described later, contains an acetal structure in the skeleton as confirmed by NMR. It is thought that the color develops at
- the oxidation reaction product may be, for example, a substance obtained by bonding two or more molecules of the alcohol, as described above. Specifically, for example, it may have a structure in which two or more molecules of the alcohol are bonded together and further oxidized.
- the "binding" form of the two or more alcohol molecules is not particularly limited, and may be, for example, addition, condensation, or the like.
- the oxidation reaction product is chemically stable and easy to handle, for example, compared to radicals, etc., so it is possible to isolate and formulate it.
- the method for producing the oxidation reaction product is, as described above, a method for producing the oxidation reaction product including an alcohol oxidation step of oxidizing the alcohol.
- the method of oxidizing alcohol is not particularly limited.
- the alcohol may be oxidized by at least one of ozone oxidation and hydrogen peroxide oxidation.
- the reaction time of the alcohol oxidation step is not particularly limited.
- the reaction time in the alcohol oxidation step is, for example, 24 hours or more or 1 day or more, 48 hours or more or 2 days or more, 72 hours or more or 3 days or more, 120 hours or more or 5 days or more, or 168 hours or more or 7 days. or more.
- the upper limit of the reaction time in the alcohol oxidation step is not particularly limited, but may be, for example, 720 hours or less or 30 days or less, or 360 hours or less or 15 days or less.
- the reaction time of the alcohol oxidation step it is preferable to lengthen the reaction time of the alcohol oxidation step in order to obtain the reaction product containing the cyclic peroxide. For example, by lengthening the reaction time of the alcohol oxidation step, it is possible to produce the cyclic peroxide, which could not be obtained by the conventional ozone oxidation reaction of glycerin. In the method for producing the oxidation reaction product, it is preferable that the reaction time of the alcohol oxidation step is not too long for production efficiency.
- the method for producing the oxidation reaction product includes an alcohol oxidation step of oxidizing the alcohol.
- the oxidation reaction product is not limited to the substance produced by this production method, and may be a substance produced by any production method as long as it has the same structure.
- the method for producing the oxidation reaction product will be described in more detail with examples.
- the method for producing the oxidation reaction product is not limited to the following explanation.
- the method for producing an oxidation reaction product can be similarly carried out using other alcohols instead of glycerin.
- the method for producing an oxidation reaction product the method of oxidizing alcohol in the alcohol oxidation step is not particularly limited and is arbitrary, and is not limited to ozone oxidation.
- the oxidation method may be, for example, at least one of ozone oxidation and hydrogen peroxide oxidation.
- the concentration of each substance, reaction temperature, reaction time, and other reaction conditions can be changed as appropriate.
- the oxidation reaction product corresponds to, for example, the step of oxidizing glycerin by contacting glycerin and ozone, more specifically, mixing glycerin and ozone (the above “alcohol oxidation step”). ) can be produced by a production method including
- the step of oxidizing glycerin may be, for example, a step of bringing a glycerin solution and an ozone-containing gas into gas-liquid contact to oxidize glycerin.
- the glycerin solution preferably has a high concentration of glycerin.
- a high-concentration glycerin solution for example, a glycerin solution having a glycerin concentration of 75% or more can be used.
- a concentrated glycerin solution with a glycerin concentration of 98% by weight or more is more preferable, and a purified glycerin solution with a concentration of 98.5% by weight or more is even more preferable.
- the solvent for glycerin is not particularly limited, and is, for example, an aqueous solvent such as water.
- the ozone-containing gas preferably has a high concentration of ozone.
- the method for producing the gas having a high ozone concentration is not particularly limited, and for example, an ozone generator that generates ozone by silently discharging oxygen gas can be used.
- oxygen gas for example, a medical oxygen cylinder may be used, or oxygen gas produced by an oxygen generator may be used.
- the method of bringing the glycerin solution and the ozone-containing gas into gas-liquid contact is not particularly limited.
- the duration of aeration is not particularly limited, and, for example, a relatively longer period of time can produce an ozonated glycerin solution containing a higher concentration of the oxidation reaction product.
- the oxidation reaction product may be used as it is without fractionating it from the mixture after the reaction (for example, the ozone-treated glycerin solution), or it may be used after fractionating the oxidation reaction product from the mixture after the reaction.
- the method of separation is not particularly limited, the oxidation reaction product can be separated from the post-reaction mixture by, for example, chromatography such as preparative thin layer chromatography.
- an oxidation reaction product having oxidizing power can be produced by a very simple and easy method.
- the oxidation reaction product can generate, for example, hydrogen peroxide.
- the oxidation reaction product can generate, for example, 1 to 4000 ppm, 10 to 4000 ppm, or 100 to 4000 ppm of hydrogen peroxide per about 4000 ppm of the oxidation reaction product in terms of hydrogen peroxide concentration.
- the glycerin may be glycerin or the glycerin derivative described above.
- the cyclic peroxide can be stably retained by allowing the cyclic peroxide to coexist with the glycerin.
- the glycerin content is, for example, 0.1-100 w/v%, preferably 0.1-50 w/v%.
- composition of the second aspect of the present invention contains other whitening ingredients in addition to the cyclic peroxides and/or oxidation reaction products containing the cyclic peroxides as active ingredients of the whitening ingredients. It's okay.
- Other whitening ingredients include arbutin, tranexamic acid, and ascorbic acid or derivatives thereof.
- composition of the second invention in the present invention may contain other ingredients added to the dosage form applied to the skin.
- the other components include components added to external preparations for skin, components added to cosmetics (including quasi-drugs), and the like.
- Components added to the external preparation for skin include, for example, pharmaceutically acceptable carriers.
- examples of the other ingredients include ingredients that are added when applied to the skin or applied transdermally. Specific examples include aqueous solvents such as water, alcohols, moisturizers, oils, softeners, agents (emollients), surfactants (solubilizers, emulsifiers), salts, thickeners, pH adjusters, UV absorbers, drugs, buffers, colorants, preservatives, fragrances and the like.
- composition of the second aspect of the present invention is, for example, solid or liquid.
- forms of the composition of the second aspect of the present invention include lotion type; emulsion type such as emulsion and cream; oil type; gel type; ointment, pack, cleanser;
- composition of the second aspect of the present invention is humans or non-human animals.
- the composition of the second aspect of the present invention can be used, for example, on a site containing melanin of the subject, and a specific example thereof is the skin.
- the amount of the composition of the second invention to be used in the present invention is not particularly limited, and can be the amount normally used according to the dosage form of the composition of the second invention in the present invention.
- composition of the second aspect of the present invention can be suitably applied to external skin preparations such as cosmetics.
- the whitening agent of the second aspect of the present invention contains a cyclic peroxide or a salt thereof.
- the whitening agent of the second aspect of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other constitutions and conditions are not particularly limited.
- the cyclic peroxide is presumed to promote the decomposition of melanin. Therefore, according to the whitening agent of the second aspect of the present invention, for example, when applied to the skin, it is possible to obtain a whitening effect on the skin.
- the whitening agent of the second aspect of the present invention can also be said to be, for example, an agent for improving spots, dullness, or freckles, an agent for suppressing melanin production, an agent for decomposing melanin, an agent for reducing skin pigmentation, a whitening agent, and the like.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or a cyclic peroxide contained in the oxidation reaction product obtained by oxidizing the alcohol. It may be a peroxide.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- composition of the second aspect of the present invention can be used for the description of the dosage form and use of the cosmetic agent of the second aspect of the present invention.
- the whitening method of the second aspect of the present invention uses the whitening composition of the second aspect of the present invention and/or the cosmetic agent of the second aspect of the present invention.
- the whitening method of the second aspect of the present invention is characterized by using the whitening composition of the second aspect of the present invention and/or the cosmetic agent of the second aspect of the present invention.
- the steps and conditions are not particularly limited.
- the cyclic peroxide contained in the composition of the second aspect of the present invention and/or the whitening agent is presumed to promote the decomposition of melanin. Therefore, according to the whitening agent of the second aspect of the present invention, for example, when applied to the skin, it is possible to obtain a whitening effect on the skin.
- the whitening method of the second aspect of the present invention can be implemented, for example, by using the whitening composition and/or the cosmetic agent on the skin of the subject. More specifically, the whitening method of the second aspect of the present invention can be carried out by bringing the whitening composition and/or the cosmetic agent into contact with the skin of the subject.
- the second aspect of the present invention is the whitening composition of the second aspect of the present invention and/or the cosmetic agent of the second aspect of the present invention, or use thereof for whitening.
- the salt when the substance can form a salt, the salt can also be used in the third aspect of the present invention unless otherwise specified.
- the salt may be an acid addition salt or a base addition salt.
- the acid forming the acid addition salt may be an inorganic acid or an organic acid
- the base forming the base addition salt may be an inorganic base or an organic base.
- inorganic acid examples include, but are not limited to, sulfuric acid, phosphoric acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, hypofluorous acid, hypochlorous acid, hypobromous acid, Hypoiodous acid, fluorous acid, chlorous acid, bromous acid, iodous acid, fluoric acid, chloric acid, bromic acid, iodic acid, perfluoric acid, perchloric acid, perbromic acid, periodic acid, etc. is given.
- the organic acid is also not particularly limited, but examples thereof include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid and acetic acid.
- the inorganic base include, but are not limited to, ammonium hydroxide, alkali metal hydroxide, alkaline earth metal hydroxide, carbonate and hydrogen carbonate. Examples include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydroxide and calcium carbonate.
- the organic base is also not particularly limited, and examples thereof include ethanolamine, triethylamine and tris(hydroxymethyl)aminomethane.
- the method for producing these salts is not particularly limited, either, and they can be produced, for example, by adding an acid or base as described above to the above compounds as appropriate by a known method.
- examples of the aromatic ring containing no heteroatom include benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, pyrene ring and the like.
- examples of heteroaromatic rings include pyridine rings and thiophene rings.
- the nitrogen-containing aromatic ring may or may not have a positive charge, for example.
- nitrogen-containing aromatic rings having no positive charge examples include pyrroline ring, pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring, quinoline ring, isoquinoline ring, acridine ring, 3,4-benzoquinoline ring, 5,6- benzoquinoline ring, 6,7-benzoquinoline ring, 7,8-benzoquinoline ring, 3,4-benzoisoquinoline ring, 5,6-benzoisoquinoline ring, 6,7-benzoisoquinoline ring, 7,8-benzoisoquinoline Rings, etc. can be mentioned.
- Positively charged nitrogen-containing aromatic rings include, for example, pyrrolinium ring, pyridinium ring, pyridazinium ring, pyrimidinium ring, pyrazinium ring, quinolinium ring, isoquinolinium ring, acridinium ring, 3,4-benzoquinolinium ring, 5,6 -benzoquinolinium ring, 6,7-benzoquinolinium ring, 7,8-benzoquinolinium ring, 3,4-benzoisoquinolinium ring, 5,6-benzoisoquinolinium ring, 6 ,7-benzoisoquinolinium ring, 7,8-benzoisoquinolinium ring, and the like.
- oxygen-containing aromatic ring or sulfur-containing aromatic ring for example, at least one of the carbon atoms or nitrogen atoms of the heteroatom-free aromatic ring or nitrogen-containing aromatic ring is replaced with at least one of an oxygen atom and a sulfur atom.
- Aromatic rings are mentioned.
- the "substituent” includes, for example, a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated fatty group hydrocarbon groups, aryl groups, heteroaryl groups, halogens, mercapto groups (-SH), alkylthio groups (-SR, R is an alkyl group) and the like.
- the chain substituent e.g., alkyl group, hydrocarbon group such as unsaturated aliphatic hydrocarbon group
- the number of carbon atoms is not particularly limited, but is, for example, 1-40, 1-32, 1-24, 1-18, 1-12, 1-6, or 1-2 (2 or more ).
- the number of ring members (the number of atoms constituting the ring) of the cyclic group is not particularly limited, but examples include 5 to 32, 5 to 24, It may be 6-18, 6-12, or 6-10.
- any isomer may be used unless otherwise specified.
- naphthyl group it may be a 1-naphthyl group or a 2-naphthyl group.
- the skin barrier function means the function of preventing evaporation of moisture from the inside of the skin and/or the function of preventing substances from entering the skin from the outside.
- oxidative stress means stress caused by reactive oxygen species.
- specific examples of the oxidative stress include damage to biomolecules (eg, proteins, lipids, nucleic acids, etc.) and damage to intracellular organs due to the reactive oxygen species.
- gene expression induction may mean changing from a state in which there is no expression of the target gene to a state in which there is expression of the target gene. It may mean that the expression level is increased.
- treatment means therapeutic treatment and/or prophylactic treatment.
- treatment means treating, curing, preventing, arresting, ameliorating, ameliorating a disease, condition, or disorder, or halting, arresting, reducing, or delaying the progression of a disease, condition, or disorder. do.
- prevention means reducing the likelihood of developing a disease or condition or delaying the onset of a disease or condition.
- the “treatment” may be, for example, treatment of a patient who develops the target disease, or treatment of a model animal of the target disease.
- the third invention of the present invention will be described more specifically with examples.
- the third invention of the present invention is not limited by the following description.
- each description in the third aspect of the present invention can be used with each other unless otherwise specified.
- the expression “ ⁇ ” when used, it is used in the sense of including numerical values or physical values before and after it.
- the expression “A and/or B” includes “only A,” “only B,” and “both A and B.”
- composition for inducing expression of skin barrier function-related gene (hereinafter referred to as the "first composition") according to the third aspect of the present invention comprises glycerin and/or a glycerin derivative and a component for inducing the expression of a skin barrier function-related gene. and wherein the skin barrier function-related gene expression-inducing component contains a cyclic peroxide or a salt thereof as an active ingredient.
- the first composition of the third aspect of the present invention is characterized by containing the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide induces the expression of proteins important for skin barrier function, such as the profilaggrin gene, which is a gene related to skin barrier function. Therefore, according to the first composition of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain the effect of inducing the expression of the skin barrier function-related gene on the skin.
- the first composition of the third aspect of the present invention contains, as described above, a component for inducing the expression of skin barrier function-related genes.
- the first composition of the third aspect of the present invention may contain the cyclic peroxide as an active ingredient of the skin barrier function-associated gene expression-inducing ingredient. It may include oxidation reaction products containing substances, or both.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing an alcohol, which will be described later.
- the content of the component for inducing the expression of the skin barrier function-related gene may be an effective amount capable of inducing the expression of the skin barrier function-related gene. 0.001 to 10 w/v%, 0.05 to 5 w/v% or 0.01 to 1 w/v%.
- the content of the cyclic peroxide may be an effective amount capable of inducing the expression of the skin barrier function-related gene, for example, 0.001. ⁇ 10 w/v%, 0.05-5 w/v% or 0.01-1 w/v%.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the heteroatom refers to an atom other than carbon and hydrogen, and may be one selected from the group consisting of, for example, an oxygen atom, a nitrogen atom, a sulfur atom, a selenium atom, a boron atom, and a silicon atom. .
- the substituent is not particularly limited, but may contain, for example, a hydroxyl group. is one selected from the group consisting of an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), and an alkylthio group (-SR, R is an alkyl group); may
- R 100 in the chemical formula (I) may be a cyclic structure having 5 to 10 ring members.
- the cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (II).
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, It may be a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, R is an alkyl group).
- the cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (1).
- the cyclic peroxide represented by the following chemical formula (1) corresponds to the case where all R 11 in the chemical formula (II) are hydrogen atoms.
- the method for producing the cyclic peroxide is not particularly limited, but for example, it can be produced by oxidizing alcohol by the method for producing the oxidation reaction product described later.
- the produced oxidation reaction product may be used as it is without purification, or the cyclic peroxide alone may be isolated and purified before use.
- the present inventors were the first to discover the phenomenon that a cyclic peroxide is obtained by oxidation of alcohol, for example, oxidation of glycerin by ozone. Although the mechanism by which the cyclic peroxide is obtained is unknown, it is speculated that, for example, by lengthening the reaction time of the oxidation reaction of alcohol as described later, a reaction product different from conventional reactions can be obtained.
- the cyclic peroxide can be isolated and formulated into a formulation because it is chemically more stable and easier to handle than radicals and the like.
- cyclic peroxides are substances that are industrially used due to their oxidizing ability.
- artemisinin which has a 7-membered ring (trioxolane) skeleton similar to the structure of the cyclic peroxide, is useful in antimalarial and won the Nobel Prize in 2015, and its derivatives are still being studied. .
- a highly safe and highly water-soluble cyclic peroxide and an oxidation reaction product are used, so that they can be suitably used for living organisms.
- the oxidizing ability of the cyclic peroxide provides the effect of inducing the expression of genes associated with skin barrier function.
- the effect of inducing the expression of the skin barrier function-related gene can be evaluated according to Example 3 described later.
- the cyclic peroxide may be a salt or a solvate such as a hydrate.
- the description of the cyclic peroxides can be incorporated into the description of the salts of the cyclic peroxides or solvates thereof.
- the oxidation reaction product is, as described above, an oxidation reaction product characterized by containing a cyclic peroxide obtained by oxidizing an alcohol.
- the method for producing the oxidation reaction product is not limited to alcohol oxidation, and any substance produced by any production method may be used as long as it has the same structure.
- the method of oxidizing the alcohol is not particularly limited.
- the alcohol oxidation may be at least one of ozone oxidation and hydrogen peroxide oxidation.
- the method for producing the oxidation reaction product is not limited to ozone oxidation of alcohol and hydrogen peroxide oxidation, and substances produced by any production method may be used as long as they have the same structure.
- the oxidation reaction product may be, for example, a mixture containing multiple oxidation reaction products.
- the oxidation reaction product may have oxidizing ability, for example.
- the oxidation reaction product may have, for example, reducing ability.
- the alcohol used as a raw material in the oxidation reaction product is not particularly limited.
- the alcohol may be a saturated alcohol.
- the alcohol may be a polyhydric alcohol.
- the alcohol may be at least one of glycerin and a glycerin derivative.
- the oxidation reaction product may include, for example, an oxidation reaction product obtained by bonding two or more molecules of the alcohol.
- the oxidation reaction product may contain, for example, the cyclic peroxide.
- the alcohol used as the raw material for the oxidation reaction product is not particularly limited, and may be, for example, a saturated alcohol or an unsaturated alcohol as described above. Further, the alcohol may be linear or branched, and may or may not contain a cyclic structure. Moreover, the alcohol may be, for example, a polyhydric alcohol or a monohydric alcohol. The valence of the polyhydric alcohol is also not particularly limited, and may be, for example, divalent, trivalent, or tetravalent. Examples of monohydric saturated alcohols include saturated alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms.
- the alcohol may be linear or branched, may or may not contain a cyclic structure, and specifically includes, for example, methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, sec-butyl alcohol, tert-butyl alcohol and the like.
- saturated polyhydric alcohols include saturated polyhydric alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms.
- the saturated polyhydric alcohol may be linear or branched, may or may not contain a cyclic structure, and specifically includes, for example, ethylene glycol (ethane-1,2-diol), Examples include propylene glycol (propane-1,2-diol), glycerin, glycerin derivatives and the like.
- the glycerin derivative is not particularly limited, but may be, for example, a glycerin polymer or a compound in which at least one hydrogen atom of glycerin is substituted with a substituent (eg, an alkyl group, etc.). Examples of the glycerin derivative include diglycerin and polyglycerin.
- the glycerin derivative may be an oxidized form of glycerin.
- the oxidation reaction product may be, for example, a substance having reducing ability, as described above.
- the oxidation reaction product may have a reducing ability derived from the functional group by having a reducing ability functional group.
- the oxidation reaction product may have a reducing ability by having an aldehyde group (formyl group), or by being a keto-enol tautomer, the keto form It may have a reducing ability derived from.
- the oxidation reaction product obtained in Example 3, which will be described later contains an acetal structure in the skeleton as confirmed by NMR. It is thought that the color develops at
- the oxidation reaction product may be, for example, a substance obtained by bonding two or more molecules of the alcohol, as described above. Specifically, for example, it may have a structure in which two or more molecules of the alcohol are bonded together and further oxidized.
- the "binding" form of the two or more alcohol molecules is not particularly limited, and may be, for example, addition, condensation, or the like.
- the oxidation reaction product is chemically stable and easy to handle, for example, compared to radicals, etc., so it is possible to isolate and formulate it.
- the method for producing the oxidation reaction product is, as described above, a method for producing the oxidation reaction product including an alcohol oxidation step of oxidizing the alcohol.
- the method of oxidizing alcohol is not particularly limited.
- the alcohol may be oxidized by at least one of ozone oxidation and hydrogen peroxide oxidation.
- the reaction time of the alcohol oxidation step is not particularly limited.
- the reaction time in the alcohol oxidation step is, for example, 24 hours or more or 1 day or more, 48 hours or more or 2 days or more, 72 hours or more or 3 days or more, 120 hours or more or 5 days or more, or 168 hours or more or 7 days. or more.
- the upper limit of the reaction time in the alcohol oxidation step is not particularly limited, but may be, for example, 720 hours or less or 30 days or less, or 360 hours or less or 15 days or less.
- the reaction time of the alcohol oxidation step it is preferable to lengthen the reaction time of the alcohol oxidation step in order to obtain the reaction product containing the cyclic peroxide. For example, by lengthening the reaction time of the alcohol oxidation step, it is possible to produce the cyclic peroxide, which could not be obtained by the conventional ozone oxidation reaction of glycerin. In the method for producing the oxidation reaction product, it is preferable that the reaction time of the alcohol oxidation step is not too long for production efficiency.
- the method for producing the oxidation reaction product includes an alcohol oxidation step of oxidizing the alcohol.
- the oxidation reaction product is not limited to the substance produced by this production method, and may be a substance produced by any production method as long as it has the same structure.
- the method for producing the oxidation reaction product will be described in more detail with examples.
- the method for producing the oxidation reaction product is not limited to the following explanation.
- the method for producing an oxidation reaction product can be similarly carried out using other alcohols instead of glycerin.
- the method for producing an oxidation reaction product the method of oxidizing alcohol in the alcohol oxidation step is not particularly limited and is arbitrary, and is not limited to ozone oxidation.
- the oxidation method may be, for example, at least one of ozone oxidation and hydrogen peroxide oxidation.
- the concentration of each substance, reaction temperature, reaction time, and other reaction conditions can be changed as appropriate.
- the oxidation reaction product corresponds to, for example, the step of oxidizing glycerin by contacting glycerin and ozone, more specifically, mixing glycerin and ozone (the above “alcohol oxidation step”). ) can be produced by a production method including
- the step of oxidizing glycerin may be, for example, a step of bringing a glycerin solution and an ozone-containing gas into gas-liquid contact to oxidize glycerin.
- the glycerin solution preferably has a high concentration of glycerin.
- a high-concentration glycerin solution for example, a glycerin solution having a glycerin concentration of 75% or more can be used.
- a concentrated glycerin solution with a glycerin concentration of 98% by weight or more is more preferable, and a purified glycerin solution with a concentration of 98.5% by weight or more is even more preferable.
- the solvent for glycerin is not particularly limited, and is, for example, an aqueous solvent such as water.
- the ozone-containing gas preferably has a high concentration of ozone.
- the method for producing the gas having a high ozone concentration is not particularly limited, and for example, an ozone generator that generates ozone by silently discharging oxygen gas can be used.
- oxygen gas for example, a medical oxygen cylinder may be used, or oxygen gas produced by an oxygen generator may be used.
- the method of bringing the glycerin solution and the ozone-containing gas into gas-liquid contact is not particularly limited.
- the duration of aeration is not particularly limited, and, for example, a relatively longer period of time can produce an ozonated glycerin solution containing a higher concentration of the oxidation reaction product.
- the oxidation reaction product may be used as it is without fractionating it from the mixture after the reaction (for example, the ozone-treated glycerin solution), or it may be used after fractionating the oxidation reaction product from the mixture after the reaction.
- the method of separation is not particularly limited, the oxidation reaction product can be separated from the post-reaction mixture by, for example, chromatography such as preparative thin layer chromatography.
- an oxidation reaction product having oxidizing power can be produced by a very simple and easy method.
- the oxidation reaction product can generate, for example, hydrogen peroxide.
- the oxidation reaction product can generate, for example, 1 to 4000 ppm, 10 to 4000 ppm, or 100 to 4000 ppm of hydrogen peroxide per about 4000 ppm of the oxidation reaction product in terms of hydrogen peroxide concentration.
- the glycerin may be glycerin or the aforementioned glycerin derivative.
- the cyclic peroxide can be stably retained by allowing the cyclic peroxide to coexist with the glycerin.
- the glycerin content is, for example, 0.1-100 w/v%, preferably 0.1-50 w/v%.
- the skin barrier function-related gene may be any gene that encodes a protein that contributes to the skin barrier function.
- Examples of the skin barrier function-related gene include profilaggrin gene, involucrin gene, serine palmitoyltransferase gene and the like.
- the skin barrier function-related gene whose expression is induced by the first composition of the third aspect of the present invention may be, for example, one type or a plurality of types.
- the profilaggrin gene, the involucrin gene, and the serine palmitoyltransferase gene include, for example, polynucleotides consisting of nucleotide sequences specified by the following Genbank accession numbers as human genes. ⁇ Profilaggrin gene: NM_002016.2 ⁇ Involucrin gene: NM_005547.2 ⁇ Serine palmitoyltransferase gene: NM_004863.3
- the first composition of the third aspect of the present invention may contain other ingredients added to the dosage form applied to the skin.
- the other components include components added to external preparations for skin, components added to cosmetics (including quasi-drugs), and the like.
- Components added to the external preparation for skin include, for example, pharmaceutically acceptable carriers.
- examples of the other ingredients include ingredients that are added when applied to the skin or applied transdermally.
- Specific examples include aqueous solvents such as water, alcohols, moisturizers, oils, softeners, agents (emollients), surfactants (solubilizers, emulsifiers), salts, thickeners, pH adjusters, UV absorbers, drugs, buffers, colorants, preservatives, fragrances and the like.
- the first composition of the third aspect of the present invention is, for example, solid or liquid.
- Forms of the first composition of the third aspect of the present invention include, for example, lotion type; emulsifier type such as milky lotion and cream; oil type: gel type; ointment, pack, cleanser; .
- the subject of use of the first composition of the third invention in the present invention is a human or non-human animal.
- the first composition of the third aspect of the present invention can be used, for example, on the skin of the subject.
- the amount of the first composition of the third invention in the present invention is not particularly limited, and can be the amount normally used according to the dosage form of the first composition of the third invention in the present invention. .
- the first composition of the third aspect of the present invention can be suitably applied to external skin preparations such as cosmetics.
- the skin barrier function-related gene expression inducer (hereinafter referred to as "first inducer") of the third aspect of the present invention includes a cyclic peroxide or a salt thereof.
- the skin barrier function-related gene expression inducer of the third aspect of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide induces the expression of proteins important for skin barrier function, such as the profilaggrin gene, which is the skin barrier function-related gene. Therefore, according to the first inducer of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain the effect of inducing the expression of the skin barrier function-related gene on the skin.
- the content of the ingredient for inducing the expression of the skin barrier function-related gene may be an effective amount capable of inducing the expression of the skin barrier function-related gene. 0.001 to 10 w/v%, 0.05 to 5 w/v% or 0.01 to 1 w/v%.
- the content of the cyclic peroxide may be an effective amount capable of inducing the expression of the skin barrier function-related gene, for example, 0.001. ⁇ 10 w/v%, 0.05-5 w/v% or 0.01-1 w/v%.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or an oxidation reaction product obtained by oxidizing the alcohol described above. It may be a cyclic peroxide contained.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- a composition for improving skin barrier function according to a third aspect of the present invention (hereinafter referred to as "second composition") comprises glycerin and/or a glycerin derivative and a component for improving skin barrier function,
- the barrier function-improving ingredient contains a cyclic peroxide or a salt thereof as an active ingredient.
- the second composition of the third aspect of the present invention is characterized by containing the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide induces the expression of proteins important for skin barrier function, such as the profilaggrin gene, which is a gene related to skin barrier function. Therefore, according to the first composition of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain the effect of inducing the expression of the skin barrier function-related gene on the skin. It can improve the barrier function.
- the content of the skin barrier function-improving component may be an effective amount capable of improving the skin barrier function, for example, 0.001 to 10 w/ v %, 0.05-5 w/v % or 0.01-1 w/v %.
- the content of the cyclic peroxide may be an effective amount capable of improving the skin barrier function, for example, 0.001 to 10 w/w/ v %, 0.05-5 w/v % or 0.01-1 w/v %.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or an oxidation reaction product obtained by oxidizing the alcohol described above. It may be a cyclic peroxide contained.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the skin barrier function can be improved. Therefore, the second composition of the third aspect of the present invention can be suitably used for treating atopic dermatitis, psoriasis vulgaris, and the like, for which the skin barrier function is lowered.
- the skin barrier function improving agent (hereinafter referred to as "improving agent") of the third aspect of the present invention comprises a cyclic peroxide or a salt thereof.
- the skin barrier function-improving agent of the third aspect of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide induces the expression of proteins important for skin barrier function, such as the profilaggrin gene, which is the skin barrier function-related gene. Therefore, according to the improving agent of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain an effect of inducing the expression of the skin barrier function-related gene on the skin, thereby improving the skin barrier function. It can be improved.
- the content of the skin barrier function improving component may be an effective amount capable of improving the skin barrier function, for example 0.001 to 10 w/v%, 0.05 to 5 w/v% or 0.01 to 1 w/v%.
- the content of the cyclic peroxide may be an effective amount capable of improving the skin barrier function, for example 0.001 to 10 w/v%, 0.05 to 5 w/v% or 0.01 to 1 w/v%.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or a cyclic peroxide contained in the oxidation reaction product obtained by oxidizing the alcohol. It may be a peroxide.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- a composition for inducing the expression of an antioxidant stress response gene according to the third aspect of the present invention (hereinafter referred to as the "third composition") comprises glycerin and/or a glycerin derivative and an antioxidant stress response gene expression-inducing component. and wherein the antioxidant stress response gene expression-inducing component contains a cyclic peroxide or a salt thereof as an active ingredient.
- the third composition of the third aspect of the present invention is characterized by containing the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide induces the expression of proteins important for antioxidant stress response, such as heme oxygenase 1 gene and NAD(P)H quinone oxidoreductase 1 gene, which are antioxidant stress response genes. . Therefore, according to the third composition of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain the effect of inducing the expression of the anti-oxidative stress response gene on the skin. It can improve oxidative stress response.
- the content of the antioxidant stress response gene expression-inducing component may be an effective amount capable of inducing the expression of the antioxidant stress response gene. 0.001 to 10 w/v%, 0.05 to 5 w/v% or 0.01 to 1 w/v%. Further, in the third composition of the third aspect of the present invention, the content of the cyclic peroxide may be an effective amount capable of inducing the expression of the antioxidant stress response gene, for example, 0.001 ⁇ 10 w/v%, 0.05-5 w/v% or 0.01-1 w/v%.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or an oxidation reaction product obtained by oxidizing the alcohol described above. It may be a cyclic peroxide contained.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the antioxidant stress response gene may be any gene that encodes a protein that contributes to oxidative stress response.
- the antioxidant stress response gene includes, for example, heme oxygenase 1 (HO-1) gene, NAD(P)H quinone oxidoreductase 1 (NAD(P)H quinone oxidoreductase 1, NQO-1) gene, and / Or a glutathione gene and the like.
- the antioxidant stress response gene whose expression is induced by the third composition of the third aspect of the present invention may be, for example, one type or a plurality of types.
- the heme oxygenase 1 gene and the NAD(P)H quinone oxidoreductase 1 gene include, for example, polynucleotides consisting of nucleotide sequences specified by the following Genbank accession numbers as human genes. ⁇ Heme oxygenase 1 gene: NM_002133.3 ⁇ NAD(P)H quinone oxidoreductase 1 gene: NM_000903.3
- the third composition of the third aspect of the present invention antioxidative stress response can be improved. Therefore, the third composition of the third aspect of the present invention can be suitably used, for example, for treatment of atopic dermatitis or the like in which the antioxidant stress response is reduced.
- the antioxidant stress response gene expression inducer of the third aspect of the present invention (hereinafter referred to as "fourth inducer”) comprises a cyclic peroxide or a salt thereof.
- the antioxidant stress response gene expression inducer of the third aspect of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide induces expression of proteins important for antioxidant stress response, such as heme oxygenase 1 gene and NAD(P)H quinone oxidoreductase 1 gene, which are antioxidant stress response genes. do. Therefore, according to the third inducer of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain the effect of inducing the expression of the anti-oxidative stress response gene on the skin. It can improve oxidative stress response.
- the content of the antioxidant stress response gene expression-inducing component may be an effective amount capable of inducing the expression of the antioxidant stress response gene. 0.001 to 10 w/v%, 0.05 to 5 w/v% or 0.01 to 1 w/v%. Further, in the third inducer of the third aspect of the present invention, the content of the cyclic peroxide may be an effective amount capable of inducing the expression of the antioxidant stress response gene, for example, 0.001 ⁇ 10 w/v%, 0.05-5 w/v% or 0.01-1 w/v%.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or an oxidation reaction product obtained by oxidizing the alcohol described above. It may be a cyclic peroxide contained.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the description of the dosage form and use of the third inducer of the third invention the description of the first composition and the third composition of the third invention can be cited.
- the anti-inflammatory composition of the third aspect of the present invention (hereinafter referred to as "fourth composition”) comprises glycerin and/or a glycerin derivative and an anti-inflammatory ingredient, and the anti-inflammatory ingredient is , including cyclic peroxides or salts thereof.
- the fourth composition of the third aspect of the present invention is characterized by containing the cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide suppresses the production of IL-1 ⁇ and prostaglandin E2, which are anti-inflammatory cytokines, as described later. Therefore, according to the fourth composition of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain an anti-inflammatory effect on the skin.
- the content of the anti-inflammatory ingredient may be an effective amount capable of suppressing inflammation. ⁇ 5 w/v% or 0.01-1 w/v%.
- the content of the cyclic peroxide may be an effective amount capable of suppressing inflammation, for example, 0.001 to 10 w/v%, 0.05 to 5 w/v% or 0.01 to 1 w/v%.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or an oxidation reaction product obtained by oxidizing the alcohol described above. It may be a cyclic peroxide contained.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the fourth composition of the third aspect of the present invention suppresses the expression and/or production of the inflammatory cytokine, for example.
- the inflammatory cytokine includes IL-1 ⁇ . Therefore, the fourth composition of the third aspect of the present invention can also be said to be, for example, an IL-1 ⁇ gene expression suppression composition and/or an IL-1 ⁇ production suppression composition.
- the fourth composition of the third aspect of the present invention suppresses the production of chemical mediators that cause inflammation, for example. Examples of the chemical mediator include prostaglandin E2. Therefore, the fourth composition of the third aspect of the present invention can also be said to be, for example, a prostaglandin E2 production inhibitory composition.
- the composition of the fourth aspect of the third aspect of the present invention can be suitably used for treating inflammatory diseases such as atopic dermatitis and psoriasis vulgaris.
- the fourth composition of the third aspect of the present invention can suitably suppress inflammation in epidermal keratinocytes present in the skin, for example. Therefore, the fourth composition of the third aspect of the present invention can also be said to be, for example, an anti-inflammatory composition in epidermal keratinocytes.
- the anti-inflammatory agent of the third aspect of the present invention contains cyclic peroxides or salts thereof.
- the antioxidant stress response gene expression inducer of the third aspect of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide suppresses the production of IL-1 ⁇ , an anti-inflammatory cytokine, as described above. Therefore, according to the anti-inflammatory agent of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain an anti-inflammatory effect on the skin.
- the content of the anti-inflammatory component may be an effective amount capable of suppressing inflammation. 5 w/v % or 0.01-1 w/v %.
- the content of the cyclic peroxide may be an effective amount capable of suppressing inflammation. 0.05-5 w/v % or 0.01-1 w/v %.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or is included in the oxidation reaction product obtained by oxidizing the alcohol described above. Cyclic peroxides may also be used.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the anti-inflammatory agent of the third aspect of the present invention suppresses the expression and/or production of the inflammatory cytokine, for example.
- the inflammatory cytokine includes IL-1 ⁇ . Therefore, the anti-inflammatory agent of the third aspect of the present invention can also be said to be, for example, an IL-1 ⁇ gene expression inhibitor and/or an IL-1 ⁇ production inhibitor.
- the anti-inflammatory agent of the third aspect of the present invention suppresses the production of chemical mediators that induce inflammation, for example. Examples of the chemical mediator include prostaglandin E2. Therefore, the anti-inflammatory agent of the third aspect of the present invention can also be said to be, for example, a prostaglandin E2 production inhibitor.
- the description of the dosage form and use of the anti-inflammatory agent of the third invention in the present invention the description of the first composition and the fourth composition of the third invention can be cited.
- the method for inducing the expression of a skin barrier function-related gene according to the third invention of the present invention (hereinafter also referred to as the "first induction method") is for inducing the expression of the skin barrier function-related gene according to the third invention of the present invention.
- the composition and/or the skin barrier function-related gene expression inducer of the third aspect of the present invention is used.
- the first induction method of the third invention of the present invention uses the first composition of the third invention of the present invention and/or the first inducer of the third invention of the present invention. is a feature, and other steps and conditions are not particularly limited.
- the cyclic peroxide contained in the first composition and/or the first inducer of the third aspect of the present invention is a skin barrier function-related gene, such as profilaggrin gene, which is important for skin barrier function. induces the expression of Therefore, according to the first induction method of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain the effect of inducing the expression of the skin barrier function-related gene on the skin.
- the first induction method of the third aspect of the present invention can be implemented, for example, by using the first composition and/or the first inducer on the skin of the subject. More specifically, the first induction method of the third aspect of the present invention can be carried out by contacting the skin of the subject with the first composition and/or the first inducer.
- the first induction method of the third aspect of the present invention is performed, for example, in vitro or in vivo .
- the method for improving skin barrier function of the third invention of the present invention (hereinafter also referred to as “improvement method") is the composition for improving skin barrier function of the third invention of the present invention and/or The agent for improving skin barrier function of the third invention is used.
- the improvement method of the third invention of the present invention is characterized by using the second composition of the third invention of the present invention and/or the improving agent of the third invention of the present invention, and other The steps and conditions of are not particularly limited.
- the cyclic peroxide contained in the second composition and/or improving agent of the third aspect of the present invention suppresses the expression of proteins important for skin barrier function, such as the profilaggrin gene, which is a gene related to skin barrier function. Induce.
- the improvement method of the third aspect of the present invention for example, when applied to the skin, it is possible to obtain the effect of inducing the expression of the skin barrier function-related gene with respect to the skin, thereby resulting in the skin barrier function. can be improved.
- the improvement method of the third aspect of the present invention can be implemented, for example, by using the second composition and/or the improving agent on the skin of the subject. More specifically, the improving method of the third aspect of the present invention can be carried out by contacting the subject's skin with the second composition and/or the improving agent.
- the improvement method of the third aspect of the present invention is carried out, for example, in vitro or in vivo .
- the method for inducing the expression of an antioxidant stress response gene according to the third invention of the present invention (hereinafter also referred to as the "third induction method") is a method for inducing expression of the antioxidant stress response gene according to the third invention of the present invention.
- the composition and/or the antioxidant stress response gene expression inducer of the third aspect of the present invention is used.
- the third induction method of the third invention of the present invention uses the third composition of the third invention of the present invention and/or the third inducer of the third invention of the present invention. is a feature, and other steps and conditions are not particularly limited.
- the cyclic peroxide contained in the third composition and/or the third inducer of the third aspect of the present invention is an antioxidant stress response gene, heme oxygenase 1 gene, NAD(P)H quinone oxide It induces the expression of proteins important for antioxidant stress response, such as the reductase 1 gene. Therefore, according to the third induction method of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain the effect of inducing the expression of the anti-oxidative stress response gene on the skin. It can improve oxidative stress response.
- the third induction method of the third aspect of the present invention can be implemented, for example, by using the third composition and/or the third inducer on the skin of the subject. More specifically, the third induction method of the third aspect of the present invention can be carried out by contacting the skin of the subject with the third composition and/or the third inducer.
- the third induction method of the third aspect of the present invention is performed, for example, in vitro or in vivo .
- the method for suppressing inflammation according to the third aspect of the present invention comprises the composition according to the fourth aspect of the third aspect of the present invention and/or the composition of the third aspect of the present invention.
- Use anti-inflammatory agents Use anti-inflammatory agents.
- the suppression method of the third aspect of the present invention is characterized by using the fourth composition of the third aspect of the present invention and/or the anti-inflammatory agent of the third aspect of the present invention, Other steps and conditions are not particularly limited.
- the cyclic peroxide contained in the fourth composition of the third aspect of the present invention and/or the anti-inflammatory agent suppresses the production of IL-1 ⁇ and the expression of prostaglandin E2, which are anti-inflammatory cytokines. Therefore, according to the suppression method of the third aspect of the present invention, for example, when applied to the skin, it is possible to obtain an anti-inflammatory effect on the skin.
- the suppression method of the third aspect of the present invention suppresses the expression and/or production of the inflammatory cytokine.
- the inflammatory cytokine includes IL-1 ⁇ . Therefore, the suppression method of the third aspect of the present invention can also be called, for example, a method for suppressing IL-1 ⁇ gene expression and/or a method for suppressing IL-1 ⁇ production.
- the suppression method of the third aspect of the present invention suppresses the production of chemical mediators that cause inflammation, for example. Examples of the chemical mediator include prostaglandin E2. Therefore, the suppression method of the third aspect of the present invention can also be said to be, for example, a method for suppressing the production of prostaglandin E2.
- the suppression method of the third aspect of the present invention can be implemented, for example, by using the fourth composition and/or the anti-inflammatory agent on the skin of the subject. More specifically, the suppression method of the third aspect of the present invention can be carried out by contacting the subject's skin with the fourth composition and/or the anti-inflammatory agent.
- the suppression method of the third aspect of the present invention is carried out, for example, in vitro or in vivo .
- the method for treating an inflammatory disease of the third invention of the present invention comprises administering to a subject the anti-inflammatory composition of the third invention of the present invention and/or the anti-inflammatory composition of the third invention of the present invention and an administration step of administering the anti-inflammatory agent of the invention of 3 above.
- the treatment method of the third invention of the present invention comprises the fourth composition of the third invention of the present invention and/or the anti-inflammatory agent of the third invention of the present invention (hereinafter also referred to as a "pharmaceutical”). is characterized by administering ), and other steps and conditions are not particularly limited.
- the treatment method according to the third aspect of the present invention uses the above medicine, so inflammation can be suppressed. Therefore, the treatment method of the third aspect of the present invention can treat inflammatory diseases.
- the treatment method of the third aspect of the present invention includes, for example, an administration step of administering the pharmaceutical, specifically, an administration step of administering the pharmaceutical to a subject.
- the medicament may be administered in vitro or in vivo .
- the administration subject and administration conditions of the pharmaceutical for example, the description of the administration subject and administration conditions in the first composition of the third aspect of the present invention can be used.
- Said subject is, for example, a subject for whom treatment is desired.
- the subject may be a patient suffering from the inflammatory disease, a patient predicted to suffer from the inflammatory disease, or a patient unknown to suffer from the inflammatory disease.
- the third invention of the present invention is the composition for inducing the expression of the skin barrier function-related gene of the third invention of the present invention and/or the composition of the third invention of the present invention for use in inducing the expression of the skin barrier function-related gene. It is the expression inducer of the skin barrier function-related gene of the invention or its use.
- the third aspect of the present invention is the composition for improving the skin barrier function of the third aspect of the present invention and/or the composition for improving the skin barrier function of the third aspect of the present invention, for use in improving the skin barrier function. remedies, or uses thereof.
- a third aspect of the present invention is a composition for inducing expression of an antioxidant stress response gene according to the third aspect of the present invention and/or a composition according to the third aspect of the present invention for use in inducing expression of an antioxidant stress response gene It is the expression inducer of the antioxidant stress response gene of the invention or its use.
- a third aspect of the present invention is the anti-inflammatory composition of the third aspect of the present invention and/or the anti-inflammatory agent of the third aspect of the present invention, or use thereof for suppressing inflammation.
- a third aspect of the present invention is the anti-inflammatory composition of the third aspect of the present invention and/or the anti-inflammatory agent of the third aspect of the present invention, or use thereof for treatment of inflammatory diseases. be.
- the salt when the substance can form a salt, the salt can also be used in the fourth aspect of the present invention unless otherwise specified.
- the salt may be an acid addition salt or a base addition salt.
- the acid forming the acid addition salt may be an inorganic acid or an organic acid
- the base forming the base addition salt may be an inorganic base or an organic base.
- inorganic acid examples include, but are not limited to, sulfuric acid, phosphoric acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, hypofluorous acid, hypochlorous acid, hypobromous acid, Hypoiodous acid, fluorous acid, chlorous acid, bromous acid, iodous acid, fluoric acid, chloric acid, bromic acid, iodic acid, perfluoric acid, perchloric acid, perbromic acid, periodic acid, etc. is given.
- the organic acid is also not particularly limited, but examples thereof include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid and acetic acid.
- the inorganic base include, but are not limited to, ammonium hydroxide, alkali metal hydroxide, alkaline earth metal hydroxide, carbonate and hydrogen carbonate. Examples include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydroxide and calcium carbonate.
- the organic base is also not particularly limited, and examples thereof include ethanolamine, triethylamine and tris(hydroxymethyl)aminomethane.
- the method for producing these salts is not particularly limited, either, and they can be produced, for example, by adding an acid or base as described above to the above compounds as appropriate by a known method.
- examples of the aromatic ring containing no heteroatom include benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, and pyrene ring.
- examples of heteroaromatic rings include pyridine rings and thiophene rings.
- the nitrogen-containing aromatic ring may or may not have a positive charge, for example.
- nitrogen-containing aromatic rings having no positive charge examples include pyrroline ring, pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring, quinoline ring, isoquinoline ring, acridine ring, 3,4-benzoquinoline ring, 5,6- benzoquinoline ring, 6,7-benzoquinoline ring, 7,8-benzoquinoline ring, 3,4-benzoisoquinoline ring, 5,6-benzoisoquinoline ring, 6,7-benzoisoquinoline ring, 7,8-benzoisoquinoline Rings, etc. can be mentioned.
- Positively charged nitrogen-containing aromatic rings include, for example, pyrrolinium ring, pyridinium ring, pyridazinium ring, pyrimidinium ring, pyrazinium ring, quinolinium ring, isoquinolinium ring, acridinium ring, 3,4-benzoquinolinium ring, 5,6 -benzoquinolinium ring, 6,7-benzoquinolinium ring, 7,8-benzoquinolinium ring, 3,4-benzoisoquinolinium ring, 5,6-benzoisoquinolinium ring, 6 ,7-benzoisoquinolinium ring, 7,8-benzoisoquinolinium ring, and the like.
- oxygen-containing aromatic ring or sulfur-containing aromatic ring for example, at least one of the carbon atoms or nitrogen atoms of the heteroatom-free aromatic ring or nitrogen-containing aromatic ring is replaced with at least one of an oxygen atom and a sulfur atom.
- Aromatic rings are mentioned.
- the "substituent” includes, for example, a hydroxyl group (-OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, an unsaturated fatty group hydrocarbon groups, aryl groups, heteroaryl groups, halogens, mercapto groups (-SH), alkylthio groups (-SR, R is an alkyl group) and the like.
- the chain substituent e.g., alkyl group, hydrocarbon group such as unsaturated aliphatic hydrocarbon group
- the number of carbon atoms is not particularly limited, but is, for example, 1-40, 1-32, 1-24, 1-18, 1-12, 1-6, or 1-2 (2 or more ).
- the number of ring members (the number of atoms constituting the ring) of the cyclic group is not particularly limited, but examples include 5 to 32, 5 to 24, It may be 6-18, 6-12, or 6-10.
- any isomer may be used unless otherwise specified.
- naphthyl group it may be a 1-naphthyl group or a 2-naphthyl group.
- protein or “polypeptide” means a polymer composed of unmodified amino acids (natural amino acids), modified amino acids, and/or artificial amino acids.
- Said polypeptide is, for example, a peptide having a length of 10 amino acids or more.
- glycosation means that proteins, polypeptides and/or amino acids are modified with sugars.
- sugars include reducing sugars such as glucose, fructose and lactose.
- saccharification reaction means a condensation reaction (aminocarbonylation reaction) between an amino group-containing compound and a carbonyl group-containing compound.
- amino group-containing compound include proteins, polypeptides, and amino acids.
- carbonyl group-containing compound include reducing sugars.
- the saccharification reaction can also be called, for example, the Maillard reaction.
- saccharification reaction product means a substance produced by a saccharification reaction.
- the saccharification reaction product include intermediate products and final products produced in the saccharification reaction.
- the glycation reaction product include proteins or polypeptides containing the AGEs; proteins or polypeptides having a crosslinked structure by AGEs; glycated proteins produced by the glycation reaction;
- the intermediate reaction products include, for example, substances during the saccharification reaction, and specific examples thereof include glyoxal, methylglyoxal and 3-deoxyglucosone.
- the AGEs include, for example, pentosidine, crossrin, pyropyridine, pyraline, carboxymethyllysine (CML), carboxyethyllysine (CEL), carboxyethyllysine, carboxymethylarginine (CMA), argupyrimidine, imidazolone compounds, glyoxal-lysine dimer ( GOLD) and methyl glyoxal-lysine dimer (MOLD).
- CML carboxymethyllysine
- CEL carboxyethyllysine
- CMA carboxymethylarginine
- imidazolone compounds imidazolone compounds
- GOLD glyoxal-lysine dimer
- MOLD methyl glyoxal-lysine dimer
- the fourth invention of the present invention will be described more specifically with examples.
- the fourth invention of the present invention is not limited by the following description.
- each description in the fourth invention of the present invention can be used with each other unless otherwise specified.
- the expression “ ⁇ ” when used, it is used in the sense of including numerical values or physical values before and after it.
- the expression “A and/or B” includes “only A,” “only B,” and “both A and B.”
- the anti-glycation composition of the fourth aspect of the present invention contains glycerin and/or a glycerin derivative and an anti-glycation ingredient, and the anti-glycation ingredient contains a cyclic peroxide or a salt thereof as an active ingredient.
- the composition of the fourth aspect of the present invention is characterized by containing the cyclic peroxide or salt thereof, and other configurations and conditions are not particularly limited.
- the cyclic peroxide has the ability to decompose the crosslinked structure of AGEs, as described later. Therefore, according to the composition of the fourth aspect of the present invention, an anti-glycation effect can be obtained.
- composition of the fourth aspect of the present invention can decompose, for example, AGEs produced by the saccharification reaction, the composition for decomposing advanced glycation end products (AGEs), It can also be referred to as a composition for degrading a protein or polypeptide having a crosslinked structure.
- the composition of the fourth aspect of the present invention can repair proteins or polypeptides by, for example, removing the crosslinked structure of AGEs or AGEs in glycated proteins, a composition for repairing glycated proteins or glycated peptides You can also say.
- the composition of the fourth aspect of the present invention contains an anti-glycation ingredient as described above.
- the composition according to the fourth aspect of the present invention may contain the cyclic peroxide as an active ingredient of the anti-glycation ingredient, or, as described later, an oxidation reaction product containing the cyclic peroxide. You may include it, and you may include both.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or may be a cyclic peroxide contained in an oxidation reaction product obtained by oxidizing an alcohol, which will be described later.
- the content of the anti-glycation component may be an effective amount capable of anti-glycation, more specifically, an effective amount capable of decomposing AGEs. 0.001-10 w/v %, 0.05-5 w/v % or 0.01-1 w/v %.
- the content of the cyclic peroxide may be an effective amount capable of anti-glycation. ⁇ 5 w/v% or 0.01-1 w/v%.
- the anti-glycation component may exhibit anti-glycation activity by, for example, suppressing the formation of AGEs or the formation of crosslinked structures of AGEs by suppressing the saccharification reaction, or the AGEs produced by the saccharification reaction.
- anti-glycation activity may be exhibited, or both activities may be exhibited.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the heteroatom refers to an atom other than carbon and hydrogen, and may be one selected from the group consisting of, for example, an oxygen atom, a nitrogen atom, a sulfur atom, a selenium atom, a boron atom, and a silicon atom. .
- the substituent is not particularly limited, but may contain, for example, a hydroxyl group. is one selected from the group consisting of an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), and an alkylthio group (-SR, R is an alkyl group); may
- R 100 in the chemical formula (I) may be a cyclic structure having 5 to 10 ring members.
- the cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (II).
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, It may be a diazo group, an alkyl group, an unsaturated aliphatic hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, R is an alkyl group).
- the cyclic peroxide may be, for example, a cyclic peroxide represented by the following chemical formula (1).
- the cyclic peroxide represented by the following chemical formula (1) corresponds to the case where all R 11 in the chemical formula (II) are hydrogen atoms.
- the method for producing the cyclic peroxide is not particularly limited, but for example, it can be produced by oxidizing alcohol by the method for producing the oxidation reaction product described later.
- the produced oxidation reaction product may be used as it is without purification, or the cyclic peroxide alone may be isolated and purified before use.
- the present inventors were the first to discover the phenomenon that a cyclic peroxide is obtained by oxidation of alcohol, for example, oxidation of glycerin by ozone. Although the mechanism by which the cyclic peroxide is obtained is unknown, it is speculated that, for example, by lengthening the reaction time of the oxidation reaction of alcohol as described later, a reaction product different from conventional reactions can be obtained.
- the cyclic peroxide can be isolated and formulated into a formulation because it is chemically more stable and easier to handle than radicals and the like.
- cyclic peroxides are substances that are industrially used due to their oxidizing ability.
- artemisinin which has a 7-membered ring (trioxolane) skeleton similar to the structure of the cyclic peroxide, is useful in antimalarial and won the Nobel Prize in 2015, and its derivatives are still being studied. .
- a highly safe and highly water-soluble cyclic peroxide and an oxidation reaction product are used, so that they can be suitably used in a living body.
- the anti-glycation effect is obtained by the oxidizing ability of the cyclic peroxide.
- the anti-glycation action can be evaluated according to Example 4 described later.
- the cyclic peroxide may be a salt or a solvate such as a hydrate.
- the description of the cyclic peroxides can be incorporated into the description of the salts of the cyclic peroxides or solvates thereof.
- the oxidation reaction product is, as described above, an oxidation reaction product characterized by containing a cyclic peroxide obtained by oxidizing an alcohol.
- the method for producing the oxidation reaction product is not limited to alcohol oxidation, and any substance produced by any production method may be used as long as it has the same structure.
- the method of oxidizing the alcohol is not particularly limited.
- the alcohol oxidation may be at least one of ozone oxidation and hydrogen peroxide oxidation.
- the method for producing the oxidation reaction product is not limited to ozone oxidation of alcohol and hydrogen peroxide oxidation, and substances produced by any production method may be used as long as they have the same structure.
- the oxidation reaction product may be, for example, a mixture containing multiple oxidation reaction products.
- the oxidation reaction product may have oxidizing ability, for example.
- the oxidation reaction product may have, for example, reducing ability.
- the alcohol used as a raw material in the oxidation reaction product is not particularly limited.
- the alcohol may be a saturated alcohol.
- the alcohol may be a polyhydric alcohol.
- the alcohol may be at least one of glycerin and a glycerin derivative.
- the oxidation reaction product may include, for example, an oxidation reaction product obtained by bonding two or more molecules of the alcohol.
- the oxidation reaction product may contain, for example, the cyclic peroxide.
- the alcohol used as the raw material for the oxidation reaction product is not particularly limited, and may be, for example, a saturated alcohol or an unsaturated alcohol as described above. Further, the alcohol may be linear or branched, and may or may not contain a cyclic structure. Moreover, the alcohol may be, for example, a polyhydric alcohol or a monohydric alcohol. The valence of the polyhydric alcohol is also not particularly limited, and may be, for example, divalent, trivalent, or tetravalent. Examples of monohydric saturated alcohols include saturated alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms.
- the alcohol may be linear or branched, may or may not contain a cyclic structure, and specifically includes, for example, methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, sec-butyl alcohol, tert-butyl alcohol and the like.
- saturated polyhydric alcohols include saturated polyhydric alcohols having 1 to 40, 1 to 32, 1 to 24, 1 to 18, 1 to 12, 1 to 6, or 1 to 2 carbon atoms.
- the saturated polyhydric alcohol may be linear or branched, may or may not contain a cyclic structure, and specifically includes, for example, ethylene glycol (ethane-1,2-diol), Examples include propylene glycol (propane-1,2-diol), glycerin, glycerin derivatives and the like.
- the glycerin derivative is not particularly limited, but may be, for example, a glycerin polymer or a compound in which at least one hydrogen atom of glycerin is substituted with a substituent (eg, an alkyl group, etc.). Examples of the glycerin derivative include diglycerin and polyglycerin.
- the glycerin derivative may be an oxidized form of glycerin.
- the oxidation reaction product may be, for example, a substance having reducing ability, as described above.
- the oxidation reaction product may have a reducing ability derived from the functional group by having a reducing ability functional group.
- the oxidation reaction product may have a reducing ability by having an aldehyde group (formyl group), or by being a keto-enol tautomer, the keto form It may have a reducing ability derived from.
- the oxidation reaction product obtained in Example 4 which will be described later, contains an acetal structure in the skeleton as confirmed by NMR. It is thought that the color develops at
- the oxidation reaction product may be, for example, a substance obtained by bonding two or more molecules of the alcohol, as described above. Specifically, for example, it may have a structure in which two or more molecules of the alcohol are bonded together and further oxidized.
- the "binding" form of the two or more alcohol molecules is not particularly limited, and may be, for example, addition, condensation, or the like.
- the oxidation reaction product is chemically stable and easy to handle, for example, compared to radicals, etc., so it is possible to isolate and formulate it.
- the method for producing the oxidation reaction product is, as described above, a method for producing the oxidation reaction product including an alcohol oxidation step of oxidizing the alcohol.
- the method of oxidizing alcohol is not particularly limited.
- the alcohol may be oxidized by at least one of ozone oxidation and hydrogen peroxide oxidation.
- the reaction time of the alcohol oxidation step is not particularly limited.
- the reaction time in the alcohol oxidation step is, for example, 24 hours or more or 1 day or more, 48 hours or more or 2 days or more, 72 hours or more or 3 days or more, 120 hours or more or 5 days or more, or 168 hours or more or 7 days. or more.
- the upper limit of the reaction time in the alcohol oxidation step is not particularly limited, but may be, for example, 720 hours or less or 30 days or less, or 360 hours or less or 15 days or less.
- the reaction time of the alcohol oxidation step it is preferable to lengthen the reaction time of the alcohol oxidation step in order to obtain the reaction product containing the cyclic peroxide. For example, by lengthening the reaction time of the alcohol oxidation step, it is possible to produce the cyclic peroxide, which could not be obtained by the conventional ozone oxidation reaction of glycerin. In the method for producing the oxidation reaction product, it is preferable that the reaction time of the alcohol oxidation step is not too long for production efficiency.
- the method for producing the oxidation reaction product includes an alcohol oxidation step of oxidizing the alcohol.
- the oxidation reaction product is not limited to the substance produced by this production method, and may be a substance produced by any production method as long as it has the same structure.
- the method for producing the oxidation reaction product will be described in more detail with examples.
- the method for producing the oxidation reaction product is not limited to the following explanation.
- the method for producing an oxidation reaction product can be similarly carried out using other alcohols instead of glycerin.
- the method for producing an oxidation reaction product the method of oxidizing alcohol in the alcohol oxidation step is not particularly limited and is arbitrary, and is not limited to ozone oxidation.
- the oxidation method may be, for example, at least one of ozone oxidation and hydrogen peroxide oxidation.
- the concentration of each substance, reaction temperature, reaction time, and other reaction conditions can be changed as appropriate.
- the oxidation reaction product corresponds to, for example, the step of oxidizing glycerin by contacting glycerin and ozone, more specifically, mixing glycerin and ozone (the above “alcohol oxidation step”). ) can be produced by a production method including
- the step of oxidizing glycerin may be, for example, a step of bringing a glycerin solution and an ozone-containing gas into gas-liquid contact to oxidize glycerin.
- the glycerin solution preferably has a high concentration of glycerin.
- a high-concentration glycerin solution for example, a glycerin solution having a glycerin concentration of 75% or more can be used.
- a concentrated glycerin solution with a glycerin concentration of 98% by weight or more is more preferable, and a purified glycerin solution with a concentration of 98.5% by weight or more is even more preferable.
- the solvent for glycerin is not particularly limited, and is, for example, an aqueous solvent such as water.
- the ozone-containing gas preferably has a high concentration of ozone.
- the method for producing the gas having a high ozone concentration is not particularly limited, and for example, an ozone generator that generates ozone by silently discharging oxygen gas can be used.
- oxygen gas for example, a medical oxygen cylinder may be used, or oxygen gas produced by an oxygen generator may be used.
- the method of bringing the glycerin solution and the ozone-containing gas into gas-liquid contact is not particularly limited.
- the duration of aeration is not particularly limited, and, for example, a relatively longer period of time can produce an ozonated glycerin solution containing a higher concentration of the oxidation reaction product.
- the oxidation reaction product may be used as it is without fractionating it from the mixture after the reaction (for example, the ozone-treated glycerin solution), or it may be used after fractionating the oxidation reaction product from the mixture after the reaction.
- the method of separation is not particularly limited, the oxidation reaction product can be separated from the post-reaction mixture by, for example, chromatography such as preparative thin layer chromatography.
- an oxidation reaction product having oxidizing power can be produced by a very simple and easy method.
- the oxidation reaction product can generate, for example, hydrogen peroxide.
- the oxidation reaction product can generate, for example, 1 to 4000 ppm, 10 to 4000 ppm, or 100 to 4000 ppm of hydrogen peroxide per about 4000 ppm of the oxidation reaction product in terms of hydrogen peroxide concentration.
- the glycerin may be glycerin or the aforementioned glycerin derivative.
- the cyclic peroxide can be stably retained by allowing the cyclic peroxide to coexist with the glycerin.
- the glycerin content is, for example, 0.1-100 w/v%, preferably 0.1-50 w/v%.
- composition of the fourth aspect of the present invention may contain other ingredients added to the dosage form applied to the skin.
- the other components include components added to external preparations for skin, components added to cosmetics (including quasi-drugs), and the like.
- Components added to the external preparation for skin include, for example, pharmaceutically acceptable carriers.
- examples of the other ingredients include ingredients that are added when applied to the skin or applied transdermally.
- Specific examples include aqueous solvents such as water, alcohols, moisturizers, oils, softeners, agents (emollients), surfactants (solubilizers, emulsifiers), salts, thickeners, pH adjusters, UV absorbers, drugs, buffers, colorants, preservatives, fragrances and the like.
- composition of the fourth aspect of the present invention is, for example, solid or liquid.
- the form of the composition of the fourth aspect of the present invention includes, for example, lotion type; emulsion type such as emulsion and cream; oil type; gel type; ointment, pack, cleanser;
- the object of use of the composition of the fourth aspect of the present invention is humans or non-human animals.
- the composition of the fourth aspect of the present invention can be used, for example, on the skin of the subject.
- the amount of the composition of the fourth aspect of the present invention to be used is not particularly limited, and can be the amount normally used according to the dosage form of the composition of the fourth aspect of the present invention.
- composition of the fourth aspect of the present invention can be suitably applied to external skin preparations such as cosmetics.
- the anti-glycation agent of the fourth aspect of the present invention includes cyclic peroxides or salts thereof.
- the anti-glycation agent of the fourth aspect of the present invention is characterized by containing a cyclic peroxide or a salt thereof, and other constitutions and conditions are not particularly limited.
- the cyclic peroxide has the ability to decompose the crosslinked structure of AGEs, as described later. Therefore, according to the anti-glycation agent of the fourth aspect of the present invention, an anti-glycation effect can be obtained.
- the anti-glycation agent of the fourth aspect of the present invention can, for example, decompose AGEs generated by the saccharification reaction, so that the agent for decomposing advanced glycation end products (AGEs), the agent for decomposing glycation reaction products, and the crosslinked structure by the end saccharification product It can also be said to be a degrading agent for proteins or polypeptides possessed.
- the anti-glycation agent of the fourth aspect of the present invention is capable of repairing proteins or polypeptides by, for example, removing the crosslinked structure of AGEs or AGEs in glycated proteins, and is therefore called a glycated protein or glycated peptide repair agent. can also
- the content of the anti-glycation component may be an effective amount capable of anti-glycation, more specifically, an effective amount capable of decomposing AGEs. 0.001 to 10 w/v%, 0.05 to 5 w/v% or 0.01 to 1 w/v%.
- the content of the cyclic peroxide may be an effective amount capable of anti-glycation. 05-5 w/v% or 0.01-1 w/v%.
- the cyclic peroxide may be a compound represented by the following chemical formula (I), or is included in the oxidation reaction product obtained by oxidizing the alcohol described above. Cyclic peroxides may also be used.
- R 100 is a cyclic structure having 3 or more ring members, may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the description of the dosage form and use of the anti-glycation agent of the fourth aspect of the present invention the description of the composition of the fourth aspect of the present invention can be used.
- the anti-glycation method of the fourth aspect of the present invention uses the anti-glycation composition of the fourth aspect of the present invention and/or the anti-glycation agent of the fourth aspect of the present invention.
- the anti-glycation method of the fourth aspect of the present invention is characterized by using the composition of the fourth aspect of the present invention and/or the anti-glycation agent of the fourth aspect of the present invention, and other The steps and conditions are not particularly limited.
- the cyclic peroxide contained in the composition of the fourth aspect of the present invention and/or the anti-glycation agent has the ability to decompose the crosslinked structure of AGEs, as described later. Therefore, according to the anti-glycation method of the fourth aspect of the present invention, an anti-glycation effect can be obtained.
- the anti-glycation method of the fourth aspect of the present invention can be carried out, for example, by using the composition and/or the anti-glycation agent on the skin of the subject. More specifically, the anti-glycation method of the fourth aspect of the present invention can be carried out by contacting the skin of the subject with the composition and/or the anti-glycation agent.
- the anti-glycation method of the fourth aspect of the present invention is performed, for example, in vitro or in vivo .
- a fourth aspect of the present invention is the anti-glycation composition of the fourth aspect of the present invention and/or the anti-glycation agent of the fourth aspect of the present invention, or use thereof for use in anti-glycation.
- Example 1 An oxidation reaction product containing the cyclic peroxide of the first invention in the present invention was produced by ozone oxidation of glycerin. Furthermore, the oxidation ability and TRP channel activity of the produced oxidation reaction products were confirmed.
- This example corresponds to an example in which the cyclic peroxide of the first aspect of the present invention was produced and used, and also to an example in which the oxidation reaction product of the first aspect of the present invention was produced and used. This corresponds to the embodiment of the method for producing an oxidation reaction product according to the first aspect of the present invention.
- an oxidation reaction product containing a cyclic peroxide of the first aspect of the present invention Concentrated glycerin and ozone are brought into gas-liquid contact, and the oxidation of the first aspect of the present invention is performed as follows.
- An ozonated glycerin solution (ozone gel) containing the reaction product was prepared.
- the concentrated glycerin means glycerin having a concentration of 98% by weight or more of the Japanese Pharmacopoeia product.
- the oxidation reaction product of the first aspect of the present invention produced in this example contains the cyclic peroxide of the first aspect of the present invention, as will be described later.
- a Teflon (registered trademark) tank with a capacity of 50 L was used as the contact tank.
- An air diffuser was installed on the bottom of the tank so that ozone could be supplied into the tank in the form of fine bubbles.
- a silent discharge ozone generator capable of generating 100 g of ozone per hour was used using a high-concentration oxygen gas containing 90% by volume or more of high-concentration oxygen as a raw material.
- reaction mixture From the glycerin solution dissolved in ozone oxidant of glycerin produced in "(1) Production of oxidation reaction product containing cyclic peroxide of the first aspect of the present invention", glycerin is separated by a silica gel column. It was removed to obtain a reaction mixture containing the cyclic peroxide of the first aspect of the present invention (hereinafter sometimes referred to as "TLC 1 spot product").
- TLC 1 spot product a reaction mixture containing the cyclic peroxide of the first aspect of the present invention
- the cyclic peroxide of the first invention of the present invention was used as it was without fractionating from this TLC1 spot product, and the oxidizing ability and TRP channel activity of the cyclic peroxide of the first invention of the present invention were evaluated. It was confirmed.
- the NMR spectrum of the reaction mixture was measured at a temperature of 300 K (27° C.) using DMSO-d 6 as solvent.
- 1-1 to 1-6 show the spectral diagrams thereof.
- FIG. 1-1 is a 1 H NMR spectrum diagram.
- FIG. 1-2 is a 13 C NMR spectrum chart.
- 1-3 are 13 C DEPT135 NMR spectrum diagrams.
- 1-4 are COZY NMR spectrum diagrams.
- 1-5 are HSQC NMR spectrum diagrams.
- 1-6 are HMBC NMR spectrum diagrams. Since complex peaks were observed as shown in FIGS. 1-1 to 1-6, the TLC1 spot product was presumed to be a mixture of multiple types of substances.
- This TLC1 spot also contained m/z 198,203 components by LCMS.
- reaction mixture TLC 1 spot product
- acetonitrile a mixture of acetonitrile
- filtered through a membrane filter a membrane filter
- the resulting filtrate was subjected to LC measurement to determine the separation conditions. optimized.
- the resulting fraction was freeze-dried, and the dry matter of the fraction was subjected to microscopic LR measurement and various NMR measurements.
- the measurement equipment (analyzer) and measurement conditions are as follows.
- Figure 1-7 shows a total ion chromatogram ( ESI-negative mode).
- the vertical axis is intensity and the horizontal axis is retention time (minutes).
- the lower "synthetic-derived OG" is the chromatogram of the TLC 1-spot sample, and the upper is the blank (acetonitrile) chromatogram.
- the TLC 1-spot product components A to L were confirmed. When these components A to L were separated and the presence or absence of coloration was confirmed with potassium iodide starch test paper, component H exhibited the strongest coloration.
- Figures 1-8 also show the mass spectra of peaks F, G and H (F, G and H fractions) in Figures 1-7.
- Figure 1-9 shows the results of studies on improving separation (improving separation conditions) for HILIC (high performance liquid chromatography).
- the vertical axis represents intensity
- the horizontal axis represents retention time (minutes).
- the upper stage is the chromatogram before separation improvement (under the same conditions as in FIG. 1-8), and the lower stage is the chromatogram after separation improvement.
- peaks 1-8 were seen after improved separation. The molecular weight of each peak was confirmed to be the molecular weight shown in FIGS.
- Figure 1-10 shows the mass spectrum (after separation improvement) of peaks 1 to 3 in Figure 1-9.
- the mass spectrum of peak 1 is in the upper part
- peak 2 is in the middle part
- peak 3 is in the lower part.
- Figure 1-11 shows the mass spectrum (after separation improvement) of peaks 4 to 6 in Figure 1-9.
- the mass spectrum of peak 4 is shown in the upper row
- peak 5 is shown in the middle row
- peak 6 is shown in the lower row.
- Figure 1-12 shows the mass spectrum (after separation improvement) of peaks 7 to 8 in Figure 1-9.
- the mass spectrum of peak 7 is shown in the upper row and peak 8 is shown in the lower row.
- the vertical axis is intensity and the horizontal axis is Raman shift (1/cm).
- Methanol-d 4 CD 3 OD
- the upper spectrum diagram is an enlarged view of the vicinity of 3.4 to 4.9 ppm in the lower spectrum diagram.
- the peaks indicated by symbols A to F are respectively represented by the same symbols A to F in the following chemical formula (1) described in FIGS. 1-14.
- some glycerin which is the starting material, remained, and that peak was also detected.
- Methanol-d 4 CD 3 OD
- FIGS. were assigned to the peaks of the carbon atoms and the hydrogen atoms bonded to the carbon atoms.
- some glycerin, which is the starting material remained, and that peak was also detected.
- Figure 1-17 also shows the HILIC chromatogram of the TLC1 spot product and glyceraldehyde dimer under the HILIC (high performance liquid chromatography) conditions of Figure 1-9.
- the upper “synthetic-derived OG” is the HILIC chromatogram of the TLC1-spot product.
- the lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown, no glyceraldehyde dimers were detected under the HILIC conditions of FIGS. 1-9.
- Figure 1-18 also shows the HILIC chromatogram of the TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (High Performance Liquid Chromatography) conditions.
- 1-19 shows an enlarged view of a part of FIG. 1-18.
- the upper “synthetic-derived OG” is the HILIC chromatogram of the TLC1 spot product.
- the lower row is the HILIC chromatogram with glyceraldehyde dimer.
- separation of components from the TLC1 spot product could not be confirmed. This is probably because the retention force of the column was weak and the elution time of the TLC 1-spot product was fast.
- the retention time of the glyceraldehyde dimer was slightly different from that of the TLC1 spot product (synthetic-derived OG). From this, it is presumed that the TLC1 spot product did not contain glyceraldehyde dimer.
- the vertical axis is intensity and the horizontal axis is magnetic flux density (G). Water was used as the measurement solvent.
- DMPO spin trapping agent
- DMPO spin trapping agent
- Figure 1-22 shows the ESR spectrum diagram of peaks 1 to 8 in Figure 1-9. Water was used as the measurement solvent. The top is an ESR spectrum diagram of a blank (solvent only) for comparison. As shown in the figure, it was confirmed that any component of peaks 1 to 8 has radical activity.
- the graph in Figure 1-23 shows the results of measuring the activities of peaks 1 to 8 in Figure 1-9 by chemiluminescence.
- the vertical axis is the emission intensity (relative intensity) at all wavelengths.
- Numbers "1" to "8" on the horizontal axis indicate the respective fractions of peaks 1 to 8.
- the numbers below the numbers represent the molecular weight of each fraction as confirmed by mass spectroscopy. As shown in the figure, it was confirmed that components other than those with a molecular weight of 180, which exhibit activity by chemiluminescence, were produced.
- TLC1 spot product produced in "(1) Production of an oxidation reaction product containing a cyclic peroxide according to the first aspect of the present invention” is used as it is without fractionation (purification). was used to confirm TRP channel activity.
- G indicates glycerin that is not ozonated.
- OG indicates glycerin oxidized with ozone using an oxygen generator (ozonated glycerin).
- the ozone oxidation of glycerin using an oxygen generator was carried out by converting the air into high-concentration oxygen (oxygen concentration of 70% or more) with the oxygen generator and ozonating the oxygen through the ozone generator.
- a gas having an ozone concentration of about 37000 ppm was used, and conditions A below were used.
- "LOG” indicates a further oxidation of "OG”.
- Production of "LOG” by oxidation of "OG” was carried out under the following condition B using a gas with an ozone concentration of about 37000 ppm obtained by ozonating oxygen from an oxygen cylinder (oxygen concentration of 99% or more) through an ozone generator. That is, the following "LOG” is the dissolved ozone oxidant of glycerin at a final concentration of 4000 ppm, which was produced in the above "(1) Production of an oxidation reaction product containing a cyclic peroxide of the first aspect of the present invention".
- This ozonated glycerin solution was used as "OG”.
- Condition B Production of “LOG”
- the tank was charged with "OG” produced according to Condition A above.
- the gas with an ozone concentration of about 37,000 ppm was aerated through the "G” in the tank for about 7 days using an air diffuser to produce an ozone-treated glycerin solution with a hydrogen peroxide concentration of 2,000 ppm.
- This ozonated glycerin solution was used as "LOG”.
- Figures 1-24 show the effect of addition of G, OG, LOG and HOG on TRPM2 (expressing cells) and Vector (TRPM2 non-expressing cells).
- the graph on the left side of FIG. 1-24 is a graph of TRPM2 (expressing cells), and the graph on the right side is a graph of Vector (non-TRPM2-expressing cells).
- Each horizontal axis indicates time (seconds).
- the time of addition of G, OG, LOG and HOG is 120 seconds (2 minutes).
- G, OG, LOG and HOG were each used as a 10% by mass aqueous solution.
- the vertical axis indicates changes in intracellular Ca 2+ concentration.
- the lower graphs of Figures 1-24 show the net intracellular Ca 2+ increase. As shown, G, OG, and LOG had higher intracellular Ca 2+ increases than HOG, indicating higher TRP channel activity, and OG and LOG had higher TRP channel activity than G. was confirmed.
- FIG. 1-25 shows the results.
- the graph on the left side of FIG. 1-25 is the result of G, and the graph on the right side of FIG. 1-25 is the result of OG.
- Each horizontal axis indicates time (seconds).
- the vertical axis indicates changes in intracellular Ca 2+ concentration, respectively.
- the lower graph in FIG. 1-25 shows the correlation between the concentrations of G and OG (horizontal axis, mass %) and the net increase in intracellular Ca 2+ (vertical axis).
- G had higher TRP channel activity at high concentrations, but OG showed high TRP channel activity even at low concentrations.
- TRP channel activity against TRPM2 was confirmed under the same conditions as in FIG. Figure 1-26 shows the results.
- the horizontal axis indicates time (seconds).
- the vertical axis indicates changes in intracellular Ca 2+ concentration.
- FIG. 1-27 shows the results.
- the graph on the left side of FIG. 1-27 is the result of LOG, and the graph on the right side of FIG. 1-27 is the result of OG.
- Each horizontal axis indicates time (seconds).
- the vertical axis indicates changes in intracellular Ca 2+ concentration, respectively.
- the lower graph in FIG. 1-27 shows the net increase in intracellular Ca 2+ (vertical axis) with and without catalase (+) for LOG and OG.
- TRP channel activity for TRPM2 was confirmed under the same conditions as in FIG. 1-24 except that the concentration (mass %) of the aqueous solution was changed.
- the results are shown in Figure 1-28.
- the graph on the left side of FIG. 1-28 is the result of OG, and the graph on the right side of FIG. 1-28 is the result of LOG.
- Each horizontal axis indicates time (seconds).
- the vertical axis indicates changes in intracellular Ca 2+ concentration, respectively.
- the lower graph in FIG. 1-28 shows the correlation between the concentrations of G and OG (horizontal axis) and changes in intracellular Ca 2+ concentration (vertical axis).
- LOG showed high TRP channel activity even at 1000-fold dilution, but OG at the same concentration did not show TRP channel activity.
- TRP channels for TRPM2 were tested under the same conditions as in FIGS. Activity was confirmed and compared to when catalase and PJ34 were not added. The results are shown in Figure 1-29.
- the upper left graph in FIG. 1-29 shows the results of comparison with and without catalase.
- the lower left graph of FIG. 1-29 shows the results of comparison with and without the addition of PJ34.
- Each horizontal axis indicates time (seconds).
- the vertical axis indicates changes in intracellular Ca 2+ concentration, respectively.
- the upper right graph in FIG. 1-29 shows the net increase in intracellular Ca 2+ (vertical axis) with and without catalase (Control).
- PJ34 is a substance represented by the following chemical formula.
- TRP channel activity for TRPM2 was confirmed under the same conditions as in FIG. compared with the case of Figure 1-30 shows the results.
- the graph on the left side of FIG. 1-30 compares results with and without the addition of dipyridyl.
- Each horizontal axis indicates time (seconds).
- the vertical axis indicates changes in intracellular Ca 2+ concentration, respectively.
- the graph on the right side of FIG. 1-30 shows the net increase in intracellular Ca 2+ (vertical axis) with and without dipyridyl (Control). As shown in the figure, it was confirmed that the addition of dipyridyl deactivated the TRP channel activity.
- FIG. 1-31 shows the results.
- the upper left graph in FIG. 1-31 shows the results for TRPM1 HEK (expressing cells), and the right graph in FIG. 1-31 shows the results for HEK (expressing cells).
- Each horizontal axis indicates time (seconds).
- the vertical axis indicates changes in intracellular Ca 2+ concentration, respectively.
- LOG shows the correlation between the concentration of LOG (horizontal axis, mass %) and net increase in intracellular Ca 2+ (vertical axis). As shown, LOG showed TRP channel activity against TRPM1 HEK (expressing cells), but almost no TRP channel activity against HEK (expressing cells).
- the TLC1 spot product was further purified so that the component with a molecular weight of 180 was the main component.
- the components were used at various concentrations to verify TRP channel activity for TRPM2 (expressing cells) and TRPMA1 (expressing cells) in the same manner as in Figures 1-31.
- the results are shown in FIGS. 1-32 and 1-33.
- "F7" indicates a component obtained by purifying the TLC1 spot product described above so that the component with a molecular weight of 180 is the main component. As shown in FIGS. 1-32 and 1-33, F7 showed no TRP channel activity against TRPM2, but did show TRP channel activity against TRPA1 (expressing cells).
- an oxidative TRP channel active substance could be produced from glycerin, which is not an olefin but has no double bond, by a simple method by ozone oxidation.
- the TLC1 spot product was separated into peaks 1 to 8 in Fig. 1-9, and the TRP channel activity was confirmed in the same manner as the above-mentioned OG with the same concentration of glycerin solution.
- all of peaks 1 to 8 had TRP channel activity, confirming their oxidative power.
- the mixture, OG had stronger TRP channel activity than any of peaks 1 to 8, and therefore had stronger oxidizing power.
- the second aspect of the present invention is not limited by the following examples. Commercially available reagents were used according to their protocol unless otherwise indicated.
- Example 2 Ozone oxidation of glycerin produced oxidation reaction products containing the cyclic peroxides. Furthermore, the whitening action of the produced oxidation reaction product was confirmed.
- This example corresponds to the example in which the cyclic peroxide was produced and used, and also to the example in which the oxidation reaction product was produced and used. It corresponds also to an Example.
- oxidation reaction product containing cyclic peroxide Concentrated glycerin and ozone are brought into gas-liquid contact, and an ozone-treated glycerin solution (ozonized glycerin) containing the oxidation reaction product is produced as follows. manufactured.
- the concentrated glycerin means glycerin having a concentration of 98% by weight or more of the Japanese Pharmacopoeia product.
- the oxidation reaction product of the second aspect of the present invention produced in this example contains the cyclic peroxide of the second aspect of the present invention, as will be described later.
- a Teflon (registered trademark) tank with a capacity of 50 L was used as the contact tank.
- An air diffuser was installed on the bottom of the tank so that ozone could be supplied into the tank in the form of fine bubbles.
- a silent discharge ozone generator capable of generating 100 g of ozone per hour was used using a high-concentration oxygen gas containing 90% by volume or more of high-concentration oxygen as a raw material.
- Subjects were 48 healthy subjects (females aged 41 to 59). Each subject was fully explained in advance based on an explanatory document (including a consent form), and consent was obtained in writing.
- test sample of Example 2-1A the test sample of Example 2-1B, the test sample of Reference Example 2-1A, and the test sample of Reference Example 2-1B were prepared.
- test sample of Example 2-1A was prepared by adding an equivalent amount of water to the ozonized glycerin of Example 2(1) to make a 50% aqueous solution of ozonized glycerin, and further adding pentylene glycol. and xanthan gum were added.
- test product of Example 2-1B was prepared by adding 9 times as much water as the ozonized glycerin of Example 2(1) to make a 10% aqueous solution of ozonized glycerin, and further adding pentylene glycol and xanthan gum. , and sodium hyaluronate were added.
- the test product of Example 2-1A and the test product of Example 2-1B had a final concentration of ozone oxide in the ozonized glycerin obtained in Example 2(1) of 80 ppm or 800 ppm. became.
- the test sample of Reference Example 2-1A and the test sample of Reference Example 2-1B were prepared in the same manner except that the concentrated glycerin was used instead of the ozonized glycerin.
- each subject was divided into the following two groups (24 subjects in each group). After washing the face twice a day (morning and night), each subject took 2 pushes (approximately 1 ml) of each test article and applied them to the designated half of the face. From the start of the test until the end of the test, each subject should not change cosmetics (skin lotion, milky lotion, serum, cream, etc.) other than the test product, and should not use new facial products. not started. The confirmatory test was conducted from April to June under an environment in which melanin production occurs over time. After being reviewed and approved by an ethics review board, this study was conducted in compliance with the Declaration of Helsinki and the ethical guidelines for medical research involving humans. (Test group 1) Half face: test product of Example 2-1A Other half face: test product of Reference Example 2-1A (test group 2) Half face: test product of Example 2-1B Other half face: test product of Reference Example 2-1B
- melanin was measured 5 times on the spots on the left and right cheeks of each subject on the day of application of each test product (week 0) and on the 4th and 8th weeks after the start of application.
- the melanin measurements were performed using a Mexameter® MX18 (Courage+Khazaka electronic GmbH, Cologne, Germany). Next, the maximum and minimum values of the five measurements were removed. Then, the average value of the remaining three measurements was taken as the melanin measurement value of each subject.
- the amount of change in the melanin measurement value was measured based on the melanin measurement value at the start of the test. Statistical tests were performed using Student's t-test, and when p ⁇ 0.05, it was determined that there was a significant difference. These results are shown in FIGS. 2-1 and 2-2.
- FIG. 2-1 is a graph showing the results of melanin measurement values over time.
- (A) shows the results of Example 2-1A and Reference Example 2-1A
- (B) shows the results of Example 2-1B and Reference Example 2-1B.
- the horizontal axis indicates the number of weeks after the start of the test
- the vertical axis indicates the measured melanin value (Melanin index).
- FIG. 2-2 is a graph showing the amount of change in measured melanin values over time.
- (A) shows the results of Example 2-1A and Reference Example 2-1A
- (B) shows the results of Example 2-1B and Reference Example 2-1B.
- the horizontal axis indicates the number of weeks after the start of the test, and the vertical axis indicates the amount of change in measured melanin value ( ⁇ Melanin index).
- ⁇ Melanin index measured melanin value
- FIGS. 2-1 and 2-2 in the skin regions to which the test article of Example 2-1A and the test article of Example 2-1B were applied, respectively, the test article of Reference Example 2-1A and the skin area to which the test article of Reference Example 2-1B was applied, the melanin measurement value decreased, and the amount of reduction increased over time. From these results, it was found that the cyclic peroxide contained in the ozone oxidant has an activity to reduce the amount of melanin in the skin, that is, has a whitening effect.
- a compound with a molecular weight of 180 (chemical formula (1)), which will be described later, can be eliminated from the ozonated glycerin by heat-treating the ozonated glycerin. Therefore, when the change in measured melanin value was similarly examined using the ozonized glycerin after the heat treatment, the melanin measured value reduction activity disappeared. Therefore, it can be said that the compound having a molecular weight of 180 (chemical formula (1)) described later is the active ingredient for the whitening action. Moreover, since the compound with a molecular weight of 180 is a cyclic peroxide, it was presumed that it exhibits a whitening effect by decomposing melanin through its oxidizing ability.
- the NMR spectrum of the reaction mixture was measured at a temperature of 300 K (27° C.) using DMSO-d 6 as solvent.
- Figures 2-3 to 2-8 show their spectrum diagrams. 2-3 are 1 H NMR spectrum diagrams. 2-4 are 13 C NMR spectrum diagrams. 2-5 are 13 C DEPT135 NMR spectrum diagrams.
- Figures 2-6 are COZY NMR spectrum diagrams.
- 2-7 are HSQC NMR spectrum diagrams.
- 2-8 are HMBC NMR spectrum diagrams. Since complex peaks were observed as shown in FIGS. 2-3 to 2-8, the TLC1 spot product was presumed to be a mixture of multiple types of substances. This TLC1 spot also contained m/z 198,203 components by LCMS.
- reaction mixture TLC 1 spot product
- the measurement equipment (analyzer) and measurement conditions are as follows.
- Figure 2-9 shows a total ion chromatogram ( ESI-negative mode).
- the vertical axis is intensity and the horizontal axis is retention time (minutes).
- the lower “synthetic-derived OG” is the chromatogram of the TLC 1-spot sample, and the upper is the blank (acetonitrile) chromatogram.
- the TLC 1-spot product components A to L were confirmed. When these components A to L were separated and the presence or absence of coloration was confirmed with potassium iodide starch test paper, component H exhibited the strongest coloration.
- Figure 2-10 also shows the mass spectra of peaks F, G and H (F, G and H fractions) in Figure 2-9.
- FIG. 2-11 shows the results of studies on improving separation (improving separation conditions) for HILIC (High Performance Liquid Chromatography).
- the vertical axis represents intensity
- the horizontal axis represents retention time (minutes).
- the upper stage is the chromatogram before separation improvement (under the same conditions as in FIG. 2-10), and the lower stage is the chromatogram after separation improvement.
- peaks 1-8 were seen after improved separation. The molecular weight of each peak was confirmed to be the molecular weight shown in FIGS.
- Figure 2-12 shows the mass spectrum (after separation improvement) of peaks 1 to 3 in Figure 2-11.
- the mass spectrum of peak 1 is shown in the upper row
- peak 2 is shown in the middle row
- peak 3 is shown in the lower row.
- Figure 2-13 shows the mass spectrum (after separation improvement) of peaks 4 to 6 in Figure 2-11.
- the mass spectrum of peak 4 is shown in the upper row
- peak 5 is shown in the middle row
- peak 6 is shown in the lower row.
- Figure 2-14 shows the mass spectrum (after separation improvement) of peaks 7 to 8 in Figure 2-11.
- the upper stage is the mass spectrum of peak 7 and the lower stage is the mass spectrum of peak 8.
- FIG. As shown, both peaks 7 and 8 were confirmed to have Mw 256.
- the vertical axis is intensity and the horizontal axis is Raman shift (1/cm).
- Methanol-d 4 CD 3 OD
- the upper spectrum diagram is an enlarged view of the vicinity of 3.4 to 4.9 ppm in the lower spectrum diagram.
- the peaks indicated by symbols A to F are represented by the same symbols A to F in the following chemical formula (1) described in FIG. 2-16.
- some glycerin which is the starting material, remained, and that peak was also detected.
- Methanol-d 4 CD 3 OD
- the upper spectrum diagram is an enlarged view of the vicinity of 60 to 105 ppm in the lower spectrum diagram.
- the peaks indicated by symbols A to F are respectively represented by the same symbols A to F in the following chemical formula (1) described in FIG. 2-17. Assigned to the carbon atom peak.
- some glycerin which is the starting material, remained, and that peak was also detected.
- Methanol-d 4 CD 3 OD
- the peaks indicated by symbols A to F are represented by the same symbols A to F in the following chemical formula (1) described in FIG. 2-18. were assigned to the peaks of the carbon atoms and the hydrogen atoms bonded to the carbon atoms.
- some glycerin, which is the starting material remained, and that peak was also detected.
- Figure 2-19 also shows the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (High Performance Liquid Chromatography) conditions of Figure 2-11.
- the upper “synthetic-derived OG” is the HILIC chromatogram of the TLC1 spot product.
- the lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown, no glyceraldehyde dimers were detected under the HILIC conditions of Figures 2-11.
- Figure 2-20 also shows the HILIC chromatogram of the TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (High Performance Liquid Chromatography) conditions.
- 2-21 shows an enlarged view of a part of FIG. 2-20.
- the upper “synthetic-derived OG” is the HILIC chromatogram of the TLC1 spot product.
- the lower row is the HILIC chromatogram with glyceraldehyde dimer.
- separation of components from the TLC1 spot product could not be confirmed. This is probably because the retention force of the column was weak and the elution time of the TLC 1-spot product was fast.
- the retention time of the glyceraldehyde dimer was slightly different from that of the TLC1 spot product (synthetic-derived OG). From this, it is presumed that the TLC1 spot product did not contain glyceraldehyde dimer.
- the vertical axis is intensity and the horizontal axis is magnetic flux density (G). Water was used as the measurement solvent.
- DMPO spin trapping agent
- DMPO spin trapping agent
- FIG. 2-24 shows the ESR spectrum diagram of peaks 1 to 8 in Figure 2-11. Water was used as the measurement solvent. The top is an ESR spectrum diagram of a blank (solvent only) for comparison. As shown in the figure, it was confirmed that any component of peaks 1 to 8 has radical activity.
- the graph in Figure 2-25 shows the results of measuring the activities of peaks 1 to 8 in Figure 2-11 by chemiluminescence.
- the vertical axis is the emission intensity (relative intensity) at all wavelengths.
- Numbers "1" to "8" on the horizontal axis indicate the respective fractions of peaks 1 to 8.
- the numbers below the numbers represent the molecular weight of each fraction as confirmed by mass spectroscopy. As shown in the figure, it was confirmed that components other than those with a molecular weight of 180, which exhibit activity by chemiluminescence, were produced.
- Example 3 Next, Example 3 will be described.
- the third aspect of the present invention is not limited by the following examples. Commercially available reagents were used according to their protocol unless otherwise indicated.
- Example 3-1 Ozone oxidation of glycerin produced oxidation reaction products containing the cyclic peroxides. Furthermore, the effect of inducing the expression of skin barrier function-related genes of the produced oxidation reaction product was confirmed.
- This example corresponds to the example in which the cyclic peroxide was produced and used, and also to the example in which the oxidation reaction product was produced and used. It corresponds also to an Example.
- oxidation reaction product containing cyclic peroxide Concentrated glycerin and ozone are brought into gas-liquid contact, and an ozone-treated glycerin solution (ozonized glycerin) containing the oxidation reaction product is produced as follows. manufactured.
- the concentrated glycerin means glycerin having a concentration of 98% by weight or more of the Japanese Pharmacopoeia product.
- the oxidation reaction product of the third aspect of the present invention produced in this example contains the cyclic peroxide of the third aspect of the present invention, as will be described later.
- a Teflon (registered trademark) tank with a capacity of 50 L was used as the contact tank.
- An air diffuser was installed on the bottom of the tank so that ozone could be supplied into the tank in the form of fine bubbles.
- a silent discharge ozone generator capable of generating 100 g of ozone per hour was used using a high-concentration oxygen gas containing 90% by volume or more of high-concentration oxygen as a raw material.
- the medium in each well was KG2 medium (100 ⁇ l/well) containing the ozonated glycerol of Example 3-1 (1) at a predetermined concentration (1, 2, or 4 (v/v)%). and further cultured for 24 hours.
- the cells were washed with phosphate buffer (PBS(-)), and an RNA extraction kit (Ambion (registered trademark) Cells-to-CT (trademark) Kits, Thermo Co. (manufactured) to extract RNA.
- cDNA was synthesized from the obtained RNA by reverse transcription reaction.
- the mRNA expression levels of the profilaggrin gene, the involucrin gene, and the serine palmitoyltransferase gene were calculated using a real-time PCR reagent and a PCR device (StepOne (trademark) real-time PCR system, Applied Biosystems). ( ⁇ Ct method).
- the following primer set was used for amplification of the mRNA of each gene, and the expression level of each gene was calculated as a relative value of the expression level of the mRNA of the GAPDH gene.
- a comparative example was carried out in the same manner except that the concentrated glycerin was used instead of the ozonized glycerin.
- Fig. 3-1 is a graph showing the expression levels of skin barrier function-related genes.
- (A) shows the expression level of the profilaggrin gene
- (B) shows the expression level of the involucrin gene
- (C) shows the result of the serine palmitoyltransferase gene.
- the horizontal axis indicates the sample concentration
- the vertical axis indicates the relative expression level of each gene.
- the ozonated glycerin-treated group (OG) showed higher levels of profilaggrin gene, involucrin gene, and serine palmitoyltransferase than the comparative example (Glycerin).
- the ozonated glycerin can induce the expression of skin barrier function-related genes.
- the ozonated glycerin contained a compound represented by the chemical formula (1) described later. Therefore, it was shown that the compound of chemical formula (1) contained in the ozonated glycerin induces the expression of skin barrier function-related genes.
- cDNA was prepared in the same manner as in Example 3-1(2).
- the expression levels of the heme oxygenase 1 gene and NAD(P)H quinone oxidoreductase 1 gene mRNA were calculated in the same manner as in Example 3-1(2) ( ⁇ Ct method).
- the following primer sets were used for amplification of the mRNA of each gene, and the expression level of each gene was calculated as a relative value of the expression level of the mRNA of the GAPDH gene.
- a comparative example was carried out in the same manner except that the concentrated glycerin was used instead of the ozonized glycerin.
- ⁇ Primer set forward primer for heme oxygenase 1 gene (SEQ ID NO: 9) 5'-TTGCCAGTGCCCAAGTTC-3' Reverse primer (SEQ ID NO: 10) 5'-TCAGCAGCTCTCTGCAACTCC-3' ⁇ NAD(P)H quinone oxidoreductase 1 gene primer set forward primer (SEQ ID NO: 11) 5'-GTGGCAGTGGGCTCCATGTACTC-3' Reverse primer (SEQ ID NO: 12) 5'-GAGTGTGCCCAATGCTATATGTCAG-3'
- Fig. 3-2 is a graph showing the expression levels of antioxidant stress response genes.
- (A) shows the expression level of the heme oxygenase 1 gene
- (B) shows the expression level of the NAD(P)H quinone oxidoreductase 1 gene.
- the horizontal axis indicates the sample concentration
- the vertical axis indicates the relative expression level of each gene.
- the ozonated glycerin-treated group (OG) had higher levels of heme oxygenase 1 gene and NAD(P)H quinone compared to the comparative example treatment group (Glycerin).
- the expression level of the oxidoreductase 1 gene was increased. These results indicate that the ozonated glycerin can induce the expression of antioxidant stress response genes. As will be described later, when the components of the ozonated glycerin and the concentrated glycerin were compared, it was found that the ozonated glycerin contained a compound represented by the chemical formula (1) described later. Therefore, it was shown that the compound of chemical formula (1) contained in the ozonated glycerin induces the expression of antioxidant stress response genes.
- Example 3-1(2) the cells were cultured in the presence of KG2 medium containing a predetermined concentration of ozonated glycerin for 24 hours or 48 hours. After the culture, the medium in each well was removed. Next, 0.5% Triton (registered trademark) X-100 solution was added at 100 ⁇ l/well to lyse the cells in each well to prepare a cell lysate.
- Triton (registered trademark) X-100 solution was added at 100 ⁇ l/well to lyse the cells in each well to prepare a cell lysate.
- reaction solution 0.1 mol/l phosphate buffer containing 2 mmol/l NADPH, 0.12 units/ml glutathione reductase, and 0.5 mmol/l EDTA
- 25 ⁇ l of cell lysate 25 ⁇ l was added to each well, and absorbance (405 nm) was measured using an absorptiometer. The amount of glutathione was calculated from the measured absorbance, and the amount of glutathione was calculated relative to the total amount of protein used in the assay, and these results are shown in Figure 3-3.
- Figure 3-3 is a graph showing the amount of glutathione peptides.
- (A) shows the peptide expression level after 24 hours of culture
- (B) shows the peptide expression level after 48 hours of culture.
- the horizontal axis indicates the sample concentration
- the vertical axis indicates the relative peptide expression level of glutathione.
- the ozonated glycerin-treated group (OG) showed an increase in the expression level of glutathione peptide compared to the comparative treatment group (Glycerin).
- the ozonated glycerin contained a compound represented by the chemical formula (1) described later. Therefore, it was shown that the compound of chemical formula (1) contained in the ozonated glycerin induces the expression of glutathione, which is an antioxidant protein.
- Example 3-1(3) the cells were cultured in the presence of KG2 medium containing a predetermined concentration of ozonated glycerin for 24 hours or 48 hours. After the culture, the medium in each well was removed. Next, the medium was replaced with a medium containing 0.003% Neutral Red (NR: manufactured by Sigma-Aldrich) and cultured at 37°C for 2 hours.
- NR Neutral Red
- Fig. 3-4 is a graph showing cell viability.
- the horizontal axis indicates the sample concentration, and the vertical axis indicates the relative expression level of glutathione.
- the ozonated glycerin-treated group (OG) had the same cell viability as the comparative example-treated group (Glycerin).
- the assay medium containing the ozonated glycerin was removed with a cotton swab, and the stratum corneum surface was washed once with 500 ⁇ l of PBS(-).
- the stratum corneum surface was washed once with 500 ⁇ l of PBS(-).
- UVB 280-315 nm, 600 mJ/cm 2
- the three-dimensional cultured epidermis was transferred to a plate to which 500 ⁇ l of a new assay medium was added, and then cultured for 24 hours under the conditions of 37° C. and 5% CO 2 .
- IL-1 ⁇ Interleukin-1 ⁇
- PGE 2 Prostaglandin E2
- FIG. 3-5 is a graph showing IL-1 ⁇ production.
- FIGS. 3-6 are graphs showing the amount of prostaglandin E2 produced.
- the horizontal axis indicates UV treatment and sample type and concentration, and the vertical axis indicates IL-1 ⁇ production or PGE 2 production.
- the ozonated glycerin-treated group (OG) had lower levels of IL-1 ⁇ production and PGE 2 production than the control group (Glycerin). had decreased. From these results, it was found that the ozonated glycerin exhibits an anti-inflammatory effect.
- Example 3-2 It was confirmed that the active ingredient in the ozonated glycerin was a cyclic peroxide.
- Example 3-1 (1) Analysis of the reaction mixture
- the ozonated glycerin of Example 3-1 (1) was found in glycerin. No cyclic peroxides were extracted and analyzed. Glycerin is removed by a silica gel column from the glycerin solution containing the ozone oxidant of glycerin produced in "Example 3-1 (1) Production of oxidation reaction product containing the cyclic peroxide", and the cyclic peroxide is A containing reaction mixture (hereinafter sometimes referred to as “TLC1 spot product”) was obtained.
- TLC1 spot product A containing reaction mixture
- the NMR spectrum of the reaction mixture was measured at a temperature of 300 K (27° C.) using DMSO-d 6 as solvent.
- 3-7 to 3-12 show the spectral diagrams.
- 3-7 are 1 H NMR spectrum diagrams.
- 3-8 are 13 C NMR spectrum diagrams.
- 3-9 are 13 C DEPT135 NMR spectrum diagrams.
- 3-10 are COZY NMR spectrum diagrams.
- 3-11 are HSQC NMR spectrum diagrams.
- 3-12 are HMBC NMR spectrum diagrams. Since complex peaks were observed as shown in FIGS. 3-7 to 3-12, the TLC1 spot product was presumed to be a mixture of multiple types of substances. This TLC1 spot also contained m/z 198,203 components by LCMS.
- reaction mixture TLC 1 spot product
- acetonitrile a reaction mixture prepared (diluted) with acetonitrile to about 3% by mass, filtered through a membrane filter, and the resulting filtrate was subjected to LC measurement to determine the separation conditions. optimized.
- the resulting fraction was freeze-dried, and the dry matter of the fraction was subjected to microscopic LR measurement and various NMR measurements.
- the measurement equipment (analyzer) and measurement conditions are as follows.
- Figure 3-13 shows a total ion chromatogram ( ESI-negative mode).
- the vertical axis is intensity and the horizontal axis is retention time (minutes).
- the lower "synthetic-derived OG" is the chromatogram of the TLC 1-spot sample, and the upper is the blank (acetonitrile) chromatogram.
- components A to L were confirmed. When these components A to L were separated and the presence or absence of coloration was confirmed with potassium iodide starch test paper, component H exhibited the strongest coloration.
- Figure 3-14 also shows the mass spectra of peaks F, G and H (F, G and H fractions) in Figure 3-13.
- Figure 3-15 shows the results of a study on improving separation (improvement of separation conditions) of HILIC (High Performance Liquid Chromatography).
- the vertical axis represents intensity
- the horizontal axis represents retention time (minutes).
- the upper stage is the chromatogram before separation improvement (under the same conditions as in FIG. 3-14), and the lower stage is the chromatogram after separation improvement.
- peaks 1-8 were seen after improved separation. The molecular weight of each peak was confirmed to be the molecular weight shown in FIGS.
- Figure 3-16 shows the mass spectra (after separation improvement) of peaks 1 to 3 in Figure 3-15.
- the mass spectrum of peak 1 is in the upper part
- peak 2 is in the middle part
- peak 3 is in the lower part.
- Figure 3-17 shows the mass spectrum (after separation improvement) of peaks 4 to 6 in Figure 3-15.
- the mass spectrum of peak 4 is shown in the upper row
- peak 5 is shown in the middle row
- peak 6 is shown in the lower row.
- Figure 3-18 shows the mass spectrum (after separation improvement) of peaks 7 to 8 in Figure 3-15.
- the mass spectrum of peak 7 is shown in the upper row and peak 8 is shown in the lower row.
- the vertical axis is intensity and the horizontal axis is Raman shift (1/cm).
- Methanol-d 4 CD 3 OD
- the upper spectrum diagram is an enlarged view of the vicinity of 3.4 to 4.9 ppm in the lower spectrum diagram.
- the peaks indicated by symbols A to F are respectively represented by the same symbols A to F in the following chemical formula (1) described in FIG. 3-20.
- some glycerin which is the starting material, remained, and that peak was also detected.
- Methanol-d 4 CD 3 OD
- the upper spectrum diagram is an enlarged view of the vicinity of 60 to 105 ppm in the lower spectrum diagram.
- the peaks indicated by symbols A to F are respectively represented by the same symbols A to F in the following chemical formula (1) described in FIG. 3-21. Assigned to the carbon atom peak.
- some glycerin which is the starting material, remained, and that peak was also detected.
- Methanol-d 4 CD 3 OD
- the peaks indicated by symbols A to F are represented by the same symbols A to F in the following chemical formula (1) described in FIG. were assigned to the carbon atoms and the hydrogen atoms bonded to the carbon atoms.
- some glycerin, which is the starting material remained, and that peak was also detected.
- Figure 3-23 also shows the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (High Performance Liquid Chromatography) conditions of Figure 3-15.
- the upper “synthetic-derived OG” is the HILIC chromatogram of the TLC1-spot product.
- the lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown, no glyceraldehyde dimer was detected under the HILIC conditions of FIGS. 3-23.
- Figure 3-24 also shows the HILIC chromatogram of the TLC1 spot product and glyceraldehyde dimer under reversed-phase HILIC (High Performance Liquid Chromatography) conditions.
- 3-25 shows an enlarged view of part of FIG. 3-24.
- the upper “synthetic-derived OG” is the HILIC chromatogram of the TLC1 spot product.
- the lower row is the HILIC chromatogram with glyceraldehyde dimer.
- separation of components from the TLC1 spot product could not be confirmed. This is probably because the retention force of the column was weak and the elution time of the TLC 1-spot product was fast.
- the retention time of the glyceraldehyde dimer was slightly different from that of the TLC1 spot product (synthetic-derived OG). From this, it is presumed that the TLC1 spot product did not contain glyceraldehyde dimer.
- the vertical axis is intensity and the horizontal axis is magnetic flux density (G). Water was used as the measurement solvent.
- DMPO spin trapping agent
- DMPO spin trapping agent
- Figure 3-28 shows the ESR spectrum diagram of peaks 1 to 8 in Figure 3-15. Water was used as the measurement solvent. The top is an ESR spectrum diagram of a blank (solvent only) for comparison. As shown in the figure, it was confirmed that any component of peaks 1 to 8 has radical activity.
- the graph in Figure 3-29 shows the results of measuring the activities of peaks 1 to 8 in Figure 3-15 by chemiluminescence.
- the vertical axis is the emission intensity (relative intensity) at all wavelengths.
- Numbers "1" to "8" on the horizontal axis indicate the respective fractions of peaks 1 to 8.
- the numbers below the numbers represent the molecular weight of each fraction as confirmed by mass spectroscopy. As shown in the figure, it was confirmed that components other than those with a molecular weight of 180, which exhibit activity by chemiluminescence, were produced.
- Example 4-1 Ozone oxidation of glycerin produced oxidation reaction products containing the cyclic peroxides. Furthermore, the anti-glycation action of the produced oxidation reaction product was confirmed.
- This example corresponds to the example in which the cyclic peroxide was produced and used, and also to the example in which the oxidation reaction product was produced and used. It corresponds also to an Example.
- oxidation reaction product containing cyclic peroxide Concentrated glycerin and ozone are brought into gas-liquid contact, and an ozone-treated glycerin solution (ozonized glycerin) containing the oxidation reaction product is produced as follows. manufactured.
- the concentrated glycerin means glycerin having a concentration of 98% by weight or more of the Japanese Pharmacopoeia product.
- the oxidation reaction product of the fourth aspect of the present invention produced in this example contains the cyclic peroxide of the fourth aspect of the present invention, as will be described later.
- a Teflon (registered trademark) tank with a capacity of 50 L was used as the contact tank.
- An air diffuser was installed on the bottom of the tank so that ozone could be supplied into the tank in the form of fine bubbles.
- a silent discharge ozone generator capable of generating 100 g of ozone per hour was used using a high-concentration oxygen gas containing 90% by volume or more of high-concentration oxygen as a raw material.
- Example liquid Diluted solution of ozonated glycerin: A solution obtained by diluting the ozonated glycerin of Example 4-1 (1) with water so that the concentration of the ozone oxidant is 10, 100, or 1000 ppm Concentrated glycerin solution 5 or 10 mmol/l PTB (solvent: 50% acetonitrile) ⁇ Hydrogen peroxide solution: a solution diluted with water so that the concentration of H 2 O 2 is 1 or 10 mmol/l
- Anti-glycation rate (%) ⁇ (AB)/C ⁇ x 100 (1)
- Figure 4-1 is a graph showing the anti-glycation rate.
- the horizontal axis indicates the type and concentration of the sample solution, and the vertical axis indicates the anti-glycation rate.
- ozonated glycerin increased the anti-glycation rate in a concentration-dependent manner.
- ozonated glycerin showed an anti-glycation rate equal to or higher than that of positive control PTB and hydrogen peroxide solution (H2O2). From these results, it was found that ozonated glycerin exhibits a very high AGE crosslinked structure cleaving activity, that is, an anti-glycation activity.
- the ozonated glycerin As will be described later, when the components of the ozonated glycerin and the concentrated glycerin were compared, the ozonated glycerin was different in that it contained the compound represented by the chemical formula (1) described later. Therefore, it was shown that the compound of chemical formula (1) contained in the ozonated glycerin exhibits anti-glycation activity.
- Example 4-2 It was confirmed that the active ingredient in the ozonated glycerin was a cyclic peroxide.
- Example 4-1 (1) Analysis of the reaction mixture
- a cyclic peroxide not found in glycerin was removed from the ozonated glycerin of Example 4-1 (1). extracted and analyzed.
- Glycerin is removed by a silica gel column from the glycerin solution containing the ozone oxidant of glycerin produced in "Example 4-1 (1) Production of oxidation reaction product containing the cyclic peroxide", and the cyclic peroxide is A containing reaction mixture (hereinafter sometimes referred to as “TLC1 spot product”) was obtained.
- FIG. 4-2 is a 1 H NMR spectrum diagram.
- FIG. 4-3 is a 13 C NMR spectrum chart.
- FIG. 4-4 is a 13 C DEPT135 NMR spectrum diagram.
- 4-5 are COZY NMR spectrum diagrams.
- 4-6 are HSQC NMR spectrum diagrams.
- 4-7 are HMBC NMR spectrum diagrams. Since complex peaks were observed as shown in FIGS. 4-2 to 4-7, the TLC1 spot product was presumed to be a mixture of multiple types of substances. This TLC1 spot also contained m/z 198,203 components by LCMS.
- reaction mixture TLC 1 spot product
- acetonitrile a reaction mixture prepared (diluted) with acetonitrile to about 3% by mass, filtered through a membrane filter, and the resulting filtrate was subjected to LC measurement to determine the separation conditions. optimized.
- the resulting fraction was freeze-dried, and the dried fraction was subjected to microscopic LR measurement and various NMR measurements.
- the measurement equipment (analyzer) and measurement conditions are as follows.
- Figure 4-8 shows a total ion chromatogram ( ESI-negative mode).
- the vertical axis is intensity and the horizontal axis is retention time (minutes).
- the lower “synthetic-derived OG” is the chromatogram of the TLC 1-spot sample, and the upper is the blank (acetonitrile) chromatogram.
- components A to L were confirmed.
- component H exhibited the strongest coloration.
- Figure 4-9 also shows the mass spectra of peaks F, G and H (F, G and H fractions) in Figure 4-8.
- Figures 4-10 show the results of studies on improving the separation of HILIC (high performance liquid chromatography) (improving separation conditions).
- the vertical axis represents intensity
- the horizontal axis represents retention time (minutes).
- the upper stage is the chromatogram before separation improvement (under the same conditions as in FIG. 4-9)
- the lower stage is the chromatogram after separation improvement.
- peaks 1-8 were seen after improved separation. The molecular weight of each peak was confirmed to be the molecular weight shown in FIGS.
- Figure 4-11 shows the mass spectrum (after separation improvement) of peaks 1 to 3 in Figure 4-10.
- the mass spectrum of peak 1 is in the upper part
- peak 2 is in the middle part
- peak 3 is in the lower part.
- Figure 4-12 shows the mass spectrum (after separation improvement) of peaks 4 to 6 in Figure 4-10.
- the mass spectrum of peak 4 is shown in the upper row
- peak 5 is shown in the middle row
- peak 6 is shown in the lower row.
- Figure 4-13 shows the mass spectrum (after separation improvement) of peaks 7 to 8 in Figure 4-10.
- the upper stage is the mass spectrum of peak 7 and the lower stage is the mass spectrum of peak 8.
- FIG. As shown, both peaks 7 and 8 were confirmed to have Mw 256.
- Methanol-d 4 CD 3 OD
- the upper spectrum diagram is an enlarged view of the vicinity of 3.4 to 4.9 ppm in the lower spectrum diagram.
- the peaks indicated by symbols A to F are respectively represented by the same symbols A to F in the following chemical formula (1) described in FIG. 4-15. Assigned to hydrogen peaks attached to carbon atoms.
- some glycerin which is the starting material, remained, and that peak was also detected.
- Methanol-d 4 CD 3 OD
- the upper spectrum diagram is an enlarged view of the vicinity of 60 to 105 ppm in the lower spectrum diagram.
- the peaks indicated by symbols A to F are respectively represented by the same symbols A to F in the following chemical formula (1) described in FIG. 4-16. Assigned to the carbon atom peak.
- some glycerin which is the starting material, remained, and that peak was also detected.
- Methanol-d 4 CD 3 OD
- the peaks indicated by symbols A to F are represented by the same symbols A to F in the following chemical formula (1) described in FIG. 4-17. were assigned to the carbon atoms and the hydrogen atoms bonded to the carbon atoms.
- some glycerin, which is the starting material remained, and that peak was also detected.
- Figure 4-18 also shows the HILIC chromatograms of the TLC1 spot product and glyceraldehyde dimer under the HILIC (High Performance Liquid Chromatography) conditions of Figure 4-10.
- the upper “synthetic-derived OG” is the HILIC chromatogram of the TLC1-spot product.
- the lower row is the HILIC chromatogram with glyceraldehyde dimer. As shown, no glyceraldehyde dimers were detected under the HILIC conditions of FIGS. 4-18.
- Figure 4-19 also shows the HILIC chromatograms of the TLC1 spot product and the glyceraldehyde dimer under reversed-phase HILIC (High Performance Liquid Chromatography) conditions.
- 4-20 shows an enlarged view of part of FIG. 4-19.
- the upper “synthetic-derived OG” is the HILIC chromatogram of the TLC1 spot product.
- the lower row is the HILIC chromatogram with glyceraldehyde dimer.
- separation of components from the TLC1 spot product could not be confirmed. This is probably because the retention force of the column was weak and the elution time of the TLC 1-spot product was fast.
- the retention time of the glyceraldehyde dimer was slightly different from that of the TLC1 spot product (synthetic-derived OG). From this, it is presumed that the TLC1 spot product did not contain glyceraldehyde dimer.
- the vertical axis is intensity and the horizontal axis is magnetic flux density (G). Water was used as the measurement solvent.
- DMPO spin trapping agent
- DMPO spin trapping agent
- FIG 4-23 shows the ESR spectrum diagram of peaks 1 to 8 in Figure 4-10. Water was used as the measurement solvent. The top is an ESR spectrum diagram of a blank (solvent only) for comparison. As shown in the figure, it was confirmed that any component of peaks 1 to 8 has radical activity.
- the graph in Figure 4-24 shows the results of measuring the activities of peaks 1 to 8 in Figure 4-10 by chemiluminescence.
- the vertical axis is the emission intensity (relative intensity) at all wavelengths.
- Numbers "1" to "8" on the horizontal axis indicate the respective fractions of peaks 1 to 8.
- the numbers below the numbers represent the molecular weight of each fraction as confirmed by mass spectroscopy. As shown in the figure, it was confirmed that components other than those with a molecular weight of 180, which exhibit activity by chemiluminescence, were produced.
- (Appendix 1) A cyclic peroxide characterized by being represented by the following chemical formula (I).
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- R 11 in the chemical formula (II) the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- Appendix 6 An oxidation reaction product obtained by oxidizing an alcohol, characterized by containing a cyclic peroxide.
- Appendix 7 The oxidation reaction product according to appendix 6, wherein the oxidation of the alcohol is at least one of ozone oxidation and hydrogen peroxide oxidation.
- Appendix 8) 8.
- Appendix 9 9.
- Appendix 10 10.
- Appendix 11 11.
- Appendix 12 12.
- Appendix 13 13.
- Appendix 14 14.
- Appendix 15 15.
- Appendix 16 16.
- Appendix 17 17.
- Appendix 18 18.
- Appendix 19 19.
- composition for whitening (Appendix 20) containing glycerin and/or glycerin derivatives and a whitening ingredient,
- a whitening composition wherein the whitening ingredient comprises, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure.
- R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- Appendix 21 In the chemical formula (I), 21.
- Appendix 22 22.
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- Appendix 26 26.
- Appendix 28 28.
- Appendix 29 29.
- Appendix 30 30.
- Appendix 31 31.
- Appendix 34 34.
- Appendix 36 36.
- Appendix 37 37.
- a whitening agent comprising a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different. (Appendix 39) In the chemical formula (I), 39.
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- the whitening agent according to paragraph 40 which is a group hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (--SH), or an alkylthio group (--SR, where R is an alkyl group).
- Appendix 43 A whitening agent comprising an oxidation reaction product containing a cyclic peroxide or a salt thereof obtained by oxidizing an alcohol.
- Appendix 44 44.
- Appendix 45 45.
- Appendix 46 46.
- Appendix 49 49.
- Appendix 51 51.
- Appendix 52 52.
- Appendix 53 53.
- Appendix 54 54.
- ⁇ Whitening method> (Appendix 55) A whitening method using the whitening composition according to any one of appendices 20 to 37 and/or the cosmetic agent according to any one of appendices 38 to 54. (Appendix 56) 56. The skin lightening method of paragraph 55, wherein said skin lightening composition and/or said cosmetic agent is applied to the skin of a subject.
- ⁇ Use> Appendix 57
- composition for inducing expression of skin barrier function-related gene (Appendix 58) containing glycerin and/or a glycerin derivative and an expression-inducing component of a gene associated with skin barrier function, A composition for inducing the expression of a skin barrier function-related gene, wherein the skin barrier function-related gene expression-inducing component comprises, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure.
- R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- Appendix 59 In the chemical formula (I), 59.
- Appendix 60 59.
- composition for inducing expression according to Appendix 58 or 59, wherein the cyclic peroxide represented by the chemical formula (I) is represented by the following chemical formula (II):
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- the composition for inducing expression according to Appendix 60 which is a group hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, R is an alkyl group).
- Appendix 62 62.
- Appendix 63 63.
- Appendix 64 64.
- Appendix 65 65.
- Appendix 66 65.
- ⁇ Composition for improving skin barrier function> (Appendix 67)
- a composition for improving skin barrier function comprising the composition for inducing the expression of a skin barrier function-related gene according to any one of Appendices 58 to 66. (Appendix 68) 68.
- composition for improvement according to Appendix 67 for use in a method for improving the skin barrier function of a subject by inducing the expression of a skin barrier function-related gene in the skin of a subject by transdermal administration.
- ⁇ Skin barrier function-related gene expression inducer> An inducer of skin barrier function-related genes, comprising a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure.
- R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- Appendix 70 In the chemical formula (I), 69.
- Appendix 71 71.
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- the derivative according to Appendix 71 which is a group hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (--SH), or an alkylthio group (--SR, where R is an alkyl group).
- Appendix 73 73.
- Appendix 74 74.
- Appendix 75 75.
- Appendix 76 76.
- ⁇ Skin barrier function improver> An agent for improving skin barrier function, comprising the skin barrier function-related gene inducer according to any one of Appendices 69 to 76. (Appendix 78) 78.
- the improving agent according to Appendix 77 for use in a method of improving the skin barrier function of a subject by inducing the expression of a skin barrier function-related gene in the skin of a subject by transdermal administration.
- composition for inducing expression of antioxidant stress response gene (Appendix 79) containing glycerin and/or a glycerin derivative and an antioxidant stress response gene expression-inducing component, A composition for inducing the expression of an antioxidant stress response gene, wherein the component for inducing the expression of the antioxidant stress response gene contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure.
- R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- Appendix 80 In the chemical formula (I), 79. The composition for inducing expression according to Appendix 79, wherein R 100 is a cyclic structure having 5 to 10 ring members.
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- the composition for inducing expression according to Appendix 81 which is a group hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, R is an alkyl group).
- Appendix 83 83.
- Appendix 84 The composition for inducing expression according to any one of Appendices 79 to 83, for use on skin.
- Appendix 85 85.
- Said antioxidant stress response gene is a Heme oxygenase 1 gene, a NAD(P)H quinone oxidoreductase 1 gene, and/or a glutathione gene, from Appendix 79 85.
- the composition for inducing expression according to any one of Appendices 79 to 86, wherein the composition for inducing expression of an antioxidant stress response gene is a composition for inducing expression of an antioxidant stress response gene in epidermal keratinocytes.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- the derivative according to Appendix 90 which is a group hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (--SH), or an alkylthio group (--SR, where R is an alkyl group).
- Appendix 92 92.
- Appendix 93 93.
- Appendix 94 from Appendix 88, wherein said antioxidant stress response gene is a Heme oxygenase 1 gene, a NAD(P)H quinone oxidoreductase 1 gene, and/or a glutathione gene 93.
- the inducer according to any one of 93 is a Heme oxygenase 1 gene, a NAD(P)H quinone oxidoreductase 1 gene, and/or a glutathione gene 93.
- Anti-inflammatory composition (Appendix 95) comprising glycerin and/or glycerin derivatives and an anti-inflammatory ingredient,
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure.
- R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- Appendix 96 In the chemical formula (I), 96.
- Appendix 97 97.
- the anti-inflammatory composition according to appendix 95 or 96 wherein the cyclic peroxide represented by the chemical formula (I) is represented by the following chemical formula (II):
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- the anti-inflammatory composition according to Clause 97 which is a group hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (--SH), or an alkylthio group (--SR, where R is an alkyl group). (Appendix 99) 99.
- Appendix 102 Any one of Appendices 95 to 101, wherein the anti-inflammatory composition is an IL-1 ⁇ gene expression-suppressing composition, an IL-1 ⁇ production-suppressing composition, and/or a prostaglandin E2 production-suppressing composition.
- the anti-inflammatory composition according to . (Appendix 103) 103.
- ⁇ Anti-inflammatory agent> (Appendix 104)
- An anti-inflammatory agent comprising a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure.
- R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- Appendix 105 In the chemical formula (I), 105.
- Appendix 106) 106.
- the anti-inflammatory agent according to appendix 104 or 105 wherein the cyclic peroxide represented by the chemical formula (I) is represented by the following chemical formula (II):
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- the anti-inflammatory agent according to paragraph 106 which is a group hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (--SH), or an alkylthio group (--SR, where R is an alkyl group).
- Appendix 108 108.
- the anti-inflammatory agent according to any one of appendices 104 to 109, wherein the anti-inflammatory agent is an IL-1 ⁇ gene expression inhibitor, an IL-1 ⁇ production inhibitor, and/or a prostaglandin E2 production inhibitor. .
- the anti-inflammatory agent according to any one of appendices 104 to 110, wherein the anti-inflammatory agent is an anti-inflammatory agent for epidermal keratinocytes.
- the anti-inflammatory agent is an anti-inflammatory agent for epidermal keratinocytes.
- Method for Inducing Expression of Skin Barrier Function-Related Gene (Appendix 112) Using the skin barrier function-related gene expression induction promoting composition according to any one of Appendices 58 to 66 and/or the skin barrier function-related gene expression induction promoting agent according to any one of Appendices 69 to 76, A method for inducing expression of a gene associated with skin barrier function. (Appendix 113) 113.
- Appendix 124 A method of suppressing inflammation using the anti-inflammatory composition according to any one of Appendices 95-103 and/or the anti-inflammatory agent according to any one of Appendices 104-111.
- Appendix 125 A method of suppression of Clause 124, wherein the subject is administered said anti-inflammatory composition and/or anti-inflammatory agent.
- Appendix 126) 126.
- the method of inducing expression according to Appendix 125 wherein the method is administered to the skin of the subject.
- Appendix 127) 127.
- Method for treating inflammatory disease (Appendix 128) A method of treating an inflammatory disease, comprising administering to a subject an anti-inflammatory composition according to any of Supplements 95-103 and/or an anti-inflammatory agent according to any of Supplements 104-111. (Appendix 129) 129. The treatment method of paragraph 128, wherein said subject is administered to the skin. (Appendix 130) 130. A method of treatment according to any of Appendixes 128 or 129 for use in vitro or in vivo .
- Appendix 131 A composition for use in inducing expression of a gene associated with skin barrier function, A composition comprising the composition for inducing the expression of a skin barrier function-related gene according to any one of Appendices 58 to 66.
- Appendix 132 An agent for use in inducing the expression of skin barrier function-related genes, The agent comprises the skin barrier function-related gene expression inducer according to any one of Appendices 69 to 76.
- Appendix 133 A composition for use in improving skin barrier function, comprising: A composition comprising the composition for improving skin barrier function according to Appendix 67 or 68.
- Appendix 134 An agent for use in improving skin barrier function, 78.
- An agent comprising the agent for improving skin barrier function according to appendix 77 or 78.
- Appendix 135) A composition for use in inducing expression of an antioxidant stress response gene, 88.
- a composition comprising the composition for inducing the expression of an antioxidant stress response gene according to any one of Appendices 79 to 87.
- An agent for use in inducing the expression of an antioxidant stress response gene The agent comprises the agent for inducing the expression of the antioxidant stress response gene according to any one of Appendices 88 to 94.
- a composition for anti-inflammatory use comprising: 103.
- a composition, wherein said composition comprises an anti-inflammatory composition according to any of Clauses 95-103.
- Anti-glycation composition (Appendix 141) comprising glycerin and/or glycerin derivatives and an anti-glycation ingredient,
- An anti-glycation composition wherein the anti-glycation component contains, as an active ingredient, a cyclic peroxide represented by the following chemical formula (I) or a salt thereof:
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure.
- R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different.
- Appendix 142 In the chemical formula (I), 142.
- Appendix 143) 143.
- the anti-glycation composition according to appendix 141 or 142 wherein the cyclic peroxide represented by the chemical formula (I) is represented by the following chemical formula (II):
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- the anti-glycation composition according to Appendix 143 which is a group hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (-SH), or an alkylthio group (-SR, where R is an alkyl group).
- Appendix 145) 145.
- Appendix 146) 146.
- R 100 is a cyclic structure having 3 or more ring members, which may be saturated or unsaturated, may be an aromatic ring or a non-aromatic ring, and has a heteroatom other than the oxygen atom in the chemical formula (I) in the cyclic structure. It may or may not have, may be a single ring or a condensed ring, R 1 is a substituent, which may be one, plural, or absent, and when plural, may be the same or different. (Appendix 150) In the chemical formula (I), 149.
- the anti-glycation agent according to appendix 149 wherein R 100 is a cyclic structure with 5 to 10 ring members.
- Appendix 151 The anti-glycation agent according to appendix 149 or 150, wherein the cyclic peroxide represented by the chemical formula (I) is represented by the following chemical formula (II):
- the substituents are each a hydroxyl group (—OH), an aldehyde group (formyl group), a hydroxyalkyl group, a sulfo group, a nitro group, a diazo group, an alkyl group, and an unsaturated fatty acid.
- the anti-glycation agent according to Appendix 151 which is a group hydrocarbon group, an aryl group, a heteroaryl group, a halogen, a mercapto group (--SH), or an alkylthio group (--SR, where R is an alkyl group).
- Appendix 153 153.
- Appendix 155) 154 An anti-glycation agent according to any of paragraphs 149-154 for use on the skin.
- compositions for use in antiglycation comprising: 148.
- a composition, wherein said composition comprises an anti-glycation composition according to any of Appendices 141-148.
- Appendix 161 An agent for use in antiglycation, An agent, wherein the agent comprises an anti-glycation agent according to any one of appendices 149-155.
- the cyclic peroxide, the oxidation reaction product, and the method for producing the oxidation reaction product of the first aspect of the present invention are highly safe, and are therefore suitable for fields such as medicines, cosmetics, foods, and supplements. In, it is extremely useful.
- the whitening composition of the second aspect of the present invention is extremely useful in the field of cosmetics, for example.
- composition for inducing the expression of skin barrier function-related genes of the third aspect of the present invention can induce the expression of skin barrier function-related genes, and is therefore extremely useful in the field of cosmetics, for example. .
- the anti-glycation composition of the fourth aspect of the present invention has anti-glycation activity, and therefore is extremely useful in the field of cosmetics, for example.
Abstract
Description
前記安全性の問題を解決するために、本発明の第1の発明における環状過酸化物は、下記化学式(I)で表されることを特徴とする。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
新たな美白成分を含有する美白用組成物および美白剤を提供するために、本発明の第2の発明における美白用組成物は、グリセリンおよび/またはグリセリン誘導体と、美白成分とを含み、
前記美白成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
新たな皮膚バリア機能関連遺伝子の発現誘導成分を含有する皮膚バリア機能関連遺伝子の発現誘導用組成物および皮膚バリア機能関連遺伝子の発現誘導剤を提供するために、本発明の第3の発明における皮膚バリア機能関連遺伝子の発現誘導用組成物は、グリセリンおよび/またはグリセリン誘導体と、皮膚バリア機能関連遺伝子の発現誘導成分とを含み、
前記皮膚バリア機能関連遺伝子の発現誘導成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
前記抗酸化ストレス応答遺伝子の発現誘導成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
前記抗炎症成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
新たな抗糖化成分を含有する抗糖化用組成物および抗糖化剤を提供するために、本発明の第4の発明における抗糖化用組成物(以下、「組成物」ともいう)は、グリセリンおよび/またはグリセリン誘導体と、抗糖化成分とを含み、
前記抗糖化成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
物を含む。
本発明の第1の発明によれば、安全性が高い環状過酸化物、酸化反応生成物、酸化反応生成物の製造方法を提供することができる。
本発明の第2の発明によれば、新たな美白成分を含有する美白用組成物および美白剤を提供することができる。
本発明の第3の発明によれば、新たな皮膚バリア機能関連遺伝子の発現誘導成分を含有する皮膚バリア機能関連遺伝子の発現誘導用組成物および皮膚バリア機能関連遺伝子の発現誘導剤を提供することができる。
本発明の第4の発明によれば、新たな抗糖化成分を含有する抗糖化用組成物および抗糖化剤を提供することができる。
まず、本発明における第1の発明を実施するための形態について説明する。ただし、本発明における第1の発明は、以下の説明により限定されない。
本発明における第1の発明の環状過酸化物は、前述のとおり、下記化学式(I)で表されることを特徴とする。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
本発明における第1の発明の酸化反応生成物は、前述のとおり、アルコールを酸化して得られる、環状過酸化物を含むことを特徴とする酸化反応生成物である。ただし、本発明における第1の発明の酸化反応生成物の製造方法は、アルコールの酸化に限定されず、同じ構造の物質であれば、どのような製造方法で製造した物質でもよい。
本発明における第1の発明の酸化反応生成物の製造方法は、前述のとおり、前記アルコールを酸化するアルコール酸化工程を含む前記本発明における第1の発明の酸化反応生成物の製造方法である。
本発明における第1の発明の環状過酸化物および本発明における第1の発明の酸化反応生成物の使用方法は、特に限定されない。例えば、本発明における第1の発明の環状過酸化物または本発明における第1の発明の酸化反応生成物がTRPチャネル活性を有する場合は、TRPチャネル活性物質として使用してもよい。その場合の使用方法は、特に限定されず、例えば、一般的なTRPチャネル活性物質の使用方法と同様であってもよい。本発明における第1の発明の環状過酸化物および本発明における第1の発明の酸化反応生成物は、前述のとおり、安全性が高いため、安全に使用することができる。また、本発明における第1の発明の環状過酸化物および本発明における第1の発明の酸化反応生成物の使用方法は、例えば、前述のとおり、反応後の混合物から分取しない状態でそのまま用いてもよいし、前記反応後の混合物から本発明における第1の発明の環状過酸化物または本発明における第1の発明の酸化反応生成物を分取した後に用いてもよい。
つぎに、本発明における第2の発明を実施するための形態について説明する。ただし、本発明における第2の発明は、以下の説明により限定されない。
本発明における第2の発明の美白用組成物(以下、「組成物」という)は、グリセリンおよび/またはグリセリン誘導体と、美白成分とを含み、前記美白成分が、有効成分として、環状過酸化物またはその塩を含む。本発明における第2の発明の組成物は、前記環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、後述するように、メラニンの分解を促進すると推定される。このため、本発明における第2の発明の組成物によれば、例えば、皮膚に適用した際に、前記皮膚に対する美白効果を得ることができる。
本発明における第2の発明の組成物は、前述のように、美白成分を含む。本発明における第2の発明の組成物は、前記美白成分の有効成分として、前記環状過酸化物を含んでもよいし、後述するように、前記環状過酸化物を含有する酸化反応生成物を含んでもよいし、両者を含んでもよい。前記環状過酸化物は、下記化学式(I)で表される化合物でもよいし、後述のアルコールを酸化して得られる酸化反応生成物に含まれる環状過酸化物でもよい。
前記環状過酸化物は、下記化学式(I)で表される。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
前記酸化反応生成物は、前述のとおり、アルコールを酸化して得られる、環状過酸化物を含むことを特徴とする酸化反応生成物である。ただし、前記酸化反応生成物の製造方法は、アルコールの酸化に限定されず、同じ構造の物質であれば、どのような製造方法で製造した物質でもよい。
前記酸化反応生成物の製造方法は、前述のとおり、前記アルコールを酸化するアルコール酸化工程を含む前記酸化反応生成物の製造方法である。
本発明における第2の発明の組成物において、前記グリセリンは、グリセリンでもよいし、前述のグリセリン誘導体でもよい。本発明における第2の発明の組成物では、前記環状過酸化物を前記グリセリンと共存させることにより、前記環状過酸化物を安定的に保持できる。
本発明における第2の発明の組成物は、前記美白成分の有効成分として、前記環状過酸化物および/または前記環状過酸化物を含有する酸化反応生成物に加えて、他の美白成分を含んでもよい。前記他の美白成分は、アルブチン、トラネキサム酸、およびアスコルビン酸またはその誘導体等があげられる。
本発明における第2の発明の組成物は、皮膚に適用する剤型に添加される他の成分を含んでもよい。具体例として、前記他の成分は、例えば、皮膚外用剤に添加される成分、化粧料(医薬部外品を含む)に添加させる成分等があげられる。前記皮膚外用剤に添加される成分は、例えば、薬学的に許容される担体等があげられる。前記他の成分は、例えば、皮膚に適用する際、または経皮的に適用される際に添加される成分があげられ、具体例として、水等の水性溶媒、アルコール、保湿剤、油剤、柔軟剤(エモリエント剤)、界面活性剤(可溶化剤、乳化剤)、塩類、増粘剤、pH調整剤、紫外線吸収剤、薬剤、緩衝剤、色剤、防腐剤、香料等があげられる。
本発明における第2の発明の組成物は、例えば、固体状または液体状である。本発明における第2の発明の組成物の形態は、例えば、ローション剤型;乳液、クリーム等の乳化剤型;オイル剤型:ジェル剤型;軟膏、パック、洗浄料;等があげられる。
本発明における第2の発明の美白剤は、環状過酸化物またはその塩を含む。本発明における第2の発明の美白剤は、環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、メラニンの分解を促進すると推定される。このため、本発明における第2の発明の美白剤によれば、例えば、皮膚に適用した際に、前記皮膚に対する美白効果を得ることができる。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
本発明における第2の発明の美白方法は、前記本発明における第2の発明の美白用組成物および/または前記本発明における第2の発明の美容剤を使用する。本発明における第2の発明の美白方法は、前記本発明における第2の発明の美白用組成物および/または前記本発明における第2の発明の美容剤を使用することが特徴であり、その他の工程および条件は、特に制限されない。本発明における第2の発明の組成物および/または美白剤が含有する環状過酸化物は、メラニンの分解を促進すると推定される。このため、本発明における第2の発明の美白剤によれば、例えば、皮膚に適用した際に、前記皮膚に対する美白効果を得ることができる。
本発明における第2の発明は、美白に用いるための、本発明における第2の発明の美白用組成物および/または本発明における第2の発明の美容剤、またはその使用である。
つぎに、本発明における第3の発明を実施するための形態について説明する。ただし、本発明における第3の発明は、以下の説明により限定されない。
本発明の第3の発明における皮膚バリア機能関連遺伝子の発現誘導用組成物(以下、「第1の組成物」という)は、グリセリンおよび/またはグリセリン誘導体と、皮膚バリア機能関連遺伝子の発現誘導成分とを含み、前記皮膚バリア機能関連遺伝子の発現誘導成分が、有効成分として、環状過酸化物またはその塩を含む。本発明における第3の発明の第1の組成物は、前記環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、後述するように、皮膚バリア機能関連遺伝子である、プロフィラグリン遺伝子等の皮膚バリア機能に重要なタンパク質の発現を誘導する。このため、本発明における第3の発明の第1の組成物によれば、例えば、皮膚に適用した際に、前記皮膚に対する皮膚バリア機能関連遺伝子の発現誘導効果を得ることができる。
本発明における第3の発明の第1の組成物は、前述のように、皮膚バリア機能関連遺伝子の発現誘導成分を含む。本発明における第3の発明の第1の組成物は、前記皮膚バリア機能関連遺伝子の発現誘導成分の有効成分として、前記環状過酸化物を含んでもよいし、後述するように、前記環状過酸化物を含有する酸化反応生成物を含んでもよいし、両者を含んでもよい。前記環状過酸化物は、下記化学式(I)で表される化合物でもよいし、後述のアルコールを酸化して得られる酸化反応生成物に含まれる環状過酸化物でもよい。
前記環状過酸化物は、下記化学式(I)で表される。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
前記酸化反応生成物は、前述のとおり、アルコールを酸化して得られる、環状過酸化物を含むことを特徴とする酸化反応生成物である。ただし、前記酸化反応生成物の製造方法は、アルコールの酸化に限定されず、同じ構造の物質であれば、どのような製造方法で製造した物質でもよい。
前記酸化反応生成物の製造方法は、前述のとおり、前記アルコールを酸化するアルコール酸化工程を含む前記酸化反応生成物の製造方法である。
本発明における第3の発明の第1の組成物において、前記グリセリンは、グリセリンでもよいし、前述のグリセリン誘導体でもよい。本発明における第3の発明の第1の組成物では、前記環状過酸化物を前記グリセリンと共存させることにより、前記環状過酸化物を安定的に保持できる。
前記皮膚バリア機能関連遺伝子は、皮膚のバリア機能に寄与するタンパク質をコードする遺伝子であればよい。前記皮膚バリア機能関連遺伝子は、例えば、プロフィラグリン(Pro filaggrin)遺伝子、インボルクリン(Involucrin)遺伝子、セリンパルミトイルトランスフェラーゼ(Serine palmitoyltransferase)遺伝子等があげられる。本発明における第3の発明の第1の組成物により、発現が誘導される皮膚バリア機能関連遺伝子は、例えば、1種類でもよいし、複数種類でもよい。前記プロフィラグリン遺伝子、インボルクリン遺伝子、およびセリンパルミトイルトランスフェラーゼ遺伝子は、例えば、ヒトの遺伝子として、下記のGenbankのアクセッション番号で特定される塩基配列からなるポリヌクレオチドが挙げられる。
・プロフィラグリン遺伝子:NM_002016.2
・インボルクリン遺伝子:NM_005547.2
・セリンパルミトイルトランスフェラーゼ遺伝子:NM_004863.3
本発明における第3の発明の第1の組成物は、皮膚に適用する剤型に添加される他の成分を含んでもよい。具体例として、前記他の成分は、例えば、皮膚外用剤に添加される成分、化粧料(医薬部外品を含む)に添加される成分等があげられる。前記皮膚外用剤に添加される成分は、例えば、薬学的に許容される担体等があげられる。前記他の成分は、例えば、皮膚に適用する際、または経皮的に適用される際に添加される成分があげられ、具体例として、水等の水性溶媒、アルコール、保湿剤、油剤、柔軟剤(エモリエント剤)、界面活性剤(可溶化剤、乳化剤)、塩類、増粘剤、pH調整剤、紫外線吸収剤、薬剤、緩衝剤、色剤、防腐剤、香料等があげられる。
本発明における第3の発明の第1の組成物は、例えば、固体状または液体状である。本発明における第3の発明の第1の組成物の形態は、例えば、ローション剤型;乳液、クリーム等の乳化剤型;オイル剤型:ジェル剤型;軟膏、パック、洗浄料;等があげられる。
本発明における第3の発明の皮膚バリア機能関連遺伝子の発現誘導剤(以下、「第1の誘導剤」という)は、環状過酸化物またはその塩を含む。本発明における第3の発明の皮膚バリア機能関連遺伝子の発現誘導剤は、環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、前述したように、前記皮膚バリア機能関連遺伝子である、プロフィラグリン遺伝子等の皮膚バリア機能に重要なタンパク質の発現を誘導する。このため、本発明における第3の発明の第1の誘導剤によれば、例えば、皮膚に適用した際に、前記皮膚に対する皮膚バリア機能関連遺伝子の発現誘導効果を得ることができる。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
本発明における第3の発明の皮膚バリア機能の改善用組成物(以下、「第2の組成物」という)は、グリセリンおよび/またはグリセリン誘導体と、皮膚バリア機能の改善成分とを含み、前記皮膚バリア機能の改善成分が、有効成分として、環状過酸化物またはその塩を含む。本発明における第3の発明の第2の組成物は、前記環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、前述するように、皮膚バリア機能関連遺伝子である、プロフィラグリン遺伝子等の皮膚バリア機能に重要なタンパク質の発現を誘導する。このため、本発明における第3の発明の第1の組成物によれば、例えば、皮膚に適用した際に、前記皮膚に対する皮膚バリア機能関連遺伝子の発現誘導効果を得ることができ、これにより皮膚バリア機能を改善できる。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
本発明における第3の発明の皮膚バリア機能の改善剤(以下、「改善剤」という)は、環状過酸化物またはその塩を含む。本発明における第3の発明の皮膚バリア機能の改善剤は、環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、前述したように、前記皮膚バリア機能関連遺伝子である、プロフィラグリン遺伝子等の皮膚バリア機能に重要なタンパク質の発現を誘導する。このため、本発明における第3の発明の改善剤によれば、例えば、皮膚に適用した際に、前記皮膚に対する皮膚バリア機能関連遺伝子の発現誘導効果を得ることができ、これにより皮膚バリア機能を改善できる。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
本発明における第3の発明の抗酸化ストレス応答遺伝子の発現誘導用組成物(以下、「第3の組成物」という)は、グリセリンおよび/またはグリセリン誘導体と、抗酸化ストレス応答遺伝子の発現誘導成分とを含み、前記抗酸化ストレス応答遺伝子の発現誘導成分が、有効成分として、環状過酸化物またはその塩を含む。本発明における第3の発明の第3の組成物は、前記環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、前述するように、抗酸化ストレス応答遺伝子である、ヘムオキシゲナーゼ1遺伝子、NAD(P)Hキノンオキシドレダクターゼ1遺伝子等の抗酸化ストレス応答に重要なタンパク質の発現を誘導する。このため、本発明における第3の発明の第3の組成物によれば、例えば、皮膚に適用した際に、前記皮膚に対する抗酸化ストレス応答遺伝子の発現誘導効果を得ることができ、これにより抗酸化ストレス応答を改善できる。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
・ヘムオキシゲナーゼ1遺伝子:NM_002133.3
・NAD(P)Hキノンオキシドレダクターゼ1遺伝子:NM_000903.3
本発明における第3の発明の抗酸化ストレス応答遺伝子の発現誘導剤(以下、「第4の誘導剤」という)は、環状過酸化物またはその塩を含む。本発明における第3の発明の抗酸化ストレス応答遺伝子の発現誘導剤は、環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、前述したように、前記抗酸化ストレス応答遺伝子である、ヘムオキシゲナーゼ1遺伝子、NAD(P)Hキノンオキシドレダクターゼ1遺伝子等の抗酸化ストレス応答に重要なタンパク質の発現を誘導する。このため、本発明における第3の発明の第3の誘導剤によれば、例えば、皮膚に適用した際に、前記皮膚に対する抗酸化ストレス応答遺伝子の発現誘導効果を得ることができ、これにより抗酸化ストレス応答を改善できる。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
本発明における第3の発明の抗炎症組成物(以下、「第4の組成物」という)は、グリセリンおよび/またはグリセリン誘導体と、抗炎症成分とを含み、前記抗炎症成分が、有効成分として、環状過酸化物またはその塩を含む。本発明における第3の発明の第4の組成物は、前記環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、後述するように、抗炎症性サイトカインであるIL-1αおよびプロスタグランジンE2の産生を抑制する。このため、本発明における第3の発明の第4の組成物によれば、例えば、皮膚に適用した際に、前記皮膚における抗炎症効果を得ることができる。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
本発明における第3の発明の抗炎症剤は、環状過酸化物またはその塩を含む。本発明における第3の発明の抗酸化ストレス応答遺伝子の発現誘導剤は、環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、前述したように、抗炎症性サイトカインであるIL-1αの産生を抑制する。このため、本発明における第3の発明の抗炎症剤によれば、例えば、皮膚に適用した際に、前記皮膚における抗炎症効果を得ることができる。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
本発明における第3の発明の皮膚バリア機能関連遺伝子の発現誘導方法(以下、「第1の誘導方法」ともいう)は、前記本発明における第3の発明の皮膚バリア機能関連遺伝子の発現誘導用組成物および/または前記本発明における第3の発明の皮膚バリア機能関連遺伝子の発現誘導剤を使用する。本発明における第3の発明の第1の誘導方法は、前記本発明における第3の発明の第1の組成物および/または前記本発明における第3の発明の第1の誘導剤を使用することが特徴であり、その他の工程および条件は、特に制限されない。本発明における第3の発明の第1の組成物および/または第1の誘導剤が含有する環状過酸化物は、皮膚バリア機能関連遺伝子である、プロフィラグリン遺伝子等の皮膚バリア機能に重要なタンパク質の発現を誘導する。このため、本発明における第3の発明の第1の誘導方法によれば、例えば、皮膚に適用した際に、前記皮膚に対する皮膚バリア機能関連遺伝子の発現誘導効果を得ることができる。
本発明における第3の発明の皮膚バリア機能の改善方法(以下、「改善方法」ともいう)は、前記本発明における第3の発明の皮膚バリア機能の改善用組成物および/または前記本発明における第3の発明の皮膚バリア機能の改善剤を使用する。本発明における第3の発明の改善方法は、前記本発明における第3の発明の第2の組成物および/または前記本発明における第3の発明の改善剤を使用することが特徴であり、その他の工程および条件は、特に制限されない。本発明における第3の発明の第2の組成物および/または改善剤が含有する環状過酸化物は、皮膚バリア機能関連遺伝子である、プロフィラグリン遺伝子等の皮膚バリア機能に重要なタンパク質の発現を誘導する。このため、本発明における第3の発明の改善方法によれば、例えば、皮膚に適用した際に、前記皮膚に対する皮膚バリア機能関連遺伝子の発現誘導効果を得ることができ、これにより皮膚のバリア機能を改善できる。
本発明における第3の発明の抗酸化ストレス応答遺伝子の発現誘導方法(以下、「第3の誘導方法」ともいう)は、前記本発明における第3の発明の抗酸化ストレス応答遺伝子の発現誘導用組成物および/または前記本発明における第3の発明の抗酸化ストレス応答遺伝子の発現誘導剤を使用する。本発明における第3の発明の第3の誘導方法は、前記本発明における第3の発明の第3の組成物および/または前記本発明における第3の発明の第3の誘導剤を使用することが特徴であり、その他の工程および条件は、特に制限されない。本発明における第3の発明の第3の組成物および/または第3の誘導剤が含有する環状過酸化物は、抗酸化ストレス応答遺伝子である、ヘムオキシゲナーゼ1遺伝子、NAD(P)Hキノンオキシドレダクターゼ1遺伝子等の抗酸化ストレス応答に重要なタンパク質の発現を誘導する。このため、本発明における第3の発明の第3の誘導方法によれば、例えば、皮膚に適用した際に、前記皮膚に対する抗酸化ストレス応答遺伝子の発現誘導効果を得ることができ、これにより抗酸化ストレス応答を改善できる。
本発明における第3の発明の炎症の抑制方法(以下、「抑制方法」ともいう)は、前記本発明における第3の発明の第4の組成物および/または前記本発明における第3の発明の抗炎症剤を使用する。本発明における第3の発明の抑制方法は、前記本発明における第3の発明の第4の組成物および/または前記本発明における第3の発明の抗炎症剤を使用することが特徴であり、その他の工程および条件は、特に制限されない。本発明における第3の発明の第4の組成物および/または抗炎症剤が含有する環状過酸化物は、抗炎症性サイトカインであるIL-1αの産生およびプロスタグランジンE2の発現を抑制する。このため、本発明における第3の発明の抑制方法によれば、例えば、皮膚に適用した際に、前記皮膚における抗炎症効果を得ることができる。
本発明における第3の発明の炎症性疾患の処置方法(以下、「処置方法」ともいう)は、対象に、前記本発明における第3の発明の抗炎症組成物および/または前記本発明における第3の発明の抗炎症剤を投与する投与工程を含む。本発明における第3の発明の処置方法は、前記本発明における第3の発明の第4の組成物および/または前記本発明における第3の発明の抗炎症剤(以下、あわせて「医薬」ともいう)を投与することが特徴であり、その他の工程および条件は、特に制限されない。本発明における第3の発明の処置方法は、前記医薬を使用するため、炎症を抑制できる。このため、本発明における第3の発明の処置方法は、炎症性疾患を処置できる。
本発明における第3の発明は、皮膚バリア機能関連遺伝子の発現誘導に用いるための、本発明における第3の発明の皮膚バリア機能関連遺伝子の発現誘導用組成物および/または本発明における第3の発明の皮膚バリア機能関連遺伝子の発現誘導剤、またはその使用である。本発明における第3の発明は、皮膚バリア機能の改善に用いるための、本発明における第3の発明の皮膚バリア機能の改善用組成物および/または本発明における第3の発明の皮膚バリア機能の改善剤、またはその使用である。本発明における第3の発明は、抗酸化ストレス応答遺伝子の発現誘導に用いるための、本発明における第3の発明の抗酸化ストレス応答遺伝子の発現誘導用組成物および/または本発明における第3の発明の抗酸化ストレス応答遺伝子の発現誘導剤、またはその使用である。本発明における第3の発明は、炎症の抑制に用いるための、本発明における第3の発明の抗炎症組成物および/または本発明における第3の発明の抗炎症剤、またはその使用である。本発明における第3の発明は、炎症性疾患の処置に用いるための、本発明における第3の発明の抗炎症組成物および/または本発明における第3の発明の抗炎症剤、またはその使用である。
つぎに、本発明における第4の発明を実施するための形態について説明する。ただし、本発明における第4の発明は、以下の説明により限定されない。
本発明における第4の発明の抗糖化用組成物は、グリセリンおよび/またはグリセリン誘導体と、抗糖化成分とを含み、前記抗糖化成分が、有効成分として、環状過酸化物またはその塩を含む。本発明における第4の発明の組成物は、前記環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、後述するように、AGEsの架橋構造の分解能を有する。このため、本発明における第4の発明の組成物によれば、抗糖化効果を得ることができる。
本発明における第4の発明の組成物は、前述のように、抗糖化成分を含む。本発明における第4の発明の組成物は、前記抗糖化成分の有効成分として、前記環状過酸化物を含んでもよいし、後述するように、前記環状過酸化物を含有する酸化反応生成物を含んでもよいし、両者を含んでもよい。前記環状過酸化物は、下記化学式(I)で表される化合物でもよいし、後述のアルコールを酸化して得られる酸化反応生成物に含まれる環状過酸化物でもよい。
前記環状過酸化物は、下記化学式(I)で表される。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
前記酸化反応生成物は、前述のとおり、アルコールを酸化して得られる、環状過酸化物を含むことを特徴とする酸化反応生成物である。ただし、前記酸化反応生成物の製造方法は、アルコールの酸化に限定されず、同じ構造の物質であれば、どのような製造方法で製造した物質でもよい。
前記酸化反応生成物の製造方法は、前述のとおり、前記アルコールを酸化するアルコール酸化工程を含む前記酸化反応生成物の製造方法である。
本発明における第4の発明の組成物において、前記グリセリンは、グリセリンでもよいし、前述のグリセリン誘導体でもよい。本発明における第4の発明の組成物では、前記環状過酸化物を前記グリセリンと共存させることにより、前記環状過酸化物を安定的に保持できる。
本発明における第4の発明の組成物は、皮膚に適用する剤型に添加される他の成分を含んでもよい。具体例として、前記他の成分は、例えば、皮膚外用剤に添加される成分、化粧料(医薬部外品を含む)に添加される成分等があげられる。前記皮膚外用剤に添加される成分は、例えば、薬学的に許容される担体等があげられる。前記他の成分は、例えば、皮膚に適用する際、または経皮的に適用される際に添加される成分があげられ、具体例として、水等の水性溶媒、アルコール、保湿剤、油剤、柔軟剤(エモリエント剤)、界面活性剤(可溶化剤、乳化剤)、塩類、増粘剤、pH調整剤、紫外線吸収剤、薬剤、緩衝剤、色剤、防腐剤、香料等があげられる。
本発明における第4の発明の組成物は、例えば、固体状または液体状である。本発明における第4の発明の組成物の形態は、例えば、ローション剤型;乳液、クリーム等の乳化剤型;オイル剤型:ジェル剤型;軟膏、パック、洗浄料;等があげられる。
本発明における第4の発明の抗糖化剤は、環状過酸化物またはその塩を含む。本発明における第4の発明の抗糖化剤は、環状過酸化物またはその塩を含むことが特徴であり、その他の構成および条件は、特に制限されない。前記環状過酸化物は、後述するように、AGEsの架橋構造の分解能を有する。このため、本発明における第4の発明の抗糖化剤によれば、抗糖化効果を得ることができる。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
本発明における第4の発明の抗糖化方法は、前記本発明における第4の発明の抗糖化用組成物および/または前記本発明における第4の発明の抗糖化剤を使用する。本発明における第4の発明の抗糖化方法は、前記本発明における第4の発明の組成物および/または前記本発明における第4の発明の抗糖化剤を使用することが特徴であり、その他の工程および条件は、特に制限されない。本発明における第4の発明の組成物および/または抗糖化剤が含有する環状過酸化物は、後述するように、AGEsの架橋構造の分解能を有する。このため、本発明における第4の発明の抗糖化方法によれば、抗糖化効果を得ることができる。
本発明における第4の発明は、抗糖化に用いるための、本発明における第4の発明の抗糖化用組成物および/または本発明における第4の発明の抗糖化剤、またはその使用である。
まず、本発明における第1の発明の実施例について説明する。ただし、本発明における第1の発明は、以下の実施例により制限されない。市販の試薬は、特に示さない限り、それらのプロトコールに基づいて使用した。
グリセリンのオゾン酸化により、本発明における第1の発明の環状過酸化物を含む酸化反応生成物を製造した。さらに、製造した酸化反応生成物の酸化能およびTRPチャネル活性を確認した。本実施例は、本発明における第1の発明の環状過酸化物を製造し使用した実施例に該当するとともに、本発明における第1の発明の酸化反応生成物を製造し使用した実施例にも該当し、さらに、本発明における第1の発明の酸化反応生成物の製造方法の実施例にも該当する。
濃グリセリンとオゾンとを気液接触させ、以下に示すようにして、本発明における第1の発明の酸化反応生成物を含むオゾン処理グリセリン溶液(オゾンジェル)を製造した。ここで、前記濃グリセリンとは、日本薬局方品の98重量%以上の濃度のグリセリンを意味する。また、本実施例で製造した本発明における第1の発明の酸化反応生成物は、後述するように、本発明における第1の発明の環状過酸化物を含む。
前記「(1)本発明における第1の発明の環状過酸化物を含む酸化反応生成物の製造」で製造したグリセリンのオゾン酸化体溶存グリセリン溶液からグリセリンをシリカゲルカラムにより除去し、本発明における第1の発明の環状過酸化物が含まれている反応混合物(以下「TLC1スポット品」ということがある。)を得た。後述するとおり、このTLC1スポット品から本発明における第1の発明の環状過酸化物を分取せずにそのまま用いて、本発明における第1の発明の環状過酸化物の酸化能およびTRPチャネル活性を確認した。
前記反応混合物(TLC1スポット品)をアセトニトリルで約3質量%に調製(希釈)し、メンブレンフィルターでろ過して得られたろ液のLC測定を行い、分離条件の最適化を行った。次に、最適化した条件でのLC測定で認められたピークの質量確認を行い、Mw=180(ピーク2)の精密分取を行った。その後、得られた分画液の凍結乾燥を行い、分画物の乾固物について顕微LR測定および各種NMR測定を行った。測定機器(分析装置)および測定条件は、下記のとおりである。
[測定機器(分析装置)]
1)精密分取LC:Waters,ACQUITY UPLC H-class Bio
2)顕微LR:SNOM/AFM/Raman複合機 WITec製alpha300RSA
3)NMR:Bruker Biospin,AVANCEIII-600 with Cryo Probe
[測定条件]
1)精密分取LC
カラム:Shodex Asahipak NH2P-50(4.6mmφ×250mm,5μm)
溶離液組成:水/アセトニトリル系グラジエント
時間(min): 0 5 15 20
水: 5 10 50 50
アセトニトリル: 95 90 50 50
流量:1.0mL/min
検出器:MS(QDa)
カラム温度:40℃
注入量:50μL
イオン化法:ESI(NEG.)
測定質量範囲(m/z):50~500
2)顕微LR
励起波長:532nm
測定波数範囲:約125~3800cm-1
対物レンズ:×100
検出器:EMCCD
3)NMR
観測周波数:600MHz(1H)、150MHz(13C)
測定溶媒:methanol-d4
測定温度:300K
化学シフト標準:測定溶媒[3.30ppm(1H)、49.80ppm(13C)]
前記「(1)本発明における第1の発明の環状過酸化物を含む酸化反応生成物の製造」で製造したTLC1スポット品を分取(精製)せずにそのまま用いてTRPチャネル活性を確認した。なお、以下において、「G」は、オゾン酸化しないグリセリンを示す。以下において、「OG」は、酸素発生装置を用いてグリセリンをオゾン酸化したもの(オゾン化グリセリン)を示す。なお、「OG」の製造において、酸素発生装置を用いたグリセリンのオゾン酸化は、空気を酸素発生装置で高濃度酸素(酸素濃度70%以上)にし、その酸素をオゾン発生装置経由でオゾン化したオゾン濃度約37000ppmの気体を用い、下記条件Aにより行った。以下において、「LOG」は、「OG」をさらに酸化したものを示す。「OG」の酸化による「LOG」の製造は、酸素ボンベ(酸素濃度99%以上)からの酸素をオゾン発生装置経由でオゾン化したオゾン濃度約37000ppmの気体を用い、下記条件Bで行った。すなわち、以下の「LOG」は、前記「(1)本発明における第1の発明の環状過酸化物を含む酸化反応生成物の製造」で製造した、グリセリンのオゾン酸化体が終濃度4000ppmで溶存したグリセリン溶液と同一である。したがって、以下の「LOG」は、TLC1スポット品のグリセリン溶液ということになる。また、以下において、「HOG」は、「OG」を80℃で168時間加熱(熱処理)したものを示す。
(条件A:「OG」の製造)
タンクに、濃度98重量%以上のグリセリン(「G」すなわちオゾン化しないグリセリン)を入れた。つぎに、散気管を用いて、前記オゾン濃度約37000ppmの気体を、前記タンク内の「G」に約7日間曝気し、グリセリンのオゾン酸化体が終濃度4000ppmで溶存したグリセリン溶液を得た。このオゾン処理グリセリン溶液を「OG」として用いた。
(条件B:「LOG」の製造)
タンクに、前記条件Aにより製造した「OG」を入れた。つぎに、散気管を用いて、前記オゾン濃度約37000ppmの気体を、前記タンク内の「G」に約7日間曝気することにより、過酸化水素濃度換算で2000ppmのオゾン処理グリセリン溶液を製造した。このオゾン処理グリセリン溶液を「LOG」として用いた。
グリセリンのオゾン酸化により、前記環状過酸化物を含む酸化反応生成物を製造した。さらに、製造した酸化反応生成物の美白作用を確認した。本実施例は、前記環状過酸化物を製造し使用した実施例に該当するとともに、前記酸化反応生成物を製造し使用した実施例にも該当し、さらに、前記酸化反応生成物の製造方法の実施例にも該当する。
濃グリセリンとオゾンとを気液接触させ、以下に示すようにして、前記酸化反応生成物を含むオゾン処理グリセリン溶液(オゾン化グリセリン)を製造した。ここで、前記濃グリセリンとは、日本薬局方品の98重量%以上の濃度のグリセリンを意味する。また、本実施例で製造した本発明における第2の発明の前記酸化反応生成物は、後述するように、本発明における第2の発明の前記環状過酸化物を含む。
被検者は、健常者(女性、41歳以上、59歳以下)48名とした。各被検者については、事前に説明文書(同意書を含む)に基づき十分に説明し、同意を書面にて取得した。
(試験群1)
半顔:実施例2-1Aの試験品
他方の半顔:参考例2-1Aの試験品
(試験群2)
半顔:実施例2-1Bの試験品
他方の半顔:参考例2-1Bの試験品
前記オゾン化グリセリン中の美白成分の有効成分を特定するために、前記実施例2(1)のオゾン化グリセリンからグリセリンには見られない環状過酸化物を抽出し、解析した。前記「実施例2(1)前記環状過酸化物を含む酸化反応生成物の製造」で製造したグリセリンのオゾン酸化体溶存グリセリン溶液からグリセリンをシリカゲルカラムにより除去し、前記環状過酸化物が含まれている反応混合物(以下「TLC1スポット品」ということがある。)を得た。
前記反応混合物(TLC1スポット品)をアセトニトリルで約3質量%に調製(希釈)し、メンブレンフィルターでろ過して得られたろ液のLC測定を行い、分離条件の最適化を行った。次に、最適化した条件でのLC測定で認められたピークの質量確認を行い、Mw=180(ピーク2)の精密分取を行った。その後、得られた分画液の凍結乾燥を行い、分画物の乾固物について顕微LR測定および各種NMR測定を行った。測定機器(分析装置)および測定条件は、下記のとおりである。
[測定機器(分析装置)]
1)精密分取LC:Waters,ACQUITY UPLC H-class Bio
2)顕微LR:SNOM/AFM/Raman複合機 WITec製alpha300RSA
3)NMR:Bruker Biospin,AVANCEIII-600 with Cryo Probe
[測定条件]
1)精密分取LC
カラム:Shodex Asahipak NH2P-50(4.6mmφ×250mm,5μm)
溶離液組成:水/アセトニトリル系グラジエント
時間(min): 0 5 15 20
水: 5 10 50 50
アセトニトリル: 95 90 50 50
流量:1.0mL/min
検出器:MS(QDa)
カラム温度:40℃
注入量:50μL
イオン化法:ESI(NEG.)
測定質量範囲(m/z):50~500
2)顕微LR
励起波長:532nm
測定波数範囲:約125~3800cm-1
対物レンズ:×100
検出器:EMCCD
3)NMR
観測周波数:600MHz(1H)、150MHz(13C)
測定溶媒:methanol-d4
測定温度:300K
化学シフト標準:測定溶媒[3.30ppm(1H)、49.80ppm(13C)]
つぎに、前記実施例3について説明する。ただし、本発明における第3の発明は、以下の実施例により制限されない。市販の試薬は、特に示さない限り、それらのプロトコールに基づいて使用した。
グリセリンのオゾン酸化により、前記環状過酸化物を含む酸化反応生成物を製造した。さらに、製造した酸化反応生成物の皮膚バリア機能関連遺伝子の発現誘導作用を確認した。本実施例は、前記環状過酸化物を製造し使用した実施例に該当するとともに、前記酸化反応生成物を製造し使用した実施例にも該当し、さらに、前記酸化反応生成物の製造方法の実施例にも該当する。
濃グリセリンとオゾンとを気液接触させ、以下に示すようにして、前記酸化反応生成物を含むオゾン処理グリセリン溶液(オゾン化グリセリン)を製造した。ここで、前記濃グリセリンとは、日本薬局方品の98重量%以上の濃度のグリセリンを意味する。また、本実施例で製造した本発明における第3の発明の前記酸化反応生成物は、後述するように、本発明における第3の発明の前記環状過酸化物を含む。
ヒト表皮角化細胞を用いて、前記オゾン化グリセリンが、皮膚バリア機能遺伝子の発現を誘導できるかを確認した。具体的には、正常ヒト表皮細胞(NHEK:クラボウ社製)を、培地(HuMedia-KG2(KG2)、クラボウ社製)に懸濁後、2.0×104cells/well/100μlとなるように96ウェルプレートに播種し、37℃、5% CO2の条件(培養条件については、以下同様)下で24時間培養した。前記培養後、各ウェルの培地を、前記実施例3-1(1)のオゾン化グリセリンを所定濃度(1、2、または4(v/v)%)で含有するKG2培地(100μl/well)に交換し、さらに、24時間培養した。つぎに、各ウェルの培地を除去後、リン酸緩衝液(PBS(-))を用いて細胞を洗浄し、RNA抽出キット(Ambion(登録商標) Cells-to-CT(商標)Kits、Thermo社製)を用いてRNAを抽出した。得られたRNAについて、逆転写反応によってcDNAを合成した。
フォワードプライマー(配列番号1)
5'-CATGGCAGCTATGGTAGTGCAGA-3'
リバースプライマー(配列番号2)
5'-ACCAAACGCACTTGCTTTACAGA-3'
・インボルクリン遺伝子用プライマーセット
フォワードプライマー(配列番号3)
5'-GCTGGAGCAGCCTGTGTTTG-3'
リバースプライマー(配列番号4)
5'-CTGGACACTGCGGGTGGTTA-3'
・セリンパルミトイルトランスフェラーゼ遺伝子用プライマーセット
フォワードプライマー(配列番号5)
5'-GCCTGTCAGCAGCTCATACCAA-3'
リバースプライマー(配列番号6)
5'-GGCCTGTCCAGTAGAGGTACCAA-3'
・GAPDH遺伝子用プライマーセット
フォワードプライマー(配列番号7)
5'-GCACCGTCAAGGCTGAGAAC-3'
リバースプライマー(配列番号8)
5'-TGGTGAAGACGCCAGTGGA-3'
ヒト表皮角化細胞を用いて、前記オゾン化グリセリンが、抗酸化ストレス応答遺伝子の発現を誘導できるかを確認した。前記実施例3-1(2)と同様にして、cDNAを調製した。前記cDNAについて、前記実施例3-1(2)と同様にして、ヘムオキシゲナーゼ1遺伝子およびNAD(P)Hキノンオキシドレダクターゼ1遺伝子のmRNAの発現量を算出した(ΔΔCt法)。各遺伝子のmRNAの増幅には、下記のプライマーセットを用い、各遺伝子の発現量は、GAPDH遺伝子のmRNAの発現量の相対値として算出した。比較例は、前記オゾン化グリセリンに変えて、前記濃グリセリンを用いた以外は同様にして実施した。これらの結果を図3-2に示す。
フォワードプライマー(配列番号9)
5'-TTGCCAGTGCCACCAAGTTC-3'
リバースプライマー(配列番号10)
5'-TCAGCAGCTCCTGCAACTCC-3'
・NAD(P)Hキノンオキシドレダクターゼ1遺伝子用プライマーセット
フォワードプライマー(配列番号11)
5'-GTGGCAGTGGCTCCATGTACTC-3'
リバースプライマー(配列番号12)
5'-GAGTGTGCCCAATGCTATATGTCAG-3'
ヒト表皮角化細胞を用いて、前記オゾン化グリセリンが、細胞毒性を有さないことを確認した。具体的には、前記実施例3-1(3)と同様にして、所定濃度のオゾン化グリセリンを含有するKG2培地の存在下で24時間または48時間培養した。前記培養後、各ウェルの培地を除去した。つぎに、0.003% Neutral Red(NR:Sigma-Aldrich社製)を含む培地に交換し、37℃で2時間培養した。PBS(-)を用いて各ウェルを洗浄後、30(v/v)%メタノールを含有する1mol/l塩酸溶液を100μl/lで添加して、NRを抽出した。得られた抽出液について、前記吸光光度計を用いて、吸光度(測定波長:550nm、参照波長:650nm)を測定し、細胞生存率を算出した。これらの結果を図3-4に示す。
ヒト表皮角化細胞を用いて、前記オゾン化グリセリンが、抗炎症作用を示すことを確認した。具体的には、3次元培養表皮(LabCyte EPI-MODEL、J-TEC社製)を、付属のアッセイ培地(assay medium)を500μl添加した24ウェルプレートにセットし、37℃、5% CO2の条件下で一晩馴化培養した。前記培養後、角層側から前記オゾン化グリセリンを所定濃度(0または1(v/v)%)で含有するアッセイ培地を30μl塗布し、37℃で24時間培養した。前記培養後、前記オゾン化グリセリンを含有するアッセイ培地をを綿棒で除去し、さらに、PBS(-) 500μlを用いて、角層表面を1回洗浄した。つぎに、綿棒を用いて、前記角質表面からPBS(-)を除去後、UVBを照射(280-315nm、600mJ/cm2)した。さらに、新たなアッセイ培地を500μl添加したプレートに、前記3次元培養表皮を移動させた後、さらに、37℃、5% CO2の条件下で24時間培養した。
前記オゾン化グリセリン中の有効成分が環状過酸化物であることを確認した。
前記オゾン化グリセリン中の皮膚バリア機能関連遺伝子の発現誘導成分の有効成分を特定するために、前記実施例3-1(1)のオゾン化グリセリンからグリセリンには見られない環状過酸化物を抽出し、解析した。前記「実施例3-1(1)前記環状過酸化物を含む酸化反応生成物の製造」で製造したグリセリンのオゾン酸化体溶存グリセリン溶液からグリセリンをシリカゲルカラムにより除去し、前記環状過酸化物が含まれている反応混合物(以下「TLC1スポット品」ということがある。)を得た。
前記反応混合物(TLC1スポット品)をアセトニトリルで約3質量%に調製(希釈)し、メンブレンフィルターでろ過して得られたろ液のLC測定を行い、分離条件の最適化を行った。次に、最適化した条件でのLC測定で認められたピークの質量確認を行い、Mw=180(ピーク2)の精密分取を行った。その後、得られた分画液の凍結乾燥を行い、分画物の乾固物について顕微LR測定および各種NMR測定を行った。測定機器(分析装置)および測定条件は、下記のとおりである。
[測定機器(分析装置)]
1)精密分取LC:Waters,ACQUITY UPLC H-class Bio
2)顕微LR:SNOM/AFM/Raman複合機 WITec製alpha300RSA
3)NMR:Bruker Biospin,AVANCEIII-600 with Cryo Probe
[測定条件]
1)精密分取LC
カラム:Shodex Asahipak NH2P-50(4.6mmφ×250mm,5μm)
溶離液組成:水/アセトニトリル系グラジエント
時間(min): 0 5 15 20
水: 5 10 50 50
アセトニトリル: 95 90 50 50
流量:1.0mL/min
検出器:MS(QDa)
カラム温度:40℃
注入量:50μL
イオン化法:ESI(NEG.)
測定質量範囲(m/z):50~500
2)顕微LR
励起波長:532nm
測定波数範囲:約125~3800cm-1
対物レンズ:×100
検出器:EMCCD
3)NMR
観測周波数:600MHz(1H)、150MHz(13C)
測定溶媒:methanol-d4
測定温度:300K
化学シフト標準:測定溶媒[3.30ppm(1H)、49.80ppm(13C)]
つぎに、前記実施例4について説明する。ただし、本発明における第4の発明は、以下の実施例により制限されない。市販の試薬は、特に示さない限り、それらのプロトコールに基づいて使用した。
グリセリンのオゾン酸化により、前記環状過酸化物を含む酸化反応生成物を製造した。さらに、製造した酸化反応生成物の抗糖化作用を確認した。本実施例は、前記環状過酸化物を製造し使用した実施例に該当するとともに、前記酸化反応生成物を製造し使用した実施例にも該当し、さらに、前記酸化反応生成物の製造方法の実施例にも該当する。
濃グリセリンとオゾンとを気液接触させ、以下に示すようにして、前記酸化反応生成物を含むオゾン処理グリセリン溶液(オゾン化グリセリン)を製造した。ここで、前記濃グリセリンとは、日本薬局方品の98重量%以上の濃度のグリセリンを意味する。また、本実施例で製造した本発明における第4の発明の前記酸化反応生成物は、後述するように、本発明における第4の発明の前記環状過酸化物を含む。
AGEsの架橋構造の切断活性については、参考文献1(Sara Vasan et al.Nature,382,pp275-278(1996))に準じて測定した。具体的には、基質として、αジケトン構造を有するAGEs架橋モデルの反応基質である1-Phenyl-1,2-propanedione(PPD)を用い、PPDの切断を検出することにより、AGEsの架橋構造の切断活性を測定した。ポジティブコントロールは、AGEsの架橋構造の切断活性を有することが知られている、N-phenacylthiazolium bromide(PTB)を用いた。
(サンプル液)
・オゾン化グリセリンの希釈液:実施例4-1(1)のオゾン化グリセリンをオゾン酸化体の濃度が10、100、または1000ppmとなるように、水で希釈した液
・濃グリセリン液
・5または10mmol/l PTB(溶媒:50%アセトニトリル)
・過酸化水素水:H2O2濃度が、1または10mmol/lとなるように水で希釈した液
(逆相HPLCの測定条件)
カラム:Cadenza CD-C18 75mm×4.6mmID(Imtakt株式会社製)
移動相:0.2%酢酸/アセトニトリル(70:30)
(2mmol/l EDTA-2Naを含む)
流速:1ml/分
測定波長:230nm
抗糖化率(%)={(A-B)/C}×100 ・・・(1)
A:測定試料中の安息香酸量
B:サンプル液中の安息香酸量
C:反応に供したPPD量(基質量)
前記オゾン化グリセリン中の有効成分が環状過酸化物であることを確認した。
前記オゾン化グリセリン中の抗糖化成分の有効成分を特定するために、前記実施例4-1(1)のオゾン化グリセリンからグリセリンには見られない環状過酸化物を抽出し、解析した。前記「実施例4-1(1)前記環状過酸化物を含む酸化反応生成物の製造」で製造したグリセリンのオゾン酸化体溶存グリセリン溶液からグリセリンをシリカゲルカラムにより除去し、前記環状過酸化物が含まれている反応混合物(以下「TLC1スポット品」ということがある。)を得た。
前記反応混合物(TLC1スポット品)をアセトニトリルで約3質量%に調製(希釈)し、メンブレンフィルターでろ過して得られたろ液のLC測定を行い、分離条件の最適化を行った。次に、最適化した条件でのLC測定で認められたピークの質量確認を行い、Mw=180(ピーク2)の精密分取を行った。その後、得られた分画液の凍結乾燥を行い、分画物の乾固物について顕微LR測定および各種NMR測定を行った。測定機器(分析装置)および測定条件は、下記のとおりである。
[測定機器(分析装置)]
1)精密分取LC:Waters,ACQUITY UPLC H-class Bio
2)顕微LR:SNOM/AFM/Raman複合機 WITec製alpha300RSA
3)NMR:Bruker Biospin,AVANCEIII-600 with Cryo Probe
[測定条件]
1)精密分取LC
カラム:Shodex Asahipak NH2P-50(4.6mmφ×250mm,5μm)
溶離液組成:水/アセトニトリル系グラジエント
時間(min): 0 5 15 20
水: 5 10 50 50
アセトニトリル: 95 90 50 50
流量:1.0mL/min
検出器:MS(QDa)
カラム温度:40℃
注入量:50μL
イオン化法:ESI(NEG.)
測定質量範囲(m/z):50~500
2)顕微LR
励起波長:532nm
測定波数範囲:約125~3800cm-1
対物レンズ:×100
検出器:EMCCD
3)NMR
観測周波数:600MHz(1H)、150MHz(13C)
測定溶媒:methanol-d4
測定温度:300K
化学シフト標準:測定溶媒[3.30ppm(1H)、49.80ppm(13C)]
上記の実施形態および実施例の一部または全部は、以下の付記のように記載されうるが、以下には限られない。
(付記1)
下記化学式(I)で表されることを特徴とする環状過酸化物。
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記2)
前記化学式(I)中、
R100が、環員数5~10の環状構造である付記1記載の環状過酸化物。
(付記3)
下記化学式(II)で表される付記1または2記載の環状過酸化物。
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記4)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である付記3記載の環状過酸化物。
(付記5)
下記化学式(1)で表される付記1から4のいずれかに記載の環状過酸化物。
アルコールを酸化して得られる、環状過酸化物を含むことを特徴とする酸化反応生成物。
(付記7)
前記アルコールの酸化が、オゾン酸化および過酸化水素酸化の少なくとも一方である付記6記載の酸化反応生成物。
(付記8)
複数の酸化反応生成物を含む混合物である付記6または7記載の酸化反応生成物。
(付記9)
酸化能を有する付記6から8のいずれかに記載の酸化反応生成物。
(付記10)
還元能を有する付記6から9のいずれかに記載の酸化反応生成物。
(付記11)
TRPチャネル活性物質を含む付記6から10のいずれかに記載の酸化反応生成物。
(付記12)
前記アルコールが、飽和アルコールである付記6から11のいずれかに記載の酸化反応生成物。
(付記13)
前記アルコールが、多価アルコールである付記6から12のいずれかに記載の酸化反応生成物。
(付記14)
前記アルコールが、グリセリンおよびグリセリン誘導体の少なくとも一方である付記6から13のいずれかに記載の酸化反応生成物。
(付記15)
前記アルコールの分子が2分子以上結合して得られた酸化反応生成物を含む、付記6から14のいずれかに記載の酸化反応生成物。
(付記16)
付記1から5のいずれかに記載の環状過酸化物を含む、付記6から15のいずれかに記載の酸化反応生成物。
(付記17)
前記アルコールを酸化するアルコール酸化工程を含む付記6から16のいずれかに記載の酸化反応生成物の製造方法。
(付記18)
前記アルコール酸化工程において、オゾン酸化および過酸化水素酸化の少なくとも一方により前記アルコールを酸化する付記17記載の酸化反応生成物の製造方法。
(付記19)
前記アルコール酸化工程における反応時間が24時間以上である付記17または18記載の酸化反応生成物の製造方法。
<美白用組成物>
(付記20)
グリセリンおよび/またはグリセリン誘導体と、美白成分とを含み、
前記美白成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む、美白用組成物:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記21)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記20に記載の美白用組成物。
(付記22)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記20または21に記載の美白用組成物:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記23)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記22に記載の美白用組成物。
(付記24)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記20から23のいずれかに記載の美白用組成物。
グリセリンおよび/またはグリセリン誘導体と、美白成分とを含み、
前記美白成分が、有効成分として、アルコールを酸化して得られる、環状過酸化物またはその塩を含む酸化反応生成物を含む、美白用組成物。
(付記26)
前記アルコールの酸化が、オゾン酸化および過酸化水素酸化の少なくとも一方である、付記25に記載の美白用組成物。
(付記27)
複数の酸化反応生成物を含む混合物である、付記25または26に記載の美白用組成物。
(付記28)
前記酸化反応生成物が、酸化能を有する、付記25から27のいずれかに記載の美白用組成物。
(付記29)
前記酸化反応生成物が、還元能を有する、付記25から28のいずれかに記載の美白用組成物。
(付記30)
前記酸化反応生成物が、メラニン分解活性、メラニン生成抑制活性、および/またはメラニンの排出促進活性を有する、付記25から29のいずれかに記載の美白用組成物。
(付記31)
前記アルコールが、飽和アルコールである、付記25から30のいずれかに記載の美白用組成物。
(付記32)
前記アルコールが、多価アルコールである、付記25から31のいずれかに記載の美白用組成物。
(付記33)
前記アルコールが、グリセリンおよびグリセリン誘導体の少なくとも一方である、付記25から32のいずれかに記載の美白用組成物。
(付記34)
前記アルコールの分子が2分子以上結合して得られた酸化反応生成物を含む、付記25から33のいずれかに記載の美白用組成物。
(付記35)
付記20から24のいずれかに記載の環状過酸化物を含む、付記25から34のいずれかに記載の美白用組成物。
(付記36)
皮膚に用いる、付記20から35のいずれかに記載の美白用組成物。
(付記37)
前記組成物は、化粧料である、付記20から36のいずれかに記載の美白用組成物。
<美白剤>
(付記38)
下記化学式(I)で表される環状過酸化物またはその塩を含む、美白剤:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記39)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記38に記載の美白剤。
(付記40)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記38または39に記載の美白剤:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記41)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記40に記載の美白剤。
(付記42)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記38から41のいずれかに記載の美白剤。
アルコールを酸化して得られる、環状過酸化物またはその塩を含む酸化反応生成物を含む、美白剤。
(付記44)
前記アルコールの酸化が、オゾン酸化および過酸化水素酸化の少なくとも一方である、付記43に記載の美白剤。
(付記45)
複数の酸化反応生成物を含む混合物である、付記43または44に記載の美白剤。
(付記46)
前記酸化反応生成物が、酸化能を有する、付記43から45のいずれかに記載の美白剤。
(付記47)
前記酸化反応生成物が、還元能を有する、付記43から46のいずれかに記載の美白剤。
(付記48)
前記酸化反応生成物が、メラニン分解活性、メラニン生成抑制活性、および/またはメラニンの排出促進活性を有する、付記43から47のいずれかに記載の美白剤。
(付記49)
前記アルコールが、飽和アルコールである、付記43から48のいずれかに記載の美白剤。
(付記50)
前記アルコールが、多価アルコールである、付記43から49のいずれかに記載の美白剤。
(付記51)
前記アルコールが、グリセリンおよびグリセリン誘導体の少なくとも一方である、付記43から50のいずれかに記載の美白剤。
(付記52)
前記アルコールの分子が2分子以上結合して得られた酸化反応生成物を含む、付記43から51のいずれかに記載の美白剤。
(付記53)
付記38から42のいずれかに記載の環状過酸化物を含む、付記43から52のいずれかに記載の美白剤。
(付記54)
皮膚に用いる、付記38から53のいずれかに記載の美白剤。
<美白方法>
(付記55)
付記20から37のいずれかに記載の美白用組成物および/または付記38から54のいずれかに記載の美容剤を使用する、美白方法。
(付記56)
対象の皮膚に、前記美白用組成物および/または前記美容剤を使用する、付記55に記載の美白方法。
<使用>
(付記57)
美白に用いるための、付記20から37のいずれかに記載の美白用組成物および/または付記38から54のいずれかに記載の美容剤。
<皮膚バリア機能関連遺伝子の発現誘導用組成物>
(付記58)
グリセリンおよび/またはグリセリン誘導体と、皮膚バリア機能関連遺伝子の発現誘導成分とを含み、
前記皮膚バリア機能関連遺伝子の発現誘導成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む、皮膚バリア機能関連遺伝子の発現誘導用組成物:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記59)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記58に記載の発現誘導用組成物。
(付記60)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記58または59に記載の発現誘導用組成物:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記61)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記60に記載の発現誘導用組成物。
(付記62)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記58から61のいずれかに記載の発現誘導用組成物。
皮膚に用いるための、付記58から62のいずれかに記載の発現誘導用組成物。
(付記64)
前記組成物は、化粧料である、付記58から63のいずれかに記載の発現誘導用組成物。
(付記65)
前記皮膚バリア機能関連遺伝子は、プロフィラグリン(Pro filaggrin)遺伝子、インボルクリン(Involucrin)遺伝子、および/またはセリンパルミトイルトランスフェラーゼ(Serine palmitoyltransferase)遺伝子である、付記58から64のいずれかに記載の発現誘導用組成物。
(付記66)
前記皮膚バリア機能関連遺伝子は、プロフィラグリン(Pro filaggrin)遺伝子である、付記58から64のいずれかに記載の発現誘導用組成物。
<皮膚バリア機能の改善用組成物>
(付記67)
付記58から66のいずれかに記載の皮膚バリア機能関連遺伝子の発現誘導用組成物を含む、皮膚バリア機能の改善用組成物。
(付記68)
経皮投与により対象の皮膚における皮膚バリア機能関連遺伝子の発現を誘導し、前記対象の皮膚バリア機能を改善させる方法に用いるための、付記67に記載の改善用組成物。
<皮膚バリア機能関連遺伝子の発現誘導剤>
(付記69)
下記化学式(I)で表される環状過酸化物またはその塩を含む、皮膚バリア機能関連遺伝子の誘導剤:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記70)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記69に記載の誘導剤。
(付記71)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記69または70に記載の誘導剤:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記72)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記71に記載の誘導剤。
(付記73)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記69から72のいずれかに記載の誘導剤。
皮膚に用いるための、付記69から73のいずれかに記載の誘導剤。
(付記75)
前記皮膚バリア機能関連遺伝子は、プロフィラグリン(Pro filaggrin)遺伝子、インボルクリン(Involucrin)遺伝子、および/またはセリンパルミトイルトランスフェラーゼ(Serine palmitoyltransferase)遺伝子である、付記69から74のいずれかに記載の誘導剤。
(付記76)
前記皮膚バリア機能関連遺伝子は、プロフィラグリン(Pro filaggrin)遺伝子である、付記69から75のいずれかに記載の誘導剤。
<皮膚バリア機能の改善剤>
(付記77)
付記69から76のいずれかに記載の皮膚バリア機能関連遺伝子の誘導剤を含む、皮膚バリア機能の改善剤。
(付記78)
経皮投与により対象の皮膚における皮膚バリア機能関連遺伝子の発現を誘導し、前記対象の皮膚バリア機能を改善させる方法に用いるための、付記77に記載の改善剤。
<抗酸化ストレス応答遺伝子の発現誘導用組成物>
(付記79)
グリセリンおよび/またはグリセリン誘導体と、抗酸化ストレス応答遺伝子の発現誘導成分とを含み、
前記抗酸化ストレス応答遺伝子の発現誘導成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む、抗酸化ストレス応答遺伝子の発現誘導用組成物:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記80)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記79に記載の発現誘導用組成物。
(付記81)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記79または80に記載の発現誘導用組成物:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記82)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記81に記載の発現誘導用組成物。
(付記83)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記79から82のいずれかに記載の発現誘導用組成物。
皮膚に用いるための、付記79から83のいずれかに記載の発現誘導用組成物。
(付記85)
前記発現誘導用組成物は、化粧料である、付記79から84のいずれかに記載の発現誘導用組成物。
(付記86)
前記抗酸化ストレス応答遺伝子は、ヘムオキシゲナーゼ1(Heme oxygenase 1)遺伝子、NAD(P)Hキノンオキシドレダクターゼ1(NAD(P)H quinone oxidoreductase 1)遺伝子、および/またはグルタチオン遺伝子である、付記79から85のいずれかに記載の発現誘導用組成物。
(付記87)
前記抗酸化ストレス応答遺伝子の発現誘導用組成物は、表皮角化細胞における抗酸化ストレス応答遺伝子の発現誘導用組成物である、付記79から86のいずれかに記載の発現誘導用組成物。
<抗酸化ストレス応答遺伝子の発現誘導剤>
(付記88)
下記化学式(I)で表される環状過酸化物またはその塩を含む、抗酸化ストレス応答遺伝子の発現誘導剤:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記89)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記88に記載の誘導剤。
(付記90)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記88または89に記載の誘導剤:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記91)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記90に記載の誘導剤。
(付記92)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記88から91のいずれかに記載の誘導剤。
皮膚に用いるための、付記88から92のいずれかに記載の誘導剤。
(付記94)
前記抗酸化ストレス応答遺伝子は、ヘムオキシゲナーゼ1(Heme oxygenase 1)遺伝子、NAD(P)Hキノンオキシドレダクターゼ1(NAD(P)H quinone oxidoreductase 1)遺伝子、および/またはグルタチオン遺伝子である、付記88から93のいずれかに記載の誘導剤。
<抗炎症組成物>
(付記95)
グリセリンおよび/またはグリセリン誘導体と、抗炎症成分とを含み、
前記抗炎症成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む、抗炎症組成物:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記96)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記95に記載の抗炎症組成物。
(付記97)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記95または96に記載の抗炎症組成物:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記98)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記97に記載の抗炎症組成物。
(付記99)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記95から98のいずれかに記載の抗炎症組成物。
皮膚に用いるための、付記95から99のいずれかに記載の抗炎症組成物。
(付記101)
前記発現誘導用組成物は、化粧料である、付記95から100のいずれかに記載の抗炎症組成物。
(付記102)
前記抗炎症組成物組成物は、IL-1α遺伝子の発現抑制組成物、IL-1αの産生抑制組成物、および/またはプロスタグランジンE2の産生抑制組成物である、付記95から101のいずれかに記載の抗炎症組成物。
(付記103)
前記抗炎症組成物は、表皮角化細胞における炎症抑制組成物である、付記95から102のいずれかに記載の抗炎症組成物。
<抗炎症剤>
(付記104)
下記化学式(I)で表される環状過酸化物またはその塩を含む、抗炎症剤:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記105)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記104に記載の抗炎症剤。
(付記106)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記104または105に記載の抗炎症剤:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記107)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記106に記載の抗炎症剤。
(付記108)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記104から107のいずれかに記載の抗炎症剤。
皮膚に用いるための、付記104から108のいずれかに記載の抗炎症剤。
(付記110)
前記抗炎症剤は、IL-1α遺伝子の発現抑制剤、IL-1αの産生抑制剤、および/またはプロスタグランジンE2の産生抑制剤である、付記104から109のいずれかに記載の抗炎症剤。
(付記111)
前記抗炎症剤は、表皮角化細胞における炎症抑制剤である、付記104から110のいずれかに記載の抗炎症剤。
<皮膚バリア機能関連遺伝子の発現誘導方法>
(付記112)
付記58から66のいずれかに記載の皮膚バリア機能関連遺伝子の発現誘導促進組成物、および/または、付記69から76のいずれかに記載の皮膚バリア機能関連遺伝子の発現誘導促進剤を使用する、皮膚バリア機能関連遺伝子の発現誘導方法。
(付記113)
対象に、前記発現誘導促進組成物、および/または、発現誘導促進剤を投与する、付記112に記載の発現誘導方法。
(付記114)
前記対象の皮膚に投与する、付記113に記載の発現誘導方法。
(付記115)
in vitroまたはin vivoで使用する、付記112から114のいずれかに記載の発現誘導方法。
<皮膚バリア機能の改善方法>
(付記116)
付記67または68に記載の皮膚バリア機能の改善組成物、および/または、付記77または78に記載の皮膚バリア機能の改善剤を使用する、皮膚バリア機能の改善方法。
(付記117)
対象に、前記皮膚バリア機能の改善組成物、および/または、皮膚バリア機能の改善剤を投与する、付記116に記載の改善方法。
(付記118)
前記対象の皮膚に投与する、付記117に記載の改善方法。
(付記119)
in vitroまたはin vivoで使用する、付記116から118のいずれかに記載の改善方法。
<抗酸化ストレス応答遺伝子の発現誘導方法>
(付記120)
付記79から87のいずれかに記載の抗酸化ストレス応答遺伝子の発現誘導促進組成物、および/または、付記88から94のいずれかに記載の抗酸化ストレス応答遺伝子の発現誘導促進剤を使用する、抗酸化ストレス応答遺伝子の発現誘導方法。
(付記121)
対象に、前記発現誘導促進組成物、および/または、発現誘導促進剤を投与する、付記120に記載の発現誘導方法。
(付記122)
前記対象の皮膚に投与する、付記121に記載の発現誘導方法。
(付記123)
in vitroまたはin vivoで使用する、付記120から122のいずれかに記載の発現誘導方法。
<炎症の抑制方法>
(付記124)
付記95から103のいずれかに記載の抗炎症組成物、および/または、付記104から111のいずれかに記載の抗炎症剤を使用する、炎症の抑制方法。
(付記125)
対象に、前記抗炎症組成物、および/または、抗炎症剤を投与する、付記124に記載の抑制方法。
(付記126)
前記対象の皮膚に投与する、付記125に記載の発現誘導方法。
(付記127)
in vitroまたはin vivoで使用する、付記124から126のいずれかに記載の抑制方法。
<炎症性疾患の処置方法>
(付記128)
対象に、付記95から103のいずれかに記載の抗炎症組成物、および/または、付記104から111のいずれかに記載の抗炎症剤を投与する、炎症性疾患の処置方法。
(付記129)
前記対象の皮膚に投与する、付記128に記載の処置方法。
(付記130)
in vitroまたはin vivoで使用する、付記128または129のいずれかに記載の処置方法。
<使用>
(付記131)
皮膚バリア機能関連遺伝子の発現誘導に用いるための、組成物であって、
前記組成物は、付記58から66のいずれかに記載の皮膚バリア機能関連遺伝子の発現誘導用組成物を含む、組成物。
(付記132)
皮膚バリア機能関連遺伝子の発現誘導に用いるための剤であって、
前記剤は、付記69から76のいずれかに記載の皮膚バリア機能関連遺伝子の発現誘導剤を含む、剤。
(付記133)
皮膚バリア機能の改善に用いるための、組成物であって、
前記組成物は、付記67または68に記載の皮膚バリア機能の改善用組成物を含む、組成物。
(付記134)
皮膚バリア機能の改善に用いるための剤であって、
前記剤は、付記77または78に記載の皮膚バリア機能の改善剤を含む、剤。
(付記135)
抗酸化ストレス応答遺伝子の発現誘導に用いるための、組成物であって、
前記組成物は、付記79から87のいずれかに記載の抗酸化ストレス応答遺伝子の発現誘導用組成物を含む、組成物。
(付記136)
抗酸化ストレス応答遺伝子の発現誘導に用いるための剤であって、
前記剤は、付記88から94のいずれかに記載の抗酸化ストレス応答遺伝子の発現誘導剤を含む、剤。
(付記137)
抗炎症に用いるための、組成物であって、
前記組成物は、付記95から103のいずれかに記載の抗炎症組成物を含む、組成物。
(付記138)
抗炎症に用いるための剤であって、
前記剤は、付記104から111のいずれかに記載の抗炎症剤を含む、剤。
(付記139)
炎症性疾患の処置に用いるための、組成物であって、
前記組成物は、付記95から103のいずれかに記載の抗炎症組成物を含む、組成物。
(付記140)
炎症性疾患の処置に用いるための剤であって、
前記剤は、付記104から111のいずれかに記載の抗炎症剤を含む、剤。
<抗糖化用組成物>
(付記141)
グリセリンおよび/またはグリセリン誘導体と、抗糖化成分とを含み、
前記抗糖化成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む、抗糖化用組成物:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記142)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記141に記載の抗糖化用組成物。
(付記143)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記141または142に記載の抗糖化用組成物:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記144)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記143に記載の抗糖化用組成物。
(付記145)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記141から144のいずれかに記載の抗糖化用組成物。
糖化反応により生じたポリペプチドおよび/またはタンパク質間の架橋構造を切断するための、付記141から145のいずれかに記載の抗糖化用組成物。
(付記147)
皮膚に用いるための、付記141から146のいずれかに記載の抗糖化用組成物。
(付記148)
前記組成物は、化粧料である、付記141から147のいずれかに記載の抗糖化用組成物。
<抗糖化剤>
(付記149)
下記化学式(I)で表される環状過酸化物またはその塩を含む、抗糖化剤:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。
(付記150)
前記化学式(I)中、
R100が、環員数5~10の環状構造である、付記149に記載の抗糖化剤。
(付記151)
前記化学式(I)で表される環状過酸化物が、下記化学式(II)で表される、付記149または150に記載の抗糖化剤:
各R11は、互いに同一でも異なっていてもよく、それぞれ、水素原子または置換基であり、同一の炭素原子に結合している2つのR11は、一体となって、オキソ基(=O)、またはチオキソ基(=S)を形成していてもよい。
(付記152)
前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、付記151に記載の抗糖化剤。
(付記153)
前記化学式(I)で表される環状過酸化物が、下記化学式(1)で表される、付記149から152のいずれかに記載の抗糖化剤。
糖化反応により生じたポリペプチドおよび/またはタンパク質間の架橋構造を切断するための、付記149から153のいずれかに記載の抗糖化剤。
(付記155)
皮膚に用いるための、付記149から154のいずれかに記載の抗糖化剤。
<抗糖化方法>
(付記156)
付記141から148のいずれかに記載の抗糖化組成物、および/または、付記149から155のいずれかに記載の抗糖化剤を使用する、抗糖化方法。
(付記157)
対象に、前記抗糖化組成物、および/または、抗糖化剤を投与する、付記156に記載の抗糖化方法。
(付記158)
前記対象の皮膚に投与する、付記157に記載の抗糖化方法。
(付記159)
in vitroまたはin vivoで使用する、付記156から158のいずれかに記載の抗糖化方法。
<使用>
(付記160)
抗糖化に用いるための、組成物であって、
前記組成物は、付記141から148のいずれかに記載の抗糖化用組成物を含む、組成物。
(付記161)
抗糖化に用いるための剤であって、
前記剤は、付記149から155のいずれかに記載の抗糖化剤を含む、剤。
以上のように、本発明における第1の発明の環状過酸化物、酸化反応生成物、酸化反応生成物の製造方法は、安全性が高いため、例えば、医薬、化粧品、食品、サプリメント等の分野において、極めて有用である。
以上のように、本発明における第2の発明の美白組成物は、例えば、化粧料等の分野において、極めて有用である。
以上のように、本発明における第3の発明の皮膚バリア機能関連遺伝子の発現誘導組成物は、皮膚バリア機能関連遺伝子の発現誘導をできるため、例えば、化粧料等の分野において、極めて有用である。
以上のように、本発明における第4の発明の抗糖化用組成物は、抗糖化活性を有するため、例えば、化粧料等の分野において、極めて有用である。
Claims (100)
- 前記化学式(I)中、
R100が、環員数5~10の環状構造である請求項1記載の環状過酸化物。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である請求項3記載の環状過酸化物。
- アルコールを酸化して得られる、環状過酸化物を含むことを特徴とする酸化反応生成物。
- 前記アルコールの酸化が、オゾン酸化および過酸化水素酸化の少なくとも一方である請求項6記載の酸化反応生成物。
- 複数の酸化反応生成物を含む混合物である請求項6または7記載の酸化反応生成物。
- 酸化能を有する請求項6から8のいずれか一項に記載の酸化反応生成物。
- 還元能を有する請求項6から9のいずれか一項に記載の酸化反応生成物。
- TRPチャネル活性物質を含む請求項6から10のいずれか一項に記載の酸化反応生成物。
- 前記アルコールが、飽和アルコールである請求項6から11のいずれか一項に記載の酸化反応生成物。
- 前記アルコールが、多価アルコールである請求項6から12のいずれか一項に記載の酸化反応生成物。
- 前記アルコールが、グリセリンおよびグリセリン誘導体の少なくとも一方である請求項6から13のいずれか一項に記載の酸化反応生成物。
- 前記アルコールの分子が2分子以上結合して得られた酸化反応生成物を含む、請求項6から14のいずれか一項に記載の酸化反応生成物。
- 請求項1から5のいずれか一項に記載の環状過酸化物を含む、請求項6から15のいずれか一項に記載の酸化反応生成物。
- 前記アルコールを酸化するアルコール酸化工程を含む請求項6から16のいずれか一項に記載の酸化反応生成物の製造方法。
- 前記アルコール酸化工程において、オゾン酸化および過酸化水素酸化の少なくとも一方により前記アルコールを酸化する請求項17記載の酸化反応生成物の製造方法。
- 前記アルコール酸化工程における反応時間が24時間以上である請求項17または18記載の酸化反応生成物の製造方法。
- 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項20に記載の美白用組成物。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項22に記載の美白用組成物。
- 皮膚に用いる、請求項20から24のいずれか一項に記載の美白用組成物。
- 前記組成物は、化粧料である、請求項20から25のいずれか一項に記載の美白用組成物。
- 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項27に記載の美白剤。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項29に記載の美白剤。
- グリセリンおよび/またはグリセリン誘導体と、皮膚バリア機能関連遺伝子の発現誘導成分とを含み、
前記皮膚バリア機能関連遺伝子の発現誘導成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む、皮膚バリア機能関連遺伝子の発現誘導用組成物:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。 - 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項32に記載の発現誘導用組成物。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項34に記載の発現誘導用組成物。
- 皮膚に用いるための、請求項32から36のいずれか一項に記載の発現誘導用組成物。
- 前記組成物は、化粧料である、請求項32から37のいずれか一項に記載の発現誘導用組成物。
- 前記皮膚バリア機能関連遺伝子は、プロフィラグリン(Pro filaggrin)遺伝子、インボルクリン(Involucrin)遺伝子、および/またはセリンパルミトイルトランスフェラーゼ(Serine palmitoyltransferase)遺伝子である、請求項32から38のいずれか一項に記載の発現誘導用組成物。
- 前記皮膚バリア機能関連遺伝子は、プロフィラグリン(Pro filaggrin)遺伝子である、請求項32から38のいずれか一項に記載の発現誘導用組成物。
- 請求項32から40のいずれか一項に記載の皮膚バリア機能関連遺伝子の発現誘導用組成物を含む、皮膚バリア機能の改善用組成物。
- 経皮投与により対象の皮膚における皮膚バリア機能関連遺伝子の発現を誘導し、前記対象の皮膚バリア機能を改善させる方法に用いるための、請求項41に記載の改善用組成物。
- 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項43に記載の誘導剤。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項45に記載の誘導剤。
- 皮膚に用いるための、請求項43から47のいずれか一項に記載の誘導剤。
- 前記皮膚バリア機能関連遺伝子は、プロフィラグリン(Pro filaggrin)遺伝子、インボルクリン(Involucrin)遺伝子、および/またはセリンパルミトイルトランスフェラーゼ(Serine palmitoyltransferase)遺伝子である、請求項43から48のいずれか一項に記載の誘導剤。
- 前記皮膚バリア機能関連遺伝子は、プロフィラグリン(Pro filaggrin)遺伝子である、請求項43から49のいずれか一項に記載の誘導剤。
- 請求項43から50のいずれか一項に記載の皮膚バリア機能関連遺伝子の誘導剤を含む、皮膚バリア機能の改善剤。
- 経皮投与により対象の皮膚における皮膚バリア機能関連遺伝子の発現を誘導し、前記対象の皮膚バリア機能を改善させる方法に用いるための、請求項51に記載の改善剤。
- グリセリンおよび/またはグリセリン誘導体と、抗酸化ストレス応答遺伝子の発現誘導成分とを含み、
前記抗酸化ストレス応答遺伝子の発現誘導成分が、有効成分として、下記化学式(I)で表される環状過酸化物またはその塩を含む、抗酸化ストレス応答遺伝子の発現誘導用組成物:
R100は、環員数3以上の環状構造であり、飽和でも不飽和でもよく、芳香環でも非芳香環でもよく、環状構造中に前記化学式(I)中の酸素原子以外のヘテロ原子を有していても有していなくてもよく、単環でも縮合環でもよく、
R1は、置換基であり、1つでもよく、複数でもよく、存在しなくてもよく、複数の場合は、互いに同一でも異なっていてもよい。 - 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項53に記載の発現誘導用組成物。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項55に記載の発現誘導用組成物。
- 皮膚に用いるための、請求項53から57のいずれか一項に記載の発現誘導用組成物。
- 前記発現誘導用組成物は、化粧料である、請求項53から58のいずれか一項に記載の発現誘導用組成物。
- 前記抗酸化ストレス応答遺伝子は、ヘムオキシゲナーゼ1(Heme oxygenase 1)遺伝子、NAD(P)Hキノンオキシドレダクターゼ1(NAD(P)H quinone oxidoreductase 1)遺伝子、および/またはグルタチオン遺伝子である、請求項53から59のいずれか一項に記載の発現誘導用組成物。
- 前記抗酸化ストレス応答遺伝子の発現誘導用組成物は、表皮角化細胞における抗酸化ストレス応答遺伝子の発現誘導用組成物である、請求項53から60のいずれか一項に記載の発現誘導用組成物。
- 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項62に記載の誘導剤。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項64に記載の誘導剤。
- 皮膚に用いるための、請求項62から66のいずれか一項に記載の誘導剤。
- 前記抗酸化ストレス応答遺伝子は、ヘムオキシゲナーゼ1(Heme oxygenase 1)遺伝子、NAD(P)Hキノンオキシドレダクターゼ1(NAD(P)H quinone oxidoreductase 1)遺伝子、および/またはグルタチオン遺伝子である、請求項62から67のいずれか一項に記載の誘導剤。
- 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項69に記載の抗炎症組成物。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項71に記載の抗炎症組成物。
- 皮膚に用いるための、請求項69から73のいずれか一項に記載の抗炎症組成物。
- 前記発現誘導用組成物は、化粧料である、請求項69から74のいずれか一項に記載の抗炎症組成物。
- 前記抗炎症組成物組成物は、IL-1α遺伝子の発現抑制組成物、IL-1αの産生抑制組成物、および/またはプロスタグランジンE2の産生抑制組成物である、請求項69から75のいずれか一項に記載の抗炎症組成物。
- 前記抗炎症組成物は、表皮角化細胞における炎症抑制組成物である、請求項69から76のいずれか一項に記載の抗炎症組成物。
- 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項78に記載の抗炎症剤。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項80に記載の抗炎症剤。
- 皮膚に用いるための、請求項78から82のいずれか一項に記載の抗炎症剤。
- 前記抗炎症剤は、IL-1α遺伝子の発現抑制剤、IL-1αの産生抑制剤、および/またはプロスタグランジンE2の産生抑制剤である、請求項78から83のいずれか一項に記載の抗炎症剤。
- 前記抗炎症剤は、表皮角化細胞における炎症抑制剤である、請求項78から84のいずれか一項に記載の抗炎症剤。
- 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項86に記載の抗糖化用組成物。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項88に記載の抗糖化用組成物。
- 糖化反応により生じたポリペプチドおよび/またはタンパク質間の架橋構造を切断するための、請求項86から90のいずれか一項に記載の抗糖化用組成物。
- 皮膚に用いるための、請求項86から91のいずれか一項に記載の抗糖化用組成物。
- 前記組成物は、化粧料である、請求項86から92のいずれか一項に記載の抗糖化用組成物。
- 前記化学式(I)中、
R100が、環員数5~10の環状構造である、請求項94に記載の抗糖化剤。 - 前記化学式(II)中のR11において、前記置換基が、それぞれ、水酸基(-OH)、アルデヒド基(ホルミル基)、ヒドロキシアルキル基、スルホ基、ニトロ基、ジアゾ基、アルキル基、不飽和脂肪族炭化水素基、アリール基、ヘテロアリール基、ハロゲン、メルカプト基(-SH)、またはアルキルチオ基(-SR、Rはアルキル基)である、請求項96に記載の抗糖化剤。
- 糖化反応により生じたポリペプチドおよび/またはタンパク質間の架橋構造を切断するための、請求項94から98のいずれか一項に記載の抗糖化剤。
- 皮膚に用いるための、請求項94から99のいずれか一項に記載の抗糖化剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280056932.0A CN117836283A (zh) | 2021-08-20 | 2022-08-18 | 环状过氧化物、氧化反应产物、氧化反应产物的制造方法和它们的用途 |
JP2023542444A JPWO2023022204A1 (ja) | 2021-08-20 | 2022-08-18 |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-134732 | 2021-08-20 | ||
JP2021134732 | 2021-08-20 | ||
JP2021195536 | 2021-12-01 | ||
JP2021-195536 | 2021-12-01 | ||
JP2021202053 | 2021-12-13 | ||
JP2021-202053 | 2021-12-13 | ||
JP2021212094 | 2021-12-27 | ||
JP2021-212094 | 2021-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023022204A1 true WO2023022204A1 (ja) | 2023-02-23 |
Family
ID=85240855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/031273 WO2023022204A1 (ja) | 2021-08-20 | 2022-08-18 | 環状過酸化物、酸化反応生成物、酸化反応生成物の製造方法、及び、それらの用途 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2023022204A1 (ja) |
TW (1) | TW202323248A (ja) |
WO (1) | WO2023022204A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014383A1 (en) * | 2000-08-15 | 2002-02-21 | Akzo Nobel N.V. | Use of trixepans in the process to modify (co) polymers |
JP2005112799A (ja) * | 2003-10-08 | 2005-04-28 | Toshiaki Miura | オレイン酸アルキルエステルオゾニド |
JP2015189735A (ja) * | 2014-03-28 | 2015-11-02 | 株式会社ブイエムシー | ヒートショックタンパク質の発現誘導剤 |
JP2020059656A (ja) | 2018-10-05 | 2020-04-16 | 株式会社ナリス化粧品 | メラニン分解促進剤 |
JP2021134732A (ja) | 2020-02-27 | 2021-09-13 | 株式会社デンソー | 燃料噴射弁駆動装置 |
JP2021195536A (ja) | 2020-06-09 | 2021-12-27 | 三洋化成工業株式会社 | 熱硬化性樹脂組成物 |
-
2022
- 2022-08-18 WO PCT/JP2022/031273 patent/WO2023022204A1/ja active Application Filing
- 2022-08-18 JP JP2023542444A patent/JPWO2023022204A1/ja active Pending
- 2022-08-19 TW TW111131343A patent/TW202323248A/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014383A1 (en) * | 2000-08-15 | 2002-02-21 | Akzo Nobel N.V. | Use of trixepans in the process to modify (co) polymers |
JP2005112799A (ja) * | 2003-10-08 | 2005-04-28 | Toshiaki Miura | オレイン酸アルキルエステルオゾニド |
JP2015189735A (ja) * | 2014-03-28 | 2015-11-02 | 株式会社ブイエムシー | ヒートショックタンパク質の発現誘導剤 |
JP2020059656A (ja) | 2018-10-05 | 2020-04-16 | 株式会社ナリス化粧品 | メラニン分解促進剤 |
JP2021134732A (ja) | 2020-02-27 | 2021-09-13 | 株式会社デンソー | 燃料噴射弁駆動装置 |
JP2021195536A (ja) | 2020-06-09 | 2021-12-27 | 三洋化成工業株式会社 | 熱硬化性樹脂組成物 |
Non-Patent Citations (3)
Title |
---|
"GenBank", Database accession no. NM_000903.3 |
SARA VASAN ET AL., NATURE, vol. 382, 1996, pages 275 - 278 |
YOSUKE ISHITSUKA: "The formation of skin barrier and defective barrier-associated skin diseases", JPN. J. CLIN. IMMUNOL., vol. 40, no. 6, 2017, pages 416 - 427 |
Also Published As
Publication number | Publication date |
---|---|
TW202323248A (zh) | 2023-06-16 |
JPWO2023022204A1 (ja) | 2023-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU716131B2 (en) | Genistein as a preventive against ultraviolet induced skin photodamage and cancer | |
US8802117B2 (en) | Melatonin and immunostimulating substance-based compositions | |
JP5319070B2 (ja) | 皮膚漂白のための無色カロテノイド | |
Samivel et al. | Inhibitory effect of ursolic acid on ultraviolet B radiation-induced oxidative stress and proinflammatory response-mediated senescence in human skin dermal fibroblasts | |
JPH07316034A (ja) | 4位、4位および5位、または4位および6位がモノ‐もしくはジ‐置換されたレゾルシノール誘導体を、色素脱失作用を有する化粧品組成物もしくは皮膚薬剤組成物に使用する方法 | |
Passi et al. | The combined use of oral and topical lipophilic antioxidants increases their levels both in sebum and stratum corneum | |
CA2408383A1 (fr) | Utilisation de l'acide ellagique comme agent cosmetique anti-pollution | |
Bensasson et al. | Potency of inhibition of human DNA topoisomerase I by flavones assessed through physicochemical parameters | |
Xia et al. | Photo-irradiation of Aloe vera by UVA—formation of free radicals, singlet oxygen, superoxide, and induction of lipid peroxidation | |
Li et al. | Protective effects of polymethoxyflavone-rich cold-pressed orange peel oil against ultraviolet B-induced photoaging on mouse skin | |
Xia et al. | UVB photoirradiation of aloe vera-formation of free radicals, singlet oxygen, superoxide, and induction of lipid peroxidation | |
WO2023022204A1 (ja) | 環状過酸化物、酸化反応生成物、酸化反応生成物の製造方法、及び、それらの用途 | |
EP2907513A1 (en) | Compositions comprising dihydroquercetin for use in methods for alleviating the effects associated with skin inflammatory disorders | |
JP2006509733A (ja) | 脱色素剤または抗突然変異および抗発癌剤として使用のチオ尿素を含んでなる医薬 | |
EP1361854B1 (fr) | Solution topique comprenant une isoflavone aglycone | |
JP2015040181A (ja) | カロテノイドの新規用途、並びにバリア機能改善薬のスクリーニング方法 | |
CN110615826A (zh) | 新型化合物、包含其的化妆料组合物及药学组合物 | |
US20120269745A1 (en) | Hydroxytyrosol compounds | |
HRP20010696A2 (en) | Resorcinol composition | |
CN117836283A (zh) | 环状过氧化物、氧化反应产物、氧化反应产物的制造方法和它们的用途 | |
JP2009203167A (ja) | サイトカイン生成抑制剤およびそれを含有する化粧品組成物 | |
JP2024502202A (ja) | グリコシル化バクテリオルベリン及びその産業応用 | |
AU2017382845B2 (en) | Methods of treating hyperpigmentation disorders | |
JP2004359657A (ja) | マトリックスメタロプロテアーゼ−9の産生を阻害するための薬剤 | |
JP6671832B2 (ja) | ヒートショックタンパク質の発現誘導剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22858521 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023542444 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022858521 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022858521 Country of ref document: EP Effective date: 20240320 |